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1. ABSTRACT 
p53 is one of the most extensively studied tumor suppressor proteins, and its gene is mutated in 50% 
of human cancers. Stress signals activate p53 and its transcriptional machinery which lead to cell-
cycle arrest, apoptosis or senescence. MDM2, its target gene product and the main negative 
regulator can bind to p53, and mark it for proteasomal degradation via its RING finger domain and 
the associated E3 ubiquitin ligase activity. Preventing the p53-MDM2 interaction via small molecule 
inhibitors appears to be the most obvious strategy to eliminate tumors harboring wild-type p53. 
However, despite extensive research, clinical responses to these drugs have been disappointing. 
Patient studies do not indicate durable tumor regression upon administration of these drugs but 
rendered adverse effects like nausea, vomiting, diarrhea and hematological disorders such as 
neutropenia and thrombocytopenia. 
In this thesis, we have aimed to evaluate MDM2 inhibitors in combination with other drugs that lead 
to either synergism or antagonism with respect to p53 response in three diverse manners. 
Firstly, we have utilized the concept of cyclotherapy and MDM2 inhibition to protect normal cells 
against agents like WEE1 inhibitors that causes replicative stress. We have found that pre-treatment 
of cells with MDM2 inhibitors shielded them from cytotoxic effects of WEE1 inhibition. This strategy 
would be beneficial in the clinics to target p53-deficient cancer cells, while protecting the p53-wild-
type normal cells. Secondly, we targeted the two negative regulators of p53, namely MDM2 and 
WIP1 by inhibitors to enhance cellular cytotoxicity. This led to an increased expression and 
occupancy of p53 at its target genes and also caused a senescent phenotype. Finally, we observed 
an unexpected antagonism between inhibitors of MDM2 and CDK4/6 regarding cell viability and p53 
response, indicating CDK4 is a supportive kinase for p53 activity.  
Thus, our studies indicate three different approaches to modulate the cytotoxic effects of MDM2 
inhibition. Taken together from our observations, we conclude that MDM2 inhibition might lead to 
patient benefit by changing the purpose of the drug; by combining it with other drugs that can mediate 
stronger toxicity; and lastly by targeting the correct population of tumors to obtain robust effects. 
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2. INTRODUCTION 
2.1 The family of TP53 – “Protector of our genome”  
In response to diverse stress stimuli and DNA damage, the tumor suppressor protein p53 executes 
various roles including cell-cycle arrest, senescence and apoptosis, thereby making it one of the 
most widely studied proteins in cancer biology. Originally identified as a 54 kDa protein bound to 
SV40 large-T antigen [1-3], the TP53 gene is frequently mutated (~50%) in human tumors [4, 5] 
rendering it non-functional.  
In cancers, p53 is often inactivated by viral proteins or by upregulation/ amplification of its negative 
regulators. Studies have also indicated germline mutations in the p53 gene resulting in a rare 
inherited autosomal dominant disorder known as Li-Fraumeni syndrome [6, 7]. Such patients are 
characterized by their high risk towards the development of sarcomas, adrenocortical carcinoma 
(ACC), breast cancer, leukemia, and brain tumors [8, 9]. Research conducted in mice deficient for 
p53 displayed normal embryonic development but were predisposed to spontaneous tumors 
including lymphoma and sarcoma; thereby confirming its tumor suppressive functions [10].  
p63 and p73 are two homologues of p53 [11, 12] with overlapping yet distinct functions. Like p53, 
p73 can be activated upon DNA damage that can lead to the elimination of cells via apoptosis [13]. 
p73 was recently described to modulate airway multiciliogenesis in mice by affecting the master 
regulator of ciliogenesis, namely FoxJ1 [14]. Mice deficient for TP73 showed defects in fluid dynamics 
in the central nervous system, neurogenesis, reproductive and social behavior [15]. Moreover, p73 
was shown to be essential for maintaining genome stability when p53 was inactivated [16]. On the 
other hand, p63 plays a major role in squamous epithelial development as observed in TP63 
knockout mice. These mice exhibited defects in epithelial tissues such as absence of hair, skin and 
sweat glands along with faulty limb and craniofacial development [17, 18]. 
2.2 Transcriptional role of p53 
p53 functions as a homotetramer and recognizes its responsive element on the DNA that consists of 
two repeats of the consensus sequence 5′-PuPuPuC(A/T)(T/A)GPyPyPy-3′ [19, 20]. However, on 
the PIG3 promoter p53 identifies a pentanucleotide microsatellite sequence (TGYCC)n (where n=15) 
[21]. It acts as a transcription factor by binding to these responsive elements and augments the rate 
of transcription [22]. A plethora of genes have been identified to be directly regulated by p53. Few of 
the best understood genes include CDKN1A or p21 [19] that is responsible for cell-cycle arrest; 
PUMA, NOXA, BAX and others that induce apoptosis [23]; and Plasminogen Activator Inhibitor -1 
(PAI-1) [24] whose expression has been linked to mediate senescence. p21 has also been described 
to cause senescence via cell-cycle arrest by suppressing the factors that promote cellular 
proliferation [25].  
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2.3 Structure of p53   
The p53 protein consists of 393 amino acids which undergoes numerous post-translational 
modifications including phosphorylation, acetylation, ubiquitination, sumoylation, and neddylation 
(Figure 2 1) [26].  
p53 comprises of two Transactivation Domains (TAD1 and TAD2) that are intrinsically disordered i.e. 
it lacks a fixed three-dimensional structure [27, 28]. These domains can bind to MDM2, a target gene 
of p53 that is also its negative regulator, and p300/cAMP Responsive Element Binding- Protein 
(CREB) Binding Protein (CBP), a histone acetyltransferase which is a general transcriptional 
coactivator [29]. 
 
 
Figure 2 1 Schematic structure of p53.  
p53 consists of two transactivation domains (TADs), a proline-rich domain (PP), a central DNA binding domain 
(DBD), a tetramerization domain (Tet) and a C-terminal regulatory domain (Reg). Adapted from [30].  
 
The N-terminus of the p53 protein is subjected to extensive post-translational modifications [31] in 
response to stress cues that lead to its activation and stabilization. The TAD2 region present at the 
N-terminus also interacts with the p62 subunit of Transcription Factor IIH (TFIIH) complex within the 
general transcriptional machinery, and this interaction is pivotal for carrying out its role as a 
transcription factor [32]. The Proline rich region spanning amino acid residues 61-92 contains five 
repeats of the sequence PXXP. This region plays a role in p53-mediated induction of apoptosis [33-
35]. The DNA binding domain of p53 is responsible for its binding to the responsive elements present 
on DNA that enables the transcription of its target genes. Most of the hotspot mutations occur within 
this region [36]. These mutations prevent sequence-specific binding of p53 to the promoter of its 
target genes. 10% of these hotspot mutations arise due to the lack of a functional protein by 
frameshift or nonsense mutations whereas the remainder is a result of missense mutations. The 
tetramerization domain enables the formation of an active p53 tetramer from two homodimers [37] 
that enables the correct conformation for binding to DNA. It also contains a Nuclear Export Signal 
(NES) between residues 340 and 351 [38] which allows the export of p53 into the cytoplasm. 
Additionally, the p53 C-Terminal Domain (CTD) undergoes extensive post-translational modifications 
that are important for the activity and stability of the protein. Of importance, MDM2-mediated 
ubiquitination leading to the degradation of p53 protein occurs within this terminal region, owing to 
the numerous lysine residues that are present [39-41]. 
 
2.4 Cellular functions of p53- “Get, set, and action” 
To maintain homeostasis in normal unstressed cycling cells, p53 is kept at low levels owing to its 
short half-life (~5-20 mins) (Figure 2 2). Additionally, these low levels are kept intact by the negative 
regulators of p53 i.e. E3 ubiquitin ligases such as MDM2/MDMX [42], P53-Associated Cellular 
protein-Testes derived (PACT) [43], Pirh2 [44], COnstitutively Photomorphogenic 1 (COP1) [45] and 
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phosphatases such as Wild-type P53-induced phosphatase 1 (also referred to as WIP1/PPM1D) [46, 
47].  
Upon exposure to various genotoxic insults including DNA damaging agents, hypoxia and nucleotide 
deprivation, p53 is stabilized and activated which leads to a steady increase in its levels (Figure 2 2). 
This is achieved by post-translational modifications on the N- and C-terminal regions that increase 
the affinity of p53 to its target genes and enable its transactivation which helps to promote either the 
elimination of the cell or support its repair, thereby preventing the risk of transmitting mutations to the 
next generation.  
 
Figure 2 2 Activation of p53 
Homeostasis of p53 levels are maintained in normal cells by MDM2. Upon ubiquitination of p53 by MDM2, p53 
undergoes proteasomal degradation via the 26S proteasomal machinery. In response to external stress, p53 
accumulates within the cell and forms a tetramer; binds to its target genes at the responsive elements and 
transcribes the various genes involved in cell-cycle arrest, apoptosis, senescence, and repair. Adapted from 
[48]. 
 
The resulting fate of the cell is largely context-dependent; whether the cell undergoes cell-cycle 
arrest, permanent cell-cycle arrest (i.e. senescence) or apoptosis. Minor DNA damage could cause 
activation of cell-cycle arrest or DNA repair mechanisms while strong p53 activating signals might 
result in senescence or apoptosis. A large amount of work has been carried out to understand the 
resulting cell fate upon different stress stimuli, at varying time points with diverse cell lines using 
Chromatin immunoprecipitation sequencing (ChIP-seq), Global-Run on sequencing (GRO-Seq) and 
RNA-sequencing (RNA-seq) studies painting a more complex picture of p53 gene regulation [49, 50]. 
An overview of the important roles of p53 and the genes responsible for them are outlined below.  
2.4.1 Cell-cycle arrest 
Transient arrest of cells at the G1-S interphase ensures detection and repair of damaged DNA before 
initiation of replication in S-phase. The G2-M transition in the cell-cycle is another checkpoint where 
cells are checked for unreplicated or damaged DNA after S-phase before they undergo mitosis 
(Figure 2 3). If left unrepaired, faulty or damaged DNA entering M-phase could lead to mitotic 
catastrophe, a form of cell death that occurs due to aneuploidy.  
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Figure 2 3 p21-mediated cell-cycle arrest. 
Upon activation of p53, p21; a CDK inhibitor, which is one of the primary target genes of p53 is transcribed 
which arrests the cells at the G1-S phase via CDK4/ Cyclin D, Rb and E2F1 proteins; S- phase by CDK1/2 and 
Cyclin A/E complexes and G2-M phase by CDK1/ Cyclin B complexes. Adapted from [51] 
 
 
CDKN1A is the primary target gene of p53 which mediates cell-cycle arrest. It is a cell-cycle 
dependent kinase (CDK) inhibitor which inhibits the kinase activity of CDK4/6, CDK1 and CDK2, 
thereby preventing the cells from progressing at G1-S, S and G2-M phases of the cell-cycle 
respectively. Although mice lacking CDKN1A were not prone to spontaneous tumors [52], they 
showed defective G1 checkpoint activity upon DNA damage and p53 activation [53, 54].  
Other p53 targets that can cause cell-cycle arrest include calveolin-1 at the G0-G1 transition [55], 
and BTG anti-proliferation factor 2 (BTG2) at the G1-S transition [56]. Likewise Growth- Arrest and 
DNA-Damage-inducible 45 alpha (GADD45 α) [57], and 14-3-3 Sigma (14-3-3 σ) [58] promote pre-
mitotic cell-cycle arrest upon DNA damage via p53 accumulation. 
2.4.2 DNA repair 
Initiating cell-cycle arrest by p53 activation at G1-S transition allows for efficient repair of damaged 
DNA prior to synthesis. p53 activates various repair pathways like Nucleotide Excision Repair (NER) 
upon DNA damage by activating DNA Damage-Binding protein 2 (DDB2) [59] and Xeroderma 
Pigmentosum, complementation group C (XPC) proteins [60]. Proliferating Cell Nuclear Antigen 
(PCNA), a co-factor that helps to recruit key players to the replication fork [61] is a p53-responsive 
target [62] which also assists in DNA repair by activating DNA damage tolerance pathways including 
Translesion DNA Synthesis (TLS). Ubiquitination of PCNA helps to recruit repair proteins like RAD6-
RAD18 that initiates DNA repair mechanisms [63]. p53 can also initiate translesion DNA synthesis in 
cells exposed to low doses of UV irradiation by activating Pol eta (POLH) [64, 65]. This activates the 
ATM/CHK2 pathway and allows the cells to bypass the damage and helps in efficient restart of the 
damaged fork.  
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2.4.3 Apoptosis 
In cases of overwhelming stress, if the DNA damage is not sufficiently repaired by the various 
mechanisms as outlined in section 2.4.2, the cells activate a programmed cascade of events that 
lead to apoptosis. This can be triggered by two types of stimuli, namely extrinsic and intrinsic. 
Extrinsic stimuli encompasses death ligands such as the Fas ligand (Fas-L) or the Tumor-Necrosis 
Factor-α (TNF-α) that bind to cell-surface receptors [66]. On the other hand, intrinsic stimuli center 
around the mitochondria upon DNA damage, UV irradiation, stress or oncogene activation that is 
regulated by the pro-apoptotic and anti-apoptotic members of the B-Cell Lymphoma 2 (Bcl-2) family 
[67]. Cysteine aspartic proteases (caspases) which have intrinsic cysteine protease activity help in 
cleaving their target proteins at aspartate residues. These enzymes play a pivotal role in apoptosis 
by cleaving nuclear lamins, Poly- ADP Ribose Polymerase (PARP), and Inhibitor of the Caspase-
activated DNAse (ICAD). This proteolytic cleavage frees the DNAse- CAD leading to DNA 
fragmentation and nuclear blebbing, consequently resulting in apoptosis.  
p53 can activate genes of both the extrinsic and the intrinsic apoptotic pathway. FAS, Tumor Necrosis 
Factor S6 (TNFS6) [68-70] and Tumor necrosis factor-Related Apoptosis-Inducing Ligand (TRAIL) 
[71, 72] are some of the genes activated upon p53 accumulation that cause caspase-dependent 
apoptosis via procaspase 8. On the other hand, p53 also activates pro-apoptotic Bcl-2 members such 
as Bcl-2-Associated X protein (BAX) [73], p53 Upregulated Modulator of Apoptosis (PUMA) [74], and 
NOXA [75] that control the release of cytochrome c from the mitochondria. The released cytochrome 
c binds to another p53 target, Apoptosis-Peptidase Activating Factor-1 (APAF-1) [76, 77] and 
procaspase 9 to form the apoptosome. This triggers the cascade of effector caspases such as 
caspase-3 and caspase-7, ultimately leading to apoptosis. 
2.4.4 Senescence 
A state of cell-cycle arrest where the cells retain their metabolic activity but cease to divide is termed 
as senescence. Induction of senescence is attributed to the suppression of malignant lesions. It is 
initiated by DNA- Double-Strand Breaks (DSBs), or acute/chronic stress within the cell. p53 activates 
p21, Promyelocytic Leukemia protein (PML) [78], Plasminogen Activator Inhibitor-1 (PAI1) [24] and 
E2F7 [79] that initiates an oncogene-induced senescence program. Apart from p53 and Rb [80-82], 
oncogene-induced senescence can also be mediated by kinases such as p38, and PI3K/AKT/mTOR 
pathways [83, 84]. By suppressing cellular proliferation, senescence acts as a barrier to the 
transformation of cells.  
2.5 Post-translational modifications on p53 
p53 undergoes numerous Post-Translational Modifications (PTM) on its N and C-terminal domains 
(Figure 2 4). In response to various stress stimuli, p53 can be phosphorylated by numerous DNA 
Damage Response (DDR) kinases like Ataxia Telangiectasia Mutated (ATM) [85-87], Ataxia 
Telangiectasia and Rad-3 related (ATR) [88], DNA-dependent Protein Kinase (DNA-PK) [89, 90], 
checkpoint kinases CHK1 and CHK2 [91], Jun NH2-terminal Kinase (JNK) [92-94], p38 [95] and 
others.  
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Particularly, in response to DNA double-strand breaks, p53 is phosphorylated at Ser15 (Ser18 in 
mouse) by ATM. ATM/ATR kinases can also mediate the phosphorylation of p53 at Ser6, Ser9, 
Ser20, Ser46 and Thr18 [96, 97].  
 
Figure 2 4 Post-translational modifications on the p53 protein. 
Important post-translational modifications on p53 are indicated at the respective domains. P signifies 
phosphorylation, Ac depicts acetylation, SUMO denotes Sumoylation, and NEDD indicates neddylation. 
Adapted from [31].  
 
Upon exposure to UV irradiation, p53 is phosphorylated at Thr81 by JNK [98] and Ser389 by p38 
kinase [99]. Homeodomain Interacting Protein Kinase 2 (HIPK2) can mediate the phosphorylation of 
p53 on Ser46 upon UV irradiation [100, 101] which has been implicated to modulate the cell fate 
towards apoptosis. All the above modifications are responsible for increasing the stability and activity 
of p53 as a transcription factor. 
Acetylation of lysine residues at the C-terminal region of p53 exposes the DNA binding domain 
leading to enhanced transcription of its targets [102]. This is carried out by the p300/CBP/PCAF 
family of Histone Acetyltransferases (HATs). Apart from the C-terminus, the DNA binding domain of 
p53 can also be acetylated at Lys120 upon DNA damage by Tip60. This is critical for mediating p53-
dependent apoptosis via BAX and PUMA [103, 104]. 
Neddylation of p53 can occur at Lys370, Lys372, Lys373 by MDM2 and Lys320, Lys321 by F-box 
protein 11 (Fbx11). The above modifications lead to the inhibition of p53-mediated transcription [105, 
106]. Sumoylation, another post-translational modification carried out by an ubiquitin-like protein 
named SUMO-1, occurs at Lys386 upon UV irradiation which enhances the activation of p53 target 
genes [107]. The exact outcome of these modifications remains largely elusive. 
While p53 is subject to various modifications that activate the protein, these post-translational 
modifications are also reversed by various proteins that attenuate this signaling axis, thereby 
negatively regulating p53 activity. Members of the Protein phosphatase 2C (PP2C) family such as 
Wild-type p53 Induced Phosphatase (WIP1 or PPM1D) are activated upon DNA damage, which can 
dephosphorylate p53, thereby leading to its downregulation [108, 109]. Thus, they act as negative 
regulators of p53 activity.  
Histone Deacetylases (HDACs) including HDAC1 and Sirtuin1 (SIRT1) can remove acetyl groups 
from p53, causing decreased transcriptional activity and cell survival upon stress stimuli [110, 111]. 
INTRODUCTION 
8 
 
In 2004, it was discovered that Set9, a histone lysine methyltransferase methylates p53 at Lys372 
which correlated with increased stability of p53 [112].  
Finally, p53 undergoes ubiquitination which is highly reversible and dynamic. It can undergo 
monoubiquitination or polyubiquitination, each leading to a distinct outcome. MDM2, an E3 ubiquitin 
ligase and a transcriptional target of p53 ubiquitinates it at Lys370, Lys372, Lys373, Lys381, Lys382 
and Lys386 [113]. This contributes to the nuclear export of p53 [114]. Increased expression of MDM2 
that is induced upon p53 activation provides a pathway for polyubiquitinating p53, thereby leading to 
its degradation. Thus, MDM2 induction by p53 forms a negative feedback loop that keeps p53 levels 
in check after the damage has been repaired [40, 115]. Independent of MDM2, the ubiquitin ligase 
Pirh2 functions as a negative regulator of p53 by binding to p53 and inhibiting its growth suppressive 
functions by ubiquitination and proteasomal degradation [44]. Furthermore, COP1 was found to be a 
p53-inducible gene, and its product binds to p53 and inhibits p53-dependent transcription and 
apoptosis in an ubiquitin-dependent manner [45]. ARF-BP1 directly binds and ubiquitinates p53 in 
p53 wild-type cells and its inactivation is essential for p53 activation [116].  
In contrast to the ubiquitinating enzymes, deubiquitinating enzymes (DUBs) are proteases that cleave 
ubiquitin-linked molecules on the last residue of ubiquitin (Gly76) after the terminal carbonyl. Herpes-
Specific Ubiquitin Specific Protease (HAUSP or USP7) was shown to strongly stabilize p53 even in 
the presence of MDM2 to induce cell-cycle arrest and apoptosis [117].  
Thus, p53 is regulated by diverse post translational modifications which lead to the activation or 
repression of its target genes in response to stress signals. In the next section, the focus will be on 
the target gene of p53 and its negative regulator – MDM2.  
2.6 “Self-controlling p53”– MDM2   
MDM2 (Murine double-minute 2) was originally identified as one of three genes which was 
overexpressed in a spontaneously transformed murine cell line (3T3 fibroblasts; [118]) and its product 
was found to bind to and downregulate p53 [119, 120]. Mice deficient for MDM2 were embryonically 
lethal, however when p53 was co-depleted, they were viable and displayed normal development 
[121, 122]. As stated earlier, MDM2 is a target gene of p53 whose product is an E3 ubiquitin ligase. 
The ubiquitin ligase activity of MDM2 is carried out by its conserved COOH terminal RING finger 
domain which can ubiquitinate p53 at its C-terminus. This causes the degradation of p53 via the 26S 
proteasome. MDM2 is an oncogene that is frequently overexpressed in sarcomas, leukemia and 
lymphoma which are associated with poor prognosis [120, 123].  
2.7 Structure of MDM2 
The MDM2 protein consists of 491 amino acid residues and interacts with the transactivation domain 
of p53 via its N-terminus (Figure 2 5) [124]. 
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Figure 2 5 Domain structure of MDM2. 
The different domains of MDM2 protein are indicated. The acidic domain and Zn finger domain are flanked by 
the p53-binding domain at the N-terminus and the Really Interesting New Gene (RING) finger domain at its C-
terminus. Adapted from [125]. 
The central acidic domain has been suggested to interact with the Retinoblastoma (Rb) protein at its 
C-pocket [126]. Binding of MDM2 with Rb prevents the E2F-Rb interaction, thereby allowing cells to 
progress through the G1-S phase of the cell-cycle. Moreover p19ARF (Alternate Reading Frame), a 
member of the INK4a gene locus was found to physically interact with MDM2, thereby preventing 
MDM2-mediated p53 degradation [127-129]. This can occur by sequestering MDM2 to the nucleolus 
along with ARF that leads to the activation of p53 in the nucleoplasm or by binding to MDM2 and 
causing its degradation. Other binding partners of MDM2 at this domain include the co-activator p300 
[130], and RPL11 which sequesters MDM2 in the nucleolus resulting in p53 stabilization [131]. 
Mutations in the zinc finger domain of MDM2 disrupts its interaction with ribosomal proteins L5, L11 
and L23 inhibiting its ubiquitin ligase activity and thereby its ability to degrade p53 [132].   
The two important domains in MDM2 protein include the N-terminus p53 binding domain and the C-
terminus RING finger domain. Crystallographic data as well as biochemical experiments have 
indicated that the N-terminus of MDM2 (25-109aa) forms a deep hydrophobic cleft into which the N-
terminal TAD (15aa amphipathic residue) of p53 binds [39, 124, 133]. Residues Phe19, Trp23, and 
Leu26 on p53 are most critical for binding to MDM2 [133, 134] while Gly58, Gly68, Val75, or Cys77 
residues on MDM2 are critical for binding to p53 [135]. The Thr18 residue on p53 was identified to 
be important for the stability of the p53 α-helix [124]. Phosphorylation of this residue abrogates p53-
MDM2 binding by nearly 10-fold while no effect on binding was detected if p53 was phosphorylated 
at Ser15 and Ser20 residues [136].  
MDM2 can function as an E3 ubiquitin ligase towards itself and p53 [41, 137, 138]. 
Monoubiquitination of p53 is mediated by MDM2 while polyubiquitination requires the ubiquitin ligase 
activity of p300 [139, 140]. Mutations in the RING finger domain (C464A) abolished the E3 ubiquitin 
ligase activity but not its interaction with p53 [141].   
Oren and colleagues also reported that MDM2 can be acetylated at its RING domain by p300 that 
accentuates the transcriptional activity of p53 due to MDM2 degradation [142]. 
Apart from this, MDM2 also contains a nuclear localization sequence (residues 181-185) and a 
nuclear export signal (residues 190-200). This helps in shuttling MDM2 in and out of the nucleus [38, 
143].  
MDMX, an MDM2 homologue can heterodimerize with MDM2 via their RING finger domains. 
However, unlike MDM2, MDMX lacks the intrinsic E3 ubiquitin ligase activity [144, 145]. Despite that, 
MDMX can bind to p53 through its p53-binding domain, which masks the TAD of p53 that leads to 
the attenuation of the transcriptional activity of p53 in a manner similar to MDM2 [146, 147]. 
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2.8 Transcriptional regulation of MDM2 
The transcription of MDM2 is regulated by two distinct promoters – P1 and P2 [148] (Figure 2 6). The 
two isoforms migrate at 90 kDa and 75 kDa respectively due to initiation of translation from two 
distinct AUG start codons. The P1 promoter is situated upstream of exon one and controls the basal 
expression of MDM2, while the P2 promoter that is present within the first intron is highly regulated 
and inducible [149]. The p53 responsive elements are present upstream of the P2 promoter; thereby 
enabling p53-induced expression of MDM2 [150].  
 
 
 
Figure 2 6 P1 and P2 promoters of MDM2.  
Schematic representation of the 5’ end of the MDM2 gene. The long isoform of the MDM2 protein includes exon 
1 and 3 while the short isoform; P2 includes the p53 binding sites located upstream of exon 2. Adapted from 
[151]. 
2.9 Post-translational regulation of MDM2 
MDM2 undergoes phosphorylation at its N-terminus p53-binding domain, central acidic domain and 
at the C-terminus RING finger domain (Figure 2 7).  
 
Figure 2 7 Phosphorylation sites on MDM2.  
Green circles indicate sites that increase MDM2/MDMX mediated inhibition of p53; orange circles depict 
inhibition of MDM2/MDMX dependent inhibition of p53. PPI indicates phosphorylations on MDM2 that affect p53 
interaction; S indicates sites that modulate the stability of MDM2 upon phosphorylation, O refers to 
phosphorylations that change the oligomerization of the protein and O/S refers to changes in oligomerization 
and stability. Drawn from  [152]. 
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In response to DNA double strand breaks, ATM can phosphorylate MDM2 at Ser395 which impairs 
its ubiquitin ligase activity on p53 and activates p53 [153]. On the other hand, WIP1 phosphatase 
maintains this balance by dephosphorylating MDM2 after the stimulus is removed [154]. Other 
kinases that can phosphorylate MDM2 include AKT which phosphorylates MDM2 at Ser166 and 
Ser186 leading to its stabilization and the subsequent inhibition of p53 [155]. Phosphorylation by 
DNA-PK at Ser17 of the MDM2 protein causes the dissociation of p53 from its negative regulators, 
thereby allowing p53 stabilization [156]. S6K1 kinase, a downstream factor of mammalian target of 
rapamycin (mTOR) pathway mediates phosphorylation of MDM2 at Ser163 in response to 
doxorubicin that hampers the ubiquitination of p53 by MDM2 [157]. Cyclin-dependent kinases - CDK1 
and CDK2 phosphorylates p53 at Thr216 that might affect MDM2 binding to other proteins [158]. c-
Abl can block ubiquitination and proteasomal degradation of p53 by phosphorylating MDM2 at Tyr394 
[159].  
P14-ARF has been shown to enhance sumoylation of MDM2 (residues 82-101) by blocking its 
ubiquitination activity [160] and thereby promoting p53 response. In addition to its role in maintaining 
p53 levels, p53-independent functions of MDM2 have been reported. Few of the important ones are 
listed below. 
2.10 p53-independent roles of MDM2 
Apart from being a negative regulator of p53, MDM2 has been described to have p53-independent 
roles. In vivo studies have shed light into the p53-independent role of MDM2 during tumorigenesis. 
Mice lacking MDM2 were found to be embryonically lethal while this phenotype could be reversed if 
p53 was co-depleted [121]. In the absence of p53, association of MDM2 with NBS1 of the 
MRE11/RAD50/NBS1 (M/R/N) DNA repair complex resulted in the inhibition of DNA double-strand 
break repair; indicating a role of MDM2 in maintaining genomic stability [161]. Studies by Mulay and 
co-workers showed that MDM2 was essential for Toll-like receptor (TLR)-mediated cytokine 
production; implicating its role in inflammation by enhanced Nuclear Factor ‘kappa-light-chain-
enhancer’ of activated B-cells (NF-κB) signaling [162]. Recent findings have also identified roles for 
chromatin-bound MDM2 in the transcriptional control of genes involved in amino acid metabolism 
and redox homeostasis [163] a well as lineage-specific genes by its interaction with the Polycomb 
repressive complexes (PRC) 1 and 2 [164].  
These p53-dependent and independent roles of MDM2 have made it an interesting drug candidate 
in cancer therapy. By targeting the MDM2-p53 interaction, we can activate the transcriptional network 
of p53 which can be used efficiently to treat p53 Wild-type (WT) tumors. The next section will provide 
a short summary. 
2.11 Targeting the oncogene – MDM2  
By interfering with the protein-protein interaction of MDM2 and p53 using peptides or other small 
molecules, treatment of cancers with wild-type p53 can be achieved (Figure 2 8).  
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Figure 2 8 Negative feedback loop of MDM2 and p53. 
Upon activation, p53 transcribes its target genes. One of its main targets, MDM2 accumulates within the cell 
which also acts as its negative regulator and marks p53 for monoubiquitination that promotes nuclear export or 
polyubiquitination followed by proteasomal degradation. Adapted from [165]. 
 
Although MDM2 and p53 have been studied extensively for over three decades, there is currently no 
Food and Drug Administration (FDA) approved drug for MDM2 inhibitors. The first small, potent and 
specific inhibitor of MDM2 came in 2004 from the company Hoffmann-La Roche where Nutlin-3a, 
one amongst many Nutlins could bind to MDM2 in vitro at an Inhibitory Concentration (IC) of 90nM. 
Nutlin could inhibit the interaction of MDM2 with p53, and activate the p53 transcriptional network, 
thereby displaying selectivity towards p53 wild-type cancer cell lines [166] (Figure 2 9).  
 
Figure 2 9 Targeting the MDM2-p53 interaction. 
MDM2 protein is indicated in yellow which binds to the TAD1 of p53. p53 (residues 17-29) backbone is indicated 
in grey with the side chains Phe19, Trp23 and Leu26 that are essential for the interaction to occur [48]. These 
inhibitors bind competitively to this pocket. 
 
After further optimization, another MDM2-p53 inhibitor RG7112 (RO5045337) entered clinical trials 
for liposarcoma patients. Although there was a clear activation of p53 indicated by increased p21 
levels and signs of apoptosis in the tumors, only a partial response was observed in patients. 
Moreover, patients suffered from severe adverse effects including neutropenia, thrombocytopenia, 
diarrhea, vomiting and nausea [167]. In addition, two out of six other MDM2 inhibitors that entered 
clinical trials have initial reports available which include RG7388 also known as Idasanutlin [168] and 
MI-77301 [165]. However, two challenges that these drugs faced in clinical trials were dose-
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dependent toxicity that led to hematological disorders and detection of p53 mutations, especially at 
the DNA binding domain of p53 in tumors that were initially wild-type.  
Other inhibitors of MDM2 that are being tested in vitro and in vivo affect its ubiquitin ligase activity at 
the RING finger domain and its interaction with MDMX. They include MEL23/24 [169], HLI98 [170], 
and RO-5963 [171]. All these drugs indicated a strong inhibition of the interaction between MDM2-
MDMX resulting in the stabilization of p53 and subsequent induction of p53-dependent apoptosis. 
p53- mimetic stapled peptides have been a topic of intense research. ATSP-7041 showed on-target 
mechanism of action by inhibiting the MDM2-MDMX interaction and activation of p53. This led to 
tumor growth suppression in an MDM2/MDMX overexpression xenograft model with favorable 
pharmacokinetic properties [172].  
APR-246 (PRIMA-1MET), a p53-mutant re-activator has shown promising results in refractory 
hematological malignancies and prostate cancer by restoring the transcriptional activity of unfolded 
wild-type or mutant p53 [173]. Induction of apoptosis was observed upon its combination with 
cisplatin and fludarabine [174, 175] in p53-mutant cancer cells. This not only increases the scope for 
combining MDM2/MDMX inhibitors in the treatment of p53-mutant cancers but could also be 
exploited in treatment regimens where p53 is mutated after administration of MDM2 antagonists. 
2.12 Scope of thesis  
This project attempts to enumerate three ways by which targeting MDM2 in the clinics can be 
improved (Figure 2 10).   
1) Adapting the purpose of the drug. MDM2 inhibitors have been exploited for targeting 
tumor cells that retain wild-type p53. In this study, we used them to protect normal cells 
against the side effects of drugs causing replicative stress such as WEE1 inhibition and 
gemcitabine [176]. 
2) Combination with other drugs. In this case, we combined inhibitors of MDM2 with inhibitors 
of another negative regulator of p53, namely WIP1, and studied the impact of p53 activation 
in tumor cells. Indeed, upon combination, we observed that p53 was activated to a greater 
extent and induced a senescent phenotype [177]. 
3) Targeting the correct population of tumors. MDM2 has been an attractive target for 
liposarcomas due to amplification of the gene. However, as mentioned, there has been no 
progress in clinics reported so far. Apart from MDM2, Cyclin- Dependent Kinase 4 (CDK4) 
is frequently co-amplified in these cancers (~90%). CDK4 is a Ser/Thr kinase that 
phosphorylates its main substrate Rb [178]. This prevents the interaction of Rb with E2F1; 
thereby allowing cells to progress from the G1 to S-phase of the cell-cycle [179, 180]. 
Targeting MDM2 and CDK4 in combination seemed to be a plausible strategy to eliminate 
these cancers. Our studies indicated that this was untrue. We observed drug antagonism 
with respect to cell viability and p53 activity upon combination and discovered a novel 
interaction partner of p53, namely the CDK4-cyclin D1 complex.  
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Figure 2 10 Strategies to fortify p53 activity.  
In this thesis, we used three different strategies to target p53. We used inhibitors to MDM2-p53, WIP1-p53, and 
CDK4/6-cyclin D; thereby enabling us to understand the interplay of these combinations and the resulting 
outcome of the cells. 
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ABSTRACT
Pharmacological inhibition of the cell cycle regulatory kinase Wee1 represents 
a promising strategy to eliminate cancer cells. Wee1 inhibitors cooperate with 
chemotherapeutics, e. g. nucleoside analogues, pushing malignant cells from S 
phase towards premature mitosis and death. However, considerable toxicities are 
observed in preclinical and clinical trials. A high proportion of tumor cells can be 
distinguished from all other cells of a patient’s body by inactivating mutations in 
the tumor suppressor p53. Here we set out to develop an approach for the selective 
protection of p53-proficient cells against the cytotoxic effects of Wee1 inhibitors. 
We pretreated such cells with Nutlin-3a, a prototype inhibitor of the p53-antagonist 
Mdm2. The resulting transient cell cycle arrest effectively increased the survival of 
cells that were subsequently treated with combinations of the Wee1 inhibitor MK-
1775 and/or the nucleoside analogue gemcitabine. In this constellation, Nutlin-3a 
reduced caspase activation and diminished the phosphorylation of Histone 2AX, an 
indicator of the DNA damage response. Both effects were strictly dependent on the 
presence of p53. Moreover, Nutlin pre-treatment reduced the fraction of cells that 
were undergoing premature mitosis in response to Wee1 inhibition. We conclude 
that the pre-activation of p53 through Mdm2 antagonists serves as a viable option to 
selectively protect p53-proficient cells against the cytotoxic effects of Wee1 inhibitors, 
especially when combined with a nucleoside analogue. Thus, Mdm2 antagonists might 
prove useful to avoid unwanted side effects of Wee1 inhibitors. On the other hand, 
when a tumor contains wild type p53, care should be taken not to induce its activity 
before applying Wee1 inhibitors.
INTRODUCTION 
Inhibitors of the kinase Wee1 are capable of 
inducing cancer cell death with high efficiency, in 
particular when combined with chemotherapeutics such 
as nucleoside analogues [1] or platinum compounds [2]. 
In particular, the Wee1 inhibitor MK-1775 has been found 
efficient to eliminate a number of cancer cell species [3, 
4], and it is currently evaluated in numerous clinical trials 
( [5] and 21 entries to clinicaltrial.gov).
Wee1 is a cell cycle regulatory kinase. It 
phosphorylates and thereby inactivates the downstream 
cyclin dependent kinases (CDKs) 1 and 2 [6, 7]while 
the cell replicates its DNA (i. e. in S phase) [8]. This 
suppression of CDKs ensures that the cell will first 
complete the replication of the entire genome before 
moving on to mitosis. Removing Wee1 by siRNA, or 
inhibiting Wee1 by small compounds, results in the 
premature onset of mitosis, thereby increasing cell death 
[3, 4]. 
Wee1 inhibition can be regarded as a way to 
exploit replicative stress for cancer treatment, as we 
have reviewed recently [9]. Tumor cells often display 
impaired abilities to ensure a smooth and uninterrupted 
replication of their DNA. Further increasing this stress 
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situation represents a viable strategy of cancer therapy. 
This can be achieved by classical chemotherapeutics, e. 
g. nucleoside analogues. Representatives of this class 
include gemcitabine (2’, 2’-difluorodeoxycytidine, dFdC), 
an analogue of deoxycytidine. Gemcitabine inhibits 
ribonucleotide reductase, thus leading to a shortage and 
imbalance of available deoxyribonucleotide triphosphates. 
Moreover, it is incorporated into newly synthesized DNA, 
leading to torsional stress and replication fork stalling [10]. 
Interfering with the replication machinery is one example 
of targeting tumor-supportive cellular machineries for 
cancer treatment, as reviewed recently [11].
Wee1 inhibition and the consecutive activation 
of CDK1 can exacerbate replicative stress by at least 
three mechanisms. Firstly, we have recently identified 
a mechanism that leads from Wee1 inhibition to the 
inactivation of Chk1, a key enzyme required to re-enable 
DNA replication in the context of replicative stress 
[12]. Moreover, Wee1 inhibition increases nucleotide 
consumption and thereby increases replicative stress [13]. 
On top of this, however, Wee1 inhibition, by enabling 
premature CDK activity during S phase, promotes 
mitosis despite the fact that their DNA is incompletely 
replicated [1]. This will either disable the completion of 
mitosis, resulting in catastrophic death, or otherwise lead 
to the formation of two daughter cells with gross genetic 
deletions, again precluding survival. 
Despite the encouraging preclinical and clinical 
findings, Wee1 inhibitors have not achieved clinical 
approval yet. One of the problems faced when evaluating 
these drug candidates consisted in the toxicity that limited 
the amount of inhibitors that can be safely administered.
Such dose limiting toxicities include myelosuppression 
and tachyarrhythmia [5]. In other words, a better 
distinction between normal cells and the tumor cells in a 
patient’s body is required, and the cytotoxic effects should 
be limited to the tumor cells as much as possible.
The most frequent genetic difference between tumor 
cells and normal cells consists in mutations within the gene 
TP53, encoding the tumor suppressor and transcription 
factor p53 [14]. When activated, e. g. by phosphorylation 
through DNA damage-induced kinases, p53 induces the 
expression of genes that induce cell cycle arrest in G1 
or G2. Strong p53 activation, e. g. by excessive DNA 
damage, can also induce cell death, most notably by 
apoptosis [15]. More than 50% of all tumors, however, 
carry an inactivating mutation in TP53. This typically 
disables the encoded p53 protein from binding to its 
cognate promoter sequences, precluding transactivation. 
In these cases, pharmacological activation of p53 will only 
pertain to normal cells but not to tumor cells.
p53 activity is kept under tight control by its 
antagonist Mdm2. Mdm2 binds and inactivates p53, and 
on top of this, it acts as an E3 ubiquitin ligase to target p53 
for proteasomal degradation. The synthesis of Mdm2 is 
induced by p53, leading to a negative regulatory feedback 
loop. Small molecule inhibitors have been developed to 
bind Mdm2, precluding p53 from binding to the same site. 
As a result, these drugs can be used to augment the levels 
of active p53, even in the absence of DNA damage [16]. 
The prototype compound of this kind has been termed 
Nutlin-3a [17], but several similar drug candidates have 
been developed since and are currently under evaluation 
in clinical studies [18].
While mostly regarded as an inhibitor of cell 
survival, p53 can also be employed to protect cells. To 
this end, Mdm2 inhibitors can be employed to activate 
p53. We have first described the protective effect of 
Mdm2 inhibition in the case of nucleoside analogues, 
e. g. gemcitabine [19]. Since p53 arrests cells in G1 or 
G2, few cells replicate their DNA upon p53 activation by 
Mdm2 inhibitors, and nucleoside analogues can no longer 
be incorporated into nascent DNA strands. As a result, 
the cells become resistant to treatment with nucleoside 
analogues. When both drugs are washed off, the cells can 
resume proliferation with only short delays. An analogous 
approach was used to achieve protection against taxanes, 
i. e. drugs that target the mitotic spindle. Pre-treatment 
with Nutlin-3a precludes cells from entering mitosis, the 
most vulnerable phase of cells in the face of taxanes, and 
it thus ensures cell survival [20]. The protective effect of 
Mdm2 against mitotic inhibitors is active for several days 
and can be further enhanced by rapamycin [21]. Thus, p53 
activation can provide protection of p53-proficient cells 
against specific classes of drugs. This strategy dates back 
to the beginning of the millennium, when low-dose DNA-
damaging agents provided protection against microtubule-
active drugs through p53 [22, 23], a principle termed 
cyclotherapy [24].
Here we show that Mdm2 inactivation successfully 
protects p53-proficient cells against the cytotoxic effects 
of Wee1 inhibition. When p53 is pre-activated, Wee1 
inhibitors alone or in combination with gemcitabine 
no longer prevent long term proliferation and survival. 
Mechanistically, p53-activation keeps cells from the 
lethal premature mitosis that is otherwise induced by Wee1 
inhibition.
RESULTS 
Mdm2 inhibition allows cells to survive the 
treatment with Wee1 inhibitor and/or gemcitabine
To assess whether pre-treatment with an Mdm2 
inhibitor affects the survival of p53-proficient cells, we 
first treated U2OS cells (human osteosarcoma, p53 wild 
type) with Nutlin-3a, the prototype pharmacological 
antagonist that binds to Mdm2 and precludes its interaction 
with p53 [17]. After a 24 hrs incubation time, the cells 
were treated with gemcitabine and/or the Wee1 inhibitor 
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MK-1775 (termed Wee1i from here on) for another 24 
hrs, while maintaining the concentration of Nutlin-3a 
(simply termed Nutlin from here on) as before. For each 
drug, control experiments using the DMSO solvent were 
performed in parallel. Subsequently, all drugs were washed 
off, followed by further incubation in regular cell culture 
media. For twelve days, the cell density was monitored 
by transmission light microscopy and automated image 
analysis (Fig. 1A). Gemcitabine alone did not lead to a 
strong impairment of cell proliferation, and also Wee1i 
Figure 1: Nutlin protects cells against Wee1 inhibition and/or gemcitabine. A. U2OS, MCF10A, HCT116 p53+/+, and HCT116 
p53-/- cells were treated with Nutlin-3a for 24 hrs, followed by treatment with MK-1775 (Wee1i), gemcitabine and continuous incubation 
with Nutlin, at the indicated drug concentrations. After another 24 hrs, all drugs were removed and fresh medium was added. Cells were 
incubated for 8-13 days and confluency was measured each day using brightfield microscopy (Celigo cell cytometer). Error bars represent 
the SD, n=3 (triplicate experiments). B. U2OS cells were treated with 8µM Nutlin for 24 hrs, followed by treatment with 1µM Wee1i and 
300nM gemcitabine, along with continuous treatment with 8µM Nutlin. At 72 hrs, the cells were lysed using the CellTiter-Glo®Reagent, 
and cell viability was measured via an ATP-dependent luciferase signal. Student’s T-test p-values are stated above the horizontal bars. Error 
bars represent the SE, n=3.
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alone only moderately prevented cell growth. When 
applied together at the same concentrations, however, the 
two drugs strongly reduced the appearance of proliferating 
cells, essentially preventing the formation of a confluent 
layer, confirming the synergy that was described before 
[12, 25-28]. Strikingly, the pre-treatment with Nutlin 
rescued the proliferation of cells that were treated with 
Wee1i alone, and even more strongly reversed the effect 
of Wee1i and gemcitabine in combination. Parallel 
experiments were performed with the non-transformed 
cell line MCF10A. Interestingly this cell line was largely 
resistant to Wee1 inhibition. However, the cells responded 
to Gemcitabine or the combination of Gemcitabine with 
Wee1i, and in both cases, this effect was alleviated by 
Nutlin. To define the role of p53 in the protection by 
Nutlin, we employed HCT116 cells, a colon cancer-
derived cell line that had been engineered to either contain 
or lack wild type p53 [36]. In the case of HCT116 p53+/+ 
cells, we observed that cell proliferation on treatment with 
gemcitabine or Wee1i, and also upon co-treatment with 
Wee1i, was strongly reduced. However, in combination 
with Nutlin, we observed a rescue in cellular proliferation. 
In HCT116 p53-/- cells, however, no such rescue by 
Nutlin was observed. Thus, the protective effect of Nutlin 
is p53-dependent. We conclude that pre-treatment with 
Nutlin has an intense protective effect and allows cells to 
survive the treatment with Wee1i, alone or in combination 
with gemcitabine.
Next, we investigated whether Nutlin pre-treatment 
also affects immediate cell viability when cells are exposed 
to gemcitabine and/or Wee1i. To test this, we treated 
U2OS cells as above, followed by a 72 hrs incubation and 
a viability assay based on the determination of cellular 
ATP levels by luciferase (Fig. 1B). All three drugs – 
gemcitabine, Nutlin, and Wee1i – led to a reduction in 
viability, presumably through a combination of cell death 
and arrested proliferation. Wee1i, alone or in combination 
with gemcitabine, reduced viability most strongly. 
Importantly, however, Nutlin rescued the viability of 
Wee1i-treated cells, with or without gemcitabine. Thus, 
Nutlin pre-treatment strongly protects cells from the 
induction of death by Wee1i.
Mdm2 inhibition attenuates caspase activity and 
the phosphorylation of Histone2AX in response to 
Wee1 inhibition
Wee1i exerts its toxic effects, at least in part, by 
inducing a DNA damage response [8, 13] and apoptosis 
[29]. We therefore tested whether Nutlin pre-treatment 
reduces any or both of these responses. U2OS cells 
were pre-treated with Nutlin or the DMSO solvent, 
followed by gemcitabine and/or Wee1i. Subsequently, 
the cleavage of poly ADP-ribose polymerase (PARP), 
a bona fide caspase substrate [30], was monitored by 
immunoblot analysis; we also probed the phosphorylation 
of Histone2AX (γH2AX), a hallmark of the DNA 
damage response [31] (Fig. 2A). Wee1i induced PARP 
cleavage as well as a strong accumulation of γH2AX 
in the presence or absence of gemcitabine, as reported 
previously [12]. Notably, however, both responses were 
clearly reduced when the cells had been pre-treated with 
Nutlin. Similar results were obtained when blocking 
caspase activities by the cell-permeant pan caspase 
inhibitor Z-VAD-FMK, suggesting that γH2AX levels 
represent the direct result of a DNA damage response, 
not an indirect consequence of caspase activation. To 
confirm the reduction in γH2AX independently, we 
assessed its accumulation by immunofluorescence and 
subsequent digital image analysis (Fig. 2B and 2C), as 
described [32]. We observed the accumulation of γH2AX 
upon treatment with gemcitabine and Wee1i, alone or in 
combination. In each case, however, Nutlin pre-treatment 
led to a highly significant reduction in the accumulation 
of γH2AX. Finally, we assessed the activity of caspases in 
cell lysates obtained from U2OS cells after drug treatment. 
We observed increased activities in samples treated with 
Wee1i, alone or and in combination with Gemcitabine; 
again, however, this was rescued upon pre-treatment with 
Nutlin (Fig. 2D; Suppl. Fig. 1). In control samples treated 
with Z-VAD-FMK, no caspase activity was observed, 
validating the assay. Taken together, Mdm2 inhibition 
attenuates both the activation of caspases as well as DNA 
response signaling upon inhibition of Wee1.
The presence of p53 is required for the protective 
effect of Nutlin-3a against Wee1 inhibition
Mdm2 is mostly known for its impact on p53, but 
additional activities of Mdm2 have been reported [33], 
and some of them may be affected by Mdm2 antagonists 
as well. To assess whether Nutlin antagonizes Wee1i 
through p53, we first assessed whether it increases the 
levels of p53 and the product of a target gene, CDKN1A/
p21 [34], in U2OS cells (Fig. 3A). As expected, Nutlin led 
to the accumulation of p53 as well as p21. Importantly, 
neither the subsequent treatment with gemcitabine nor 
the exposure to Wee1i led to any gross changes in the 
levels of p53 or p21 when cells had been pre-treated with 
Nutlin. We did, however, observe the accumulation of p53 
but not p21 when the cells were treated with gemcitabine 
and/or Wee1i alone. This is in agreement with previous 
analyses indicating that DNA damage (as observed by 
γH2AX accumulation) during S phase stabilizes p53 but 
nonetheless attenuates the induction of p21 [35]. In any 
case, the effects of Nutlin on p53 levels and activity were 
not compromised by gemcitabine and/or Wee1i. 
To define the role of p53 in the negative impact of 
Nutlin on γH2AX accumulation, we transfected U2OS 
cells with siRNA to p53. This knockdown abolished the 
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Figure 2: Nutlin prevents caspase activation and γH2AX accumulation in response to Wee1 inhibitor and/or gemcitabine. 
A. U2OS cells were treated with 8µM Nutlin for 24 hrs, followed by treatment with 1µM Wee1 inhibitor, 300nM gemcitabine, and/or 8µM 
Nutlin in the absence and presence of 50µM ZVAD-FMK for another 24 hrs. Cells were harvested and immunoblot analysis was performed 
to detect poly-ADP ribose polymerase (PARP) and γH2AX. B., C. U2OS cells were treated as in (A). The cells were then fixed and stained for 
γH2AX by immunofluorescence. Detection and analysis was performed using automated immunofluorescence microscopy (BD Pathway). 
Figure panel (B) shows images of γH2AX staining for each treatment condition. Quantitation of γH2AX intensities was done using the 
BD pathway analysis tool and depicted in figure panel (C). Error bars represent the SD, n=3. D. U2OS cells were treated with 8µM Nutlin 
for 24 hrs, followed by treatment with 1µM Wee1 inhibitor, 300nM gemcitabine, 8µM Nutlin in the absence and presence (Supplementary 
Figure 1) of 50µM ZVAD-FMK for another 24 hrs. The cells were harvested and lysed for caspase activity assay. Fluorescent intensity 
measurements were obtained for each treatment. The activity (arbitrary units of fluorescence/min) was calculated for each treatment at the 
linear part of the curve (cf. Supplementary Figure 1). Error bars represent the S.D, n=3.
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influence of Nutlin on γH2AX (Fig. 3B), indicating that 
the protective effective of Nutlin against Wee1i depends 
on p53.
Next, we assessed the protective effect of Nutlin in a 
system of isogenic cells that only differ in their p53 status. 
HCT116 cells that either contained or lacked wild type p53 
[36] were employed for this purpose. Again, these cells 
were pre-treated with Nutlin, followed by gemcitabine 
and/or Wee1i, and the accumulation of cleaved PARP as 
well as γH2AX was assessed by immunoblot analysis 
(Fig. 3C). In the case of cells containing wild type p53, 
Nutlin prevented both caspase activity and the DNA 
damage response, similar to U2OS cells. When TP53 had 
been deleted, however, Nutlin did not influence any of 
these responses. In conclusion, p53 is strictly required for 
the protective effects of Nutlin against Wee1i. Thus, p53 
activity is the principal mediator of this protection.
Figure 3: p53 is required for the protective effect of Nutlin. A. U2OS cells were treated with 8µM Nutlin for 24 hrs, followed 
by treatment with 1µM Wee1 inhibitor, 300nM gemcitabine and 8µM Nutlin for another 24 hrs as indicated. Cells were harvested and 
immunoblot analysis was performed to detect p53 and its target gene product p21. B. U2OS cells transfected with siRNA were treated 
with 8µM Nutlin at 24 hrs post-transfection, then incubated for additional 24 hrs, followed by treatment with 1µM Wee1 inhibitor, 300nM 
gemcitabine and 8µM Nutlin for another 24 hrs as indicated. Immunoblot analysis was performed to detect p53 and its target gene product 
p21, as well as γH2AX. C. An isogenic pair of HCT116 cells with or without a targeted deletion of TP53 was pre-treated with 8µM Nutlin 
for 24 hrs, followed by treatment with Wee1 inhibitor, gemcitabine and Nutlin for another 24 hrs. Cells were harvested and subjected to 
immunoblot analysis to detect PARP and γH2AX.
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Nutlin-3a prevents the accumulation of cells 
in premature mitosis when exposed to Wee1 
inhibitor
Wee1 acts to prevent the premature onset of mitosis, 
and its inhibition is known to trigger chromosome 
condensation and cell division, even before the replication 
of cellular DNA is complete. This condition – often 
referred to as premature mitosis – leads to a catastrophic 
situation and cell death [1]. Premature mitosis is even 
further enhanced when Wee1 inhibitors are combined with 
DNA-damaging agents, such as nucleoside analogues or 
platinum compounds [12, 25, 26, 28]. On the other hand, 
p53 often prevents even the entry of cells into S phase, 
or otherwise acts to block the transition into mitosis [37]. 
We therefore tested whether Mdm2 inhibition and p53 
activation might prevent premature mitosis when cells are 
exposed to Wee1i. Firstly, we determined the amount of 
U2OS cells actively synthesizing DNA upon pre-treatment 
with Nutlin and/or subsequent treatment with Wee1i (Fig. 
4A). Nutlin strongly reduced the number of cells in S 
phase, as determined by the incorporation of the labeling 
nucleoside analogue 5-ethynyl-2’-deoxyuridine (EdU) 
andreported previously [19]. Notably, the treatment with 
Wee1i also reduced the amount of EdU-incorporating 
cells, presumably due to interruptions in S phase. 
However, even in this situation, Nutlin further reduced 
the percentage of DNA-synthesizing cells, arguing that 
Nutlin keeps cells out of S phase regardless of subsequent 
Wee1i treatment. And indeed, propidium iodide staining of 
the cells revealed that Nutlinpretreated cells were largely 
accumulating with a DNA content corresponding to G1 
or G2/M, regardless of their subsequent treatment (Suppl. 
Fig. 2).
Next, we compared the extent of entry into 
mitosis when U2OS cells were treated with Wee1i and/
or gemcitabine, in the presence or absence of Nutlin 
pre-treatment. Wee1i, alone or in combination with 
gemcitabine, strongly augmented the accumulation of 
Histone3 (H3) that was phosphorylated at Serine 10, a 
marker of cells in mitosis [38] (Fig. 4B). Of note, however, 
Nutlin pre-treatment reduced the phospho-H3 signal in all 
combinations of Wee1i and gemcitabine. Thus, Nutlinpre-
treatment reduces the accumulation of mitotic cells upon 
exposure to Wee1i. 
Similar investigations were carried out in isogenic 
HCT116 cells with or without p53. Again, these cells were 
pre-treated with Nutlin, followed by gemcitabine and/or 
Wee1i, and the accumulation of Histone 3 (H3) that was 
phosphorylated at Serine 10 was assessed by immunoblot 
analysis (Fig. 4C). As expected, Wee1i increased the 
levels of phospho-H3, whereas Nutlin prevented this 
accumulation. Importantly, however, this was only 
observed in p53-proficient cells. When p53 was absent, 
Wee1 inhibition still induced phospho-H3 accumulation, 
but this was not affected by Nutlin.
Immunoblot analysis does not distinguish 
between regular and premature mitosis. In order to find 
out how Nutlin affects the accumulation of cells that 
prematurely enter cell division, we treated U2OS cells 
with combinations of the three drugs, followed by two-
dimensional flow cytometry, quantifying both the DNA 
content and the amount of phosphorylated H3 in every 
cell (Fig. 4D and 4E). Cells with a DNA content below 
4N but a phospho-H3 content above the baseline were 
considered prematurely mitotic. As expected, Wee1i 
led to the accumulation of cells in premature mitosis, 
especially when combined with gemcitabine. However, 
this number was strongly reduced when pre-treating 
the cells with Nutlin . We conclude that Nutlin prevents 
premature mitosis in cells that are confronted with Wee1i, 
alone or in combination with gemcitabine. We propose 
that this mechanism is at least partially responsible for the 
protection of Wee1i-treated cells against Nutlin.
DISCUSSION
According to our results, the pharmacological 
inhibition of Mdm2 prevents the toxicity of a Wee1 
inhibitor, in the presence or absence of the nucleoside 
analogue gemcitabine. In agreement, the Mdm2-inhibitor 
Nutlin prevents the accumulation of phosphorylated H2AX 
and the activation of apoptosis in response to Wee1i. 
As expected, this protective effect conferred by Nutlin 
strictly requires the presence of p53. Mechanistically, 
p53 diminishes the onset of premature mitosis by Wee1i 
and/or gemcitabine. We propose that Nutlin, by inducing 
the CDK inhibitor p21, interferes with G1-S transition 
and thus prevents replicative stress in the first place. In 
addition, p21 also attenuates CDK1 activity [39] and may 
thereby diminish premature mitosis even in those cells that 
nonetheless entered S phase (Fig. 5).
These observations are suggesting two major 
conclusions. Firstly, the therapeutic effect of Wee1 
inhibitors may be reduced or even abolished if wild type 
p53 is activated prior to Wee1 inhibition. This not only 
argues against the combination of Mdm2 inhibitors with 
Wee1 inhibitors to treat p53-wildtype cancers. Rather, 
p53 is activated by most DNA-damaging therapeutic 
regimens, including irradiation and chemotherapy, e. g. by 
platinum compounds, topoisomerase inhibitors, alkylating 
agents, and many others [40]. When combining any of 
these chemotherapeutics with Wee1 inhibitors, it appears 
advisable to administer the Wee1 inhibitor before or at 
least simultaneously with chemotherapy, but not shortly 
after it. Otherwise, it is conceivable that the pre-activated 
p53 will interfere with cell cycle progression and thus with 
the efficacy of Wee1 inhibitors. In contrast, the presence 
of wild type but not pre-activated p53 does not seem to 
preclude the cytotoxic activity of a Wee1 inhibitor  [41]. 
Notably, these considerations only applies to tumors that 
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Figure 4: p53 prevents accumulation of cells in premature mitosis. A. U2OS cells were treated with 8µM Nutlin for 24 hrs, 
followed by treatment with 1µM Wee1 inhibitor and 8µM Nutlin for another 24 hrs. Two hours before fixation, 5µM of 5-Ethynyl-2’-
deoxyuridine (EdU) was added. Afterwards, cells were stained for EdU, and the percentage of cells with EdU staining intensities of 800 
unitsor more was plotted. Error bars represent the SD, n=3. B. U2OS cells were treated with 8µM Nutlin for 24 hrs, followed by treatment 
with 1µM Wee1 inhibitor, 300nM gemcitabine and 8µM Nutlin for another 24 hrs. Immunoblot analysis was performed to detect Histone3 
with a phosphorylation at Serine 10, a hallmark of mitosis. C. An isogenic pair of HCT116 cells with or without a targeted deletion of TP53 
was pre-treated with 8µM Nutlin-3 for 24 hrs, followed by treatment with Wee1 inhibitor, gemcitabine and Nutlin for another 24 hrs. Cells 
were harvested and subjected to immunoblot analysis to detect Histone H3 with a phosphorylation at Serine 10, p53, and total histone H3. 
D., E. U2OS cells were pre-treated with nutlin-3 as in Fig. 2B and 2C, followed by treatment with 1µM Wee1 inhibitor, 300nM gemcitabine 
and 8µM Nutlin for 8 hrs. The cells were fixed, stained for phospho-H3 along with propidiumiodide (PI) labelling, and analyzed by flow 
cytometry. The red boxes demarcate cells in premature mitosis. Figure panel (D) represents the percentage of cells stained positive for 
phospho-H3. 
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retain wild type p53, thus in about 50% of all human 
malignancies.
Secondly, our results suggest a strategy that may 
ultimately help to prevent unwanted toxicities of Wee1 
inhibitors. Such toxicities, e. g. myelosuppression and 
tachyarrhythmia, have been reported [5] and may currently 
limit the usefulness of this class of drugs, especially when 
combining them with conventional chemotherapy, and 
despite their highly promising anti-cancer activity in 
preclinical models [2, 25, 26, 28, 42-47]. In those cases 
where p53 is absent or mutant and thus unable to activate 
its target genes, the administration of Nutlin or similar 
Mdm2 inhibitors will not interfere with the efficacy of 
Wee1 inhibitors against tumor cells, as exemplified by 
p53-/- HCT116 cells in this study (Fig. 3B). However, 
normal cells from such patients still contain wild type p53. 
The reversible activation of p53 by an Mdm2 antagonist 
can thus be expected to attenuate the toxic effects imposed 
by Wee1 inhibitors on non-cancerous cells. Thus, besides 
their use to eliminate cancer cells that contain wild type 
p53 but hyperactive Mdm2, Mdm2-inhibitors may prove 
useful as a means to prevent unwanted side effects of 
Wee1 inhibitors.
Such a use of Mdm2 inhibitors for avoiding the 
toxicities of cancer treatment is not limited to Wee1-
inhibitors. Rather, Nutlin and related compounds were 
suggested to prevent the side effects of other anti-cancer 
compounds. We have previously found that Nutlin also 
acts to reduce the toxicities of nucleoside analogues in 
p53-proficient cells [19], and similar protective effects 
have been reported for taxanes[20, 48], HDAC inhibitors 
[49], resveratrol, [50], and other chemotherapeutics 
[51-56]. Furthermore, the protective effect of Mdm2-
inhibitors is to be expected for any compound that 
affects cell survival predominantly in S or M phase. 
This includes inhibitors of Chk1 [57] and ATR [58], 
which increase replicative stress and promote premature 
mitosis; when combined with platinum compounds and 
Figure 5: Depiction of protective mechanisms triggered by Mdm2 inhibition. Gemcitabine halts progression through S phase 
by interfering with DNA replication. In the presence of Wee1 inhibitors, hyperactive CDK1 triggers premature mitosis despite incomplete 
DNA replication, usually resulting in cell death. When Mdm2 inhibitors activate p53 and thereby increase the levels of the CDK inhibitor 
p21, the transition from G1 to S phase is inhibited. Moreover, CDK1 inhibition by p21 reduces premature entry in mitosis. Taken together, 
pre-treatment of p53-proficient cells with an inhibitor of Mdm2 attenuates the cytotoxic effects of Wee1 inhibition. In the scheme, activators 
of cell cycle progression are depicted in red, inhibitors of cell cycle progression in blue, and drugs in green. Arrows indicate activation, 
lines that end with a bar indicate inhibition.
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anthracyclines, the same was observed for inhibitors of 
MK2 [59]. Inhibition of Chk1 and Wee1 in combination 
was particularly effective [1, 45, 46] but faces the risk of 
unacceptable toxicities, which may be ameliorated by pre-
treatment with Mdm2 inhibitors. Furthermore, substances 
with predominant toxicity to cells in mitosis are no 
longer limited to taxanes. Rather, tubulin stabilizers like 
epothilones as well as signaling inhibitors that preclude 
a smooth transition through mitosis, e. g. inhibitors of 
aurora or polo-like kinases [60], also represent suitable 
candidates for combination with Mdm2 antagonists, to 
limit their toxicities to normal cells. All these approaches 
would take advantage of the most commonly encountered 
genetic difference between human malignancies and 
non-transformed cells, i. e. a mutation in TP53, to tailor 
therapeutic strategies specifically towards cancer cells 
and away from other cells in a patient’s body. In this 
way, it is expected that therapies will not only become 
more tolerable to a patient, but that the maximum doses 
of tumor-drugs can be augmented to increase therapeutic 
efficacy.
As a word of caution, the side effects of Mdm2 
antagonists need to be considered in these strategies as 
well. At present, not much is known about how well such 
antagonists are tolerated, but a dozen phase I studies with 
Mdm2 antagonists have been registered (clinicaltrials.
gov). It is conceivable that Mdm2 inhibition may increase 
the death of those cells that are particularly sensitive 
towards p53 (an unwanted on-target effect). A recent study 
on mice with a global but inducible genetic ablation of 
Mdm2 revealed that such sensitive tissues not only involve 
the bone marrow and the gut, but also the kidney [61]. 
However, an important difference between this model and 
pharmacological antagonists is the transient nature of the 
latter. While the genetic ablation of Mdm2 is complete 
and permanent, pharmacological Mdm2-inhibitors can 
abrogate Mdm2 activity to an extent that can be adapted to 
the situation, and Mdm2 can quickly revert to normal p53 
antagonism after discontinuing drug administration. The 
impact of Nutlin alone on the survival was only moderate 
in most cases of a panel of p53-proficient cell lines [62, 
63]. Only in cells with high amplifications of the Mdm2 
gene, cells appear to become addicted to this oncogene, 
rendering them exquisitely sensitive to Nutlin [62]. Since 
such amplifications are not present in normal cells, we 
expect that toxicities of Mdm2-antagonizing drugs will be 
manageable. The same is true for other reported effects of 
Nutlin, such as DNA breakage [64]or endoreduplication 
[65] in some cell lines. However, careful assessment of 
ongoing clinical trials involving Mdm2 antagonists will be 
required. This will then help to avoid unwanted toxicities 
by adapting the drug doses and schedules, and possibly by 
chemically modifying the drugs to reduce their impact on 
p53-sensitive normal tissues. Moreover, the combination 
of Mdm2 antagonists with Wee1 inhibitors will require 
evaluation in animal models before being taken to the 
clinics.
Taken together, our results suggest that p53 is an 
important determinant of how Wee1 inhibitors can be used 
in the clinics. On the one hand, p53 activation in tumor 
cells must be avoided to prevent negative drug interference 
with Wee1 inhibitors when a tumor carries wild type p53. 
On the other hand, however, in p53-mutant tumors, the 
administration of an Mdm2 antagonist appears as a highly 
promising opportunity to circumvent the toxicities of 
Wee1 inhibitors and many other drugs that act in a cell 
cycle specific manner.
MATERIALS AND METHODS
Culturing of human cell lines
U2OS (human osteosarcoma) and HCT116 
(colorectal carcinoma) cells were cultured in DMEM and 
McCoy’s, respectively,with 10% FCS, 200µM L-glutamine 
and antibiotics – 50U/ml Penicillin and Streptomycin, and 
10µg/ml Ciprofloxacin (Bayer). In addition, medium for 
U2OS cells contained 20µg/ml Tetracycline. All media 
and chemicals except Ciprofloxacin were from Invitrogen. 
MCF10A (non-transformed breast epithelial) cells were 
cultured in DMEM/F-12 with 5% horse serum (Sigma 
H1138), 0.5µg/ml hydrocortisone (Sigma H-0888), 
0.1µg/ml cholera toxin (Sigma C-8052), 20ng/ml Human 
EGF(Sigma E-9644), and 1:1000 Insulin (Sigma I-9278).
Preparation of whole cell lysates
Cells were seeded in 6-well plates (1.6 x 105 
cells per well) for the drug treatment. Cell lysates were 
prepared on ice. The cells were scraped off into the 
medium and pelleted by centrifugation at 1500xg for 
3 min at 4°C, followed by one wash in PBS. The cells 
were resuspended in 100µl RIPA lysis buffer (1% Triton 
X, 1% desoxycholate, 0.1% SDS, 150 mMNaCl, 10 mM 
EDTA, 20 mMTris-HCl pH 7.5, 100.000KIE Aprotinin) 
freshly supplemented with 2M urea, 1mg/ml leupeptine/
aprotinine, 0.1M pepstatin A, 0.1M pefabloc. After 20 
min of shaking at 4°C, the lysates were centrifuged at 
15,700xg for 10min. Bicinchoninic acid (BCA) assay 
was used to normalize the concentration of proteins in the 
supernatant. The samples were then boiled with Laemmli 
buffer, followed by SDS-PAGE.
Transfection of human cells
Using lipofectamine 2000, we carried out transient 
transfection of U2OS cells with siRNA to knock-down 
p53, and a corresponding control siRNA as a control. 
Lipofectamine and siRNA were dissolved separately 
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in DMEM only (without FCS, or and antibiotics) and 
incubated at room temperature (RT) for 5 min. They were 
then combined and incubated for another 20 min at RT. 
In one well of a 6-well plate, 280,000 cells were seeded 
in 1.6 mL DMEM with 10% FCS, and 400 μL of the 
lipofectamine-siRNA mix was added drop-wise, followed 
by a 48 hrs incubation. 
Immunoblot analysis
Blots on nitrocellulose or PVDF membranes were 
stained with the following antibodies. Phosphorylated 
Ser 139 H2AX (05-636, Millipore), PARP (9542, Cell 
Signaling Technology), beta-Actin (ab6276-100, Abcam), 
phospho-H3 Ser 10 (3377, Cell signaling), p53 (sc-126, 
Santa Cruz Biotech), p21 (OP64, Calbiochem). Secondary 
antibodies coupled to horseradish peroxidase H3 (ab1791, 
Abcam) (Jackson Immunoresearch) were used for 
chemiluminescent detection (Millipore).
Immunofluorescence analysis
For immunofluorescence microscopy, the automated 
microscope Pathway 855 (Becton Dickinson, Franklin 
Lakes, NJ, United States) was used to read fluorescence 
intensity in 96-well plates. For confocal microscopy, 
the LSM 510 laser scanning microscope (Carl Zeiss, 
Germany) was used.
The cells were fixed in 3.7% paraformaldehyde for 
20 min, followed by permeabilization with 0.5% Triton-X 
in PBS for 15 min and blocking for 15 min using blocking 
solution (3% BSA in PBS). The primary antibody to 
phospho-H2AX (05-636, Millipore), diluted in blocking 
solution, was added for 1 h, followed by incubation with a 
secondary antibody (Alexa-Fluor 546) and Hoechst 33342 
(Invitrogen) diluted in blocking solution for 45 min.
For EdU staining, permeabilization was followed 
by exposure to Click- iTEdU reaction cocktail (C10351, 
Invitrogen) for 30 min. The cell nuclei were counterstained 
with Hoechst 33342. 
Images were captured and analyzed using the BD 
Pathway software, wherein the region of interest (ROI), 
in this case the cell nuclei, were defined by Hoechst 
stain, and the average intensity of the antibody-coupled 
fluorescence within each ROI was determined. 
Caspase activity assay
Cells were seeded in 6-well plates (1.6 x 10 (to the 
power of 5) cells per well) and treated with drugs. 24 
hrs post-treatment, the cells were harvested (inclusive of 
medium) and centrifuged at 1500xg for 5 min at 4oC. The 
pelleted cells were resuspended in 250µl caspase lysis 
buffer (1M Tris-HCl, 2mM MgCl2, 150mM NaCl, 10mM 
DTT, Roche complete mini protease-inhibitor mix). They 
were shock-frozen thrice in liquid nitrogen and centrifuged 
at 15,000xg for 15 min at 4oC. 40µl of lysate per well in 
a 96-well plate was distributed in triplicates. 10µl of Ac-
DEVD-AMC substrate (working concentration 25µM) 
(ALX-260-031 Enzo) was added to each sample. Caspase 
activity was measured using a fluorometer (Synergy MX 
267137) at excitation wavelength 380nm and emission 
wavelength 460nm every 10 min for 4 hrs at 37oC. 
Cell cycle analysis by flow cytometry
Cells were seeded in 6-well plates and treated with 
the drugs. After fixation in ethanol, the cells were washed 
in wash solution (0.05% Triton-X in PBS), followed by 
incubation in staining solution (2% FCS, 0.2% Triton-X in 
PBS) with phospho-H3 antibody (3377, Cell signaling) for 
2 hrs and then with secondary antibody (coupled to Alexa-
Fluor 488) for one hour. Subsequently, the cells were 
resuspended in 0.5 mg/ml RNAse A solution andincubated 
for 30 min at 37°C. Directly before measurement, 
propidium iodide (final concentration: 30 µg/ml) was 
added. Samples were measured using the flow cytometer 
Guava PCA-96 Base System (Millipore).
Cell proliferation assay
Cells were seeded in 96-well plates or 24-well 
plates, treated after 18-24 hrs, and the confluency of 
the cells was measured using a Celigo cell cytometer 
(Cyntellect; labeled as Day0). After 24 hrs, the medium 
was replaced with fresh media; the confluency was 
determined again (Day1); subsequent measurements were 
made every 24 hrs and media was changed every 48 hrs.
Cell viability assay
Cells were seeded in 96-well plates with white 
walls and bottom and treated after 18-24 hrs. Cells 
treated with DMSO in a concentration which responds to 
the highest concentration of the drugs added were used 
as a control. Remaining wells without cells were filled 
with medium in order to obtain a value for background 
luminescence. Each experiment was incubated for 72 
hrs. For measuring the luminescence, the CellTiter-
Glo®Luminescence Cell Viability Assay (Promega) was 
used. CellTiter-Glo®Reagent was added in a 1:1 ratio to 
the cell culture medium in a well. The plate was placed 
on an orbital shaker for 10 min for induction of cell lysis. 
Subsequently, the luciferase signal was measured on a 
LuminometerDLReady™Centro LB 960 reader. 
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Statistical analysis
Statistical significance was determined using the 
unpaired, two-tailed Student’s T-test. Significance was 
assumed for p-values below 0.05. Asterisks in figures 
indicate resulting p-values as follows: * p < 0.05, ** p 
< 0.01, *** p < 0.001. n.s. = not significant. n in figure 
legends indicates the number of independent experiments.
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ABSTRACT
Targeting the Mdm2 oncoprotein by drugs has the potential of re-establishing 
p53 function and tumor suppression. However, Mdm2-antagonizing drug candidates, 
e. g. Nutlin-3a, often fail to abolish cancer cell growth sustainably. To overcome 
these limitations, we inhibited Mdm2 and simultaneously a second negative regulator 
of p53, the phosphatase Wip1/PPM1D. When combining Nutlin-3a with the Wip1 
inhibitor GSK2830371 in the treatment of p53-proficient but not p53-deficient cells, 
we observed enhanced phosphorylation (Ser 15) and acetylation (Lys 382) of p53, 
increased expression of p53 target gene products, and synergistic inhibition of cell 
proliferation. Surprisingly, when testing the two compounds individually, largely 
distinct sets of genes were induced, as revealed by deep sequencing analysis of 
RNA. In contrast, the combination of both drugs led to an expression signature that 
largely comprised that of Nutlin-3a alone. Moreover, the combination of drugs, or the 
combination of Nutlin-3a with Wip1-depletion by siRNA, activated p53-responsive 
genes to a greater extent than either of the compounds alone. Simultaneous inhibition 
of Mdm2 and Wip1 enhanced cell senescence and G2/M accumulation. Taken together, 
the inhibition of Wip1 might fortify p53-mediated tumor suppression by Mdm2 
antagonists.
INTRODUCTION
The tumor suppressor p53 is mutant in roughly 50% 
of all human malignancies, making it the most frequently 
mutated gene in human cancers. However, this notion also 
implies that another 50% of cancers still carry wild type 
p53 and nonetheless become malignant. In these cases, 
the tumor-suppressive activity of p53 is attenuated by 
regulatory mechanisms [1].
The best-characterized activity of p53 consists in 
transcriptional activation, through binding to its cognate 
promoter elements and recruiting transcription initiation 
factors as well as chromatin modifiers. This activity can be 
induced by cell stress signaling events, through a cascade 
of phosphorylations and acetylations. The p53-responsive 
genes and their products induce cell cycle arrest and/
or senescence (e. g. p21/CDKN1A), or apoptosis (e. g. 
Puma/BBC3). A third set of p53-inducible genes provides 
negative feedback on p53 activity, thereby attenuating the 
initial p53 response. 
The expression of the negative regulator Mdm2 
can be induced by p53. The Mdm2 protein binds to p53 
and interferes with transactivation. Moreover, Mdm2 is 
an E3 ubiquitin ligase, leading to p53 ubiquitination and 
proteasomal destabilization. The Mdm2 gene is amplified 
in a considerable proportion of malignant tumors, most 
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notably in sarcomas. In these cases, excessive amounts 
of Mdm2 largely abolish the tumor suppressive activity 
of p53. However, even when the copy number of the 
Mdm2 gene is normal, the p53-antagonizing activity of 
Mdm2 can still be exaggerated in tumors. The most well-
established mechanisms for this consist in the silencing 
of a negative regulator of Mdm2, p14ARF (the second 
product of the gene CDKN2A), or in the enhanced 
expression of the heterodimerization partner of Mdm2, 
MdmX/Mdm4 [2]. 
Given the frequent silencing of p53 by the Mdm2 
oncoprotein in tumors, it is conceivable that disrupting the 
interaction between the two proteins might re-establish 
p53-mediated tumor suppression [3]. Furthermore, the 
p53-binding structure on Mdm2, a hydrophobic pocket 
domain, can be occupied by a small molecule, making this 
one of the earliest example of “drugging” a protein-protein 
interaction. The most established compound to achieve 
this is Nutlin-3a [4], shortly referred to as Nutlin from 
here on. Nutlin binds to Mdm2, competing with p53. As a 
consequence, p53 becomes more active as a transcription 
factor and accumulates as a relatively stable protein, due 
to the lack of ubiquitination by Mdm2 [4]. 
Most cells respond to Nutlin largely by a reversible 
cell cycle arrest. Only a few cell lines - the majority of 
which containing heavily amplified Mdm2 - respond with 
apoptosis, thus rendering the drug efficient in cell killing. 
In the meantime, a number of drug candidates with similar 
structure and/or activity as Nutlin have been developed 
and have entered clinical trials [3, 5]. A major concern in 
these trials consists in a possible lack of efficacy. Since 
many tumor cells merely arrest in response to Nutlin but 
resume proliferation once the drug is taken off, the clinical 
response might be transient at best. One way to get around 
this problem is to select tumors with a high frequency of 
Mdm2 amplifications, e. g. dedifferentiated liposarcomas 
[6, 7]. Another way to fortify the efficacy of Nutlin and 
related drugs would be to combine them with additional 
compounds. This require targets that, when inactivated 
along with Mdm2, trigger an additive or even synergistic 
response.
Besides Mdm2, at least one additional p53-
responsive gene product antagonizes p53 activity. The 
gene Wip1/PPM1D, originally named after its plant 
homologue “wound-induced protein” [8], is induced by 
p53 [9]. Its product is a phosphatase that dephosphorylates 
a variety of proteins that are substrates to the kinase 
Ataxia Telangiectasia Mutated (ATM) [10] or related 
DNA damage-responsive pathways, e. g. ATM itself, 
Chk2 [11, 12], Chk1 [13] Histone 2AX [14-16], Mdm2 
[17] and p53 [13, 18]. The phosphorylation of p53 
near its aminoterminus (e. g. at the residues Ser15 and 
Ser20) facilitates the association of acetyl transferases 
(e. g. p300 and CBP) with p53 and the subsequent 
acetylation of carboxyterminal residues [19]. This in turn 
enhances the binding of p53 to its target promoters. The 
phosphorylated aminoterminal domain then activates 
transcription, rendering p53 phosphorylation an essential 
trigger for gene activation [19]. When p53 induces Wip1, 
the dephosphorylation of p53 counteracts this activity 
and thus provides a negative feedback, similar to Mdm2. 
Like Mdm2, Wip1 can drive malignancy. This can 
happen through gene amplification, but also by truncating 
mutations near the 3’ end of the coding region, destroying 
a negative regulatory domain of the Wip1 protein [20-24]. 
Most Wip1/PPM1D-amplified tumors harbor wild type 
p53, further arguing that the inactivation of p53 is at least 
one of the major activities of Wip1 [25].
Specific Wip1 inhibitors have recently been 
designed. In particular, the drug candidate GSK2830371 
was shown to efficiently and specifically interfere with the 
phosphatase activity of Wip1 through allosteric inhibition 
[26]. These inhibitors increase the phosphorylation of 
Wip1 substrates, including p53, and lead to a moderate 
increase in the expression of some p53 target genes. 
However, the cytotoxic efficacy of the inhibitors seemed 
moderate [26].
Of note, Mdm2 and Wip1 are acting by largely 
independent mechanisms. While Mdm2 triggers the 
degradation of p53 through the proteasome, Wip1 
dephosphorylates its transactivating domain. This argues 
that inhibiting just one of these antagonists may be 
insufficient for full p53 activation. Instead, it would be 
more plausible to boost p53 activity by targeting both 
of these major antagonists simultaneously. In fact, the 
depletion or inactivation of both Wip1 and Mdm2 yields 
strong p53 activity [27-30].
Here we show that the combined inhibition of 
Mdm2 and Wip1 indeed abolishes cell proliferation in 
a synergistic and sustainable fashion. When applied 
together, Nutlin-3a and GSK2830371 induce strong 
accumulation of phosphorylated and acetylated p53. They 
also induce the accumulation of p53 target gene products 
in a p53-dependent fashion. Importantly, the genes 
induced by Mdm2 inhibition vs. Wip1 inhibition alone 
were largely distinct. Combining both drugs, however, 
primarily activated a large set of p53-responsive genes. 
Many of these genes were induced to a greater extent 
by the combination, rather than by Nutlin alone. Taken 
together, inhibiting Mdm2 and Wip1 simultaneously may 
represent a viable strategy to achieve strong p53 activation 
and permanent growth arrest, thereby diminishing or even 
preventing tumor progression.
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RESULTS
Combined inhibition of Mdm2 and Wip1 
synergistically diminishes cell proliferation
We tested the efficacy and sustainability of 
treatment with the Mdm2 inhibitor Nutlin-3a (Nutlin), the 
Wip1/PPM1D inhibitor GSK2830371 (Wip1i), and their 
combination. The cell lines chosen for this study were 
MCF-7 (breast carcinoma) and U2OS (osteosarcoma), 
based on their known amplification (MCF-7) [23] or 
activating truncation (U2OS) [20] of Wip1. After treating 
the cells for 48 or 72 h, the drugs were removed and 
the cells were continuously incubated for ten days. Cell 
proliferation was followed by automated translucent 
Figure 1: Synergistic impairment of cell proliferation by inhibition of Mdm2 and Wip1. A. Co-treatment by Wip1i and 
Nutlin impedes cell growth in MCF-7 and U2OS cells. MCF-7 and U2OS cells were treated with Nutlin-3a (Nutlin), GSK2830371 (Wip1i) 
and its combinations at the indicated concentrations. After 48h and 72h of treatment, the drugs were removed and fresh medium was 
added. Cell confluency was measured every day using bright field microscopy (Celigo cell cytometer). Media was changed every 2-3 
days, explaining the fluctuations in cell proliferation. B. Synergistic activity of Nutlin and Wip1i on MCF-7 and U2OS cells. MCF-7 and 
U2OS cells were treated with Nutlin and Wip1i at their IC25 and IC50, respectively, with continuous incubation. The cell confluency was 
measured daily as in A. Using the Chou-Talalay method [31], the combination index (CI) was calculated. At day 6, strong synergism was 
reflected by CI values way below 1.
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microscopy. Both drugs were used at concentrations known 
to increase p53 levels or to enhance the phosphorylation of 
ATM substrates (Supplemental Figure S1). Nonetheless, 
neither of the drugs prevented cell proliferation over 
this period of time, although Wip1 inhibition did slow 
down the growth rate to some extent. In contrast, the 
combination of both inhibitors profoundly compromised 
the outgrowth of both cell lines and prevented confluency 
over the entire duration of the experiment, with the MCF-7 
cells being particularly responsive (Figure 1A). Thus, the 
two drugs did cooperate to abolish cancer cell proliferation 
in a sustainable fashion.
To determine whether the two compounds act in 
a formally synergistic way, we first determined the drug 
concentrations that reduce cell proliferation by 25% or 
50% (IC25 and IC50, respectively). The drugs were then 
continuously applied to the cells at IC25 and IC50, alone 
or in combination, and the reduction in proliferation was 
determined six days after drug removal (Figure 1B). 
This allowed us to calculate the combination index (CI) 
according to the algorithm by Chou and Talalay [31]. As 
a result, CIs far below 1 were obtained, indicating strong 
synergism between the drugs. Thus, inhibition of Mdm2 
and Wip1 not only add up to impair cell growth, but they 
truly synergize to provide permanent growth arrest.
Figure 2: Accumulation of phosphorylated and acetylated p53 upon combined treatment. A. MCF-7 and U2OS cells were 
treated with Nutlin and Wip1i as indicated. After 24 h, immunoblot analysis was performed to assay for the activation of p53 - phospho p53 
and acetylated p53 - and its target gene products p21 and Mdm2. Actin staining served as the loading control.
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Figure 3: Activation of the p53 response upon co-treatment with Nutlin and Wip1i, dependent on p53 A. Co-treatment 
with Nutlin and Wip1i leads to a p53 dependent response. An isogenic pair of HCT116 cells with and without a targeted deletion of TP53 
[32] was treated with Nutlin and Wip1i as indicated. After 24 h, the cells were harvested to prepare protein lysates. Immunoblot analysis 
was performed to determine the amounts of p53 and its target gene products. B. Decrease in cell proliferation upon combined treatment is 
dependent on p53. Confluency for HCT116 cells with or without p53 was monitored for 5 days. The cells were treated with DMSO, Nutlin, 
Wip1i and their combination for 48h and 72h. Then, fresh medium was added and cell proliferation was monitored. 
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In combination with Wip1 inhibitor, Nutlin 
induces the accumulation of phosphorylated and 
acetylated p53
To elucidate the mechanism of action underlying 
this drug synergism, we assessed the levels and 
modifications of p53, as well as the levels of p53-
inducible gene products by immunoblot analysis. Wip1 
inhibition alone did not detectably affect the activity of 
p53 in MCF-7 cells, whereas in U2OS cells, it mildly 
increased the phosphorylation of p53 at serine 15 and its 
acetylation at lysine 382. Correspondingly, the p53 target 
gene products p21 and Mdm2 were somewhat increased 
by Wip1 inhibition in U2OS cells but not in MCF-7 cells. 
Nutlin alone increased the levels of p53 and its target 
gene products in both cell lines. Importantly, when both 
drugs were combined, modified p53 strongly accumulated, 
along with p21 and Mdm2 (Figure 2). Of note, none of 
the treatments led to substantial increases in the cleavage 
of poly-(ADP ribose) polymerase (PARP), strongly 
suggesting that the observed reduction in cell numbers (cf. 
Figure 1) was not primarily a result of apoptosis. Along 
the same line, caspase activity was not induced by Nutlin 
or the combination of Nutlin with Wip1i (Supplemental 
Figure S2). In conclusion, Wip1 inhibition and Mdm2 
inhibition cooperate to increase the phosphorylation and 
acetylation of p53, and to enhance the expression of the 
p53 target genes p21 and Mdm2.
The induction of p21 and Mdm2, and growth 
inhibition by the drug combination, depend on 
p53
Next, we tested whether the inhibitors of Wip1 and 
Mdm2 are increasing p21 and Mdm2 levels in a p53-
dependent fashion. To this end, we treated HCT116 cells 
(colon carcinoma, wild type p53, activating truncation of 
Wip1 [20]) or an HCT116-derived cell line with targeted 
disruption of the p53-encoding genes [32] with the same 
drugs, alone or in combination. As expected, we observed 
the accumulation of p21 and Mdm2 only in the p53-
proficient cells (Figure 3A), thereby largely excluding 
off-target effects or any other p53-independent effects 
of Wip1 and Mdm2 inhibition. In HCT116 cells again, 
the two drugs cooperated to induce the accumulation 
of phosphorylated and acetylated p53, and to enhance 
the expression of p53 target genes. Furthermore, we 
monitored the proliferation of HCT116 cells with and 
without p53 in response to the drugs. Reduced cell 
proliferation upon treatment with Nutlin and/or Wip1i was 
only observed in p53-proficient cells but not when p53 
was deleted (Figure 3B). Thus, the efficacy of Nutlin and 
Wip1i strictly depends on p53. Finally, we tested whether 
the knockdown of Wip1 could mimic Wip1 inhibition. 
We first depleted Wip1 from U2OS cells by siRNA and 
then monitored the expression of p53-responsive genes 
by quantitative RT-PCR, in the presence or absence of 
Nutlin. Indeed, the depletion of Wip1 increased the ability 
of Nutlin to augment the expression levels of p21, PUMA 
and PIG3 (Supplemental Figure S3A-S3D). Furthermore, 
when depleting Wip1 by siRNA, Nutlin compromised 
cell proliferation to a greater extent than upon control 
transfection (Supplemental Figure S3E). Thus, Wip1 
depletion largely phenocopies Wip1 inhibition when 
combined with an Mdm2 inhibitor, strongly suggesting 
that the cooperation of Nutlin and Wip1i actually depends 
on targeting Wip1.
While each compound induces distinct gene 
sets, the combination largely enhances the gene 
signature of Nutlin
To obtain a comprehensive overview on the genes 
induced by each of the drugs and their combination, we 
performed deep sequencing analysis of the RNA obtained 
from MCF-7 cells after treatment. As expected, large 
numbers of genes were found significantly regulated 
by each treatment (Figure 4A, Supplemental Table 
1). Surprisingly, the overlap between genes that were 
upregulated by Nutlin and by Wip1 inhibition was very 
limited, comprising only 7% of the Nutlin-responsive 
genes. Thus, Wip1 inhibition alone induces only a small 
subset of p53-responsive genes, including CDKN1A, FAS, 
and Mdm2. Otherwise, it appears to regulate genes by 
other means, e. g. through the phosphorylation of signaling 
factors that ultimately affect gene expression. Even more 
strikingly, however, the combination of Nutlin and Wip1i 
elicited a gene expression signature that was far closer 
to Nutlin alone than to Wip1i alone. The combination 
largely recapitulated the genes induced by Nutlin alone 
but enhanced their number by inducing additional genes, 
most of which had not been found inducible by either 
drug alone. In addition, gene induction was enhanced for 
a lot of Nutlin-responsive genes in the additional presence 
of Wip1i. Similarly, while Wip1i did not suppress the 
expression levels of any gene to a significant extent, 
Nutlin induced downregulation of p53-repressed genes. 
The mechanism of p53-mediated gene repression involves 
the CDK inhibitor p21 and a repressive complex, as 
described previously [33-36]. Importantly, co-treatment 
with Wip1i and Nutlin led to the repression of a broader 
set of genes which included virtually all the genes that had 
been repressed by Nutlin alone, again supporting the view 
that the combination broadens and intensifies p53 activity 
(Figure 4B), and in agreement with previous studies on the 
role of Wip1 in the G2-M checkpoint [37]. 
Next, we sought to determine the induction of p53-
responsive genes in a more quantitative fashion, after 
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Figure 4: Broadened p53 response upon combined drug treatment, but not upon Wip1 inhibition alone. A. Heat map with 
log2-fold changes, resulting from mRNA-sequencing analysis of MCF-7 cells. Nutlin denotes cells treated with Nutlin at 10µM for 16 h 
compared to DMSO treatment. Wip1i denotes cells treated with GSK 2830371 at 10µM, and Nutlin+Wip1i denotes cells treated with both 
drugs at the same concentrations, all for 16 h and compared to DMSO treatment. Only genes with Iog2-fold change ≥ 0.85 and an adjusted 
p-value ≤ 0.05 were included into the heat map. The number of differentially regulated genes under each condition were Nutlin - 474, Wip1i 
- 272, Nutlin+Wip1i - 1853. For single genes, cf. Supplemental Table 1. B. Venn diagrams depicting the significantly downregulated and 
upregulated genes in MCF-7 cells. Using the Bio-Venn software (www.cmbi.ru.nl/cdd/biovenn/index.php), the significantly upregulated 
and downregulated genes were plotted under each condition - Nutlin, Wip1i and Nutlin+Wip1i, each vs. DMSO. The Iog2-fold change was 
≥ 0.85 for Nutlin, Wip1i, and Nutlin+Wip1i, and the adjusted p-value was ≤ 0.05 for each sector. the corresponding numbers of genes are 
indicated. C. Enhancement of p53-induced mRNA synthesis by combined inhibition of Wip1 and Mdm2. MCF-7 cells were treated with 
the indicated combinations of inhibitors, followed by RNA preparation after 16 h. Gene expression was quantified by real-time RT-PCR 
(mean±SEM, n = 3). D. GO term analysis and functional annotation. Gene set enrichment analysis (GSEA) from C2 curated gene sets 
(provided by the Molecular Signatures Database (MSigDB) v5.0 [60, 61]) was performed using variance stabilized RNA-Seq reads from 
Nutlin and Nutlin+Wip1i treated samples. Selected enrichment plots from gene sets induced by Nutlin and Nutlin+Wip1i are provided 
as examples. Ranking tables for induced gene sets are provided to demonstrate increased appearance of p53-responsive gene sets in the 
combination treatment compared to single treatment with Nutlin.
Oncotarget31630www.impactjournals.com/oncotarget
treatment of MCF-7 cells with each or both of the two 
drugs. When analyzing mRNA levels by quantitative 
RT-PCR, we found that the combination of both drugs 
can induce p53-responsive genes up to 50-fold, whereas 
single drugs never exceeded 10-fold (Figure 4C). Thus, 
combining both drugs leads to a far more efficient 
induction of p53 activity than either compound alone. 
Of note, this degree of induction was greater than what 
was expected based on the immunoblot analysis shown 
in Figures 2 and 3. This may be due to the destabilization 
of p21 [38] and Mdm2 [39] proteins (but not mRNA) 
through the DNA damage response signaling elicited by 
Wip1 inhibition. Nonetheless, based on the plethora of 
additional p53-responsive genes induced, we propose that 
the boost in p53 activity through the combination of both 
inhibitors provides an explanation for the sustained growth 
arrest of p53-proficient cells observed in Figure 1.
Finally, gene set enrichment analysis (GSEA) 
revealed that “irradiation” and “p53 signaling pathway” 
were by far the most significantly enriched terms 
associated with the genes induced by the simultaneous 
treatment with Nutlin and Wip1i (Figure 4D; Supplemental 
Table 2). Remarkably, gene sets regarding p53 signaling 
pathways were induced to a much greater extent in the 
combination treatment in comparison to the Nutlin 
treatment alone, as indicated by GSEA term ranking. 
Nutlin and the combination of Nutlin with Wip1i 
preferentially induce genes with promoters that 
physically bind p53
When comparing the induced genes with a database 
of promoters that had been found to associate with p53 
in response to Nutlin ([40] Gene Omnibus database ID 
GSE47043), it turned out that the set of Nutlin-plus-
Wip1i-inducible genes was highly enriched for promoter 
occupation by p53. This enrichment was found to a 
lesser degree with both of the single drugs, but not in the 
control-treated cells (Figure 5A and 5B). We furthermore 
identified p53 promoter binding on genes which were even 
more responsive towards the combination treatment than 
single Nutlin treatment. Indeed, we identified an especially 
strong p53 promoter correlation on these genes, indicating 
that their transactivation depended on both p53 activity 
and stability. In comparison, genes that were repressed 
by Nutlin and further repressed by the combinatorial 
treatment did not show comparable p53 binding, perhaps 
reflecting indirect regulation (Figure 5C and 5D).
Taken together, these results indicate that the 
combination of the two inhibitors induces genes that have 
p53 associated with their promoters. This notion strongly 
suggests that the differential gene regulation by the two 
inhibitors is a direct consequence of the observed p53 
activation.
Combined inhibition of Wip1 and Mdm2 induces 
cell senescence
Finally, we assessed possible mechanisms of how 
the combination of Nutlin and Wip1i abolishes cell 
proliferation. Of note, we had not observed enhanced 
caspase activity or PARP cleavage (Figure 2 and 
Supplemental Figure 2), and apoptosis-related pathways 
were not among the top hits of our GSEA analysis (Figure 
4D), arguing against the idea that apoptosis makes a 
major contribution to drug efficacy in this case. On the 
other hand, the cells no longer proliferated after combined 
treatment, even when the drugs had been removed for 
more than a week (Figure 1A). We therefore suspected 
that senescence and/or permanent cell cycle arrest was 
induced upon drug treatment. Senescence was initially 
described as a mechanism of normal cell aging, due to loss 
of telomeres. More recently, however, acute senescence 
was shown to confer the efficacy of chemotherapeutics in 
many cases [41]. Nutlin induces senescence in a variety of 
tumor cell lines, albeit to different degrees [42]. We tested 
whether Wip1i further enhances the amount of senescent 
cells upon Nutlin treatment. p53-proficient HCT116 cells 
display senescence-associated beta-galactosidase activity 
upon treatment with chemotherapeutics [43] and were now 
assessed as to their senescence response upon treatment 
with Nutlin and Wip1. Indeed, Nutlin induced senescence 
in a fraction of cells, but this was further enhanced by 
Wip1i, whereas the inhibition of Wip1 alone did not lead 
to a detectable senescence response. Actually, the drug 
combination exceeded the efficacy of the gemcitabine 
control in senescence induction (Figure 6A and 6B). Next, 
we analyzed the cell cycle profile upon treatment with 
Nutlin, Wip1i and their combination in U2OS cells as well 
as p53-proficient or p53-deficient HCT116 cells, using 
propidium iodide (PI) staining and flow cytometry. In 
p53-proficient cells, Nutlin alone or together with Wip1i 
reduced the number of cells in S-phase, corresponding to 
the capability of p53 to induce cell cycle arrest. However, 
the combination of Wip1i and Nutlin also increased the 
amount of cells with a 4 n DNA content, corresponding to 
G2 or M (Figure 6C). This accumulation was dependent 
on p53 and was still observed at 48 h after removing the 
drugs (Supplemental Figure S4A- S4D). In conclusion, the 
combined inhibition of Mdm2 and Wip1 not only induces 
senescence in a fraction of p53-proficient cells, but also 
induces a sustainable arrest in G2/M.
DISCUSSION
Reviving the tumor suppressive activity of p53 
has long been attempted for cancer treatment. With the 
development of Mdm2 inhibitors, this strategy appeared 
feasible but with limited efficacy. Here we show that the 
simultaneous inhibition of an additional p53-antagonist, 
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Figure 5: Induction of p53-bound genes by Nutlin and Wip1 inhibition. A. Heat map of p53 at transcription start sites of genes 
in MCF-7 cells after Nutlin treatment. Chip data on p53-promoter-associations are displayed, red color reflecting the degree of association 
with p53. Group 1 indicates those genes which were significantly upregulated by both Nutlin alone and Nutlin+Wip1i treatment in the 
RNA-Seq analysis from Figure 4. Group 2 indicates those genes that were significantly upregulated upon Nutlin+Wip1i treatment but 
not by Nutlin alone. Group 3 indicates those genes that were significantly downregulated upon Nutlin and Nutlin+Wip1i and group 4 
indicates those genes that were downregulated upon Nutlin+Wip1i treatment but not by Nutlin alone. B. Profiler image of p53 occupancy at 
transcription start sites of genes in MCF-7cells after Nutlin treatment. The profiler image (right) provides the average p53 signal obtained ± 
3kb from the transcriptional start site for the genes at each of the above-mentioned conditions. ChIP-seq track data for Nutlin-3a-stimulated 
MCF-7 cells was obtained from p53 ChIP-Sequencing [40] and downloaded from the Gene Omibus database (ID GSE47043). C. Heat map 
of p53 on the TSSs of genes dependent on both p53 activity and stability. For better evaluation, we distinguished the genes from A, group 
1 and 3, into two classifications, i. e. genes that were induced/downregulated further by the combined treatment in comparison to Nutlin 
alone (1 and 3), and the ones which were already induced/repressed by Nutlin alone to the maximum extent (2 and 4). D. Profiler image of 
p53 occupancy at TSSs of genes dependent on p53 activity and stability. The p53 promoter signal was aggregated along the TSSs of these 
genes as described in C, and a profiler image is displayed on the right.
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Figure 6: Enhanced cell senescence and G2/M accumulation by the drug combination. A. Senescence-associated beta-
galactosidase (SAB) induced by inhibition of Mdm2 and Wip1. HCT116 p53+/+ were seeded and treated with the indicated combinations 
of Nutlin and Wip1i (10 µM), or with 30 nM Gemcitabine (positive control), for 48h. Senescent cells were stained using a senescence-
associated beta-galactosidase cell staining protocol (Cell Signaling #9860). In the upper row, phase contrast images are provided to visualize 
all cells, whereas in the lower row, the same areas are shown without contrast, allowing the detection of the blue stain. B. Quantification 
of SAB accumulation. Using bright field microscopy, 10 images under each condition (A) were taken. Quantitative analysis was carried 
out using ImageJ, and the percentage of senescent cells to total cells was calculated. (mean±SEM). C. Flow cytometry to determine 
the percentage of cells in each phase of the cell cycle. P53-proficient HCT116 cells were treated with the drugs for 24 h and harvested 
immediately for cell cycle analysis. Using propidium iodide, the percentage of cells in each phase was determined. For the full set of data, 
cf. Supplemental Figure S4. D. Cooperation of Nutlin and Wip1i to enhance p53 activity and cell growth arrest. p53 receives negative 
feedback upon induction of Mdm2 and Wip1. When both feedback regulators are targeted by drugs simultaneously, p53 activity is enhanced 
to a greater extent than with each drug alone. As a result, the cells undergo sustainable cell cycle arrest and/or senescence.
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Wip1/PPM1D, further enhances the activity of p53. 
Combined inhibitors have a considerably greater activity 
in conferring cell growth arrest, p53 accumulation, and the 
induction of p53-responsive genes. Thus, the combination 
of such drugs may provide a stronger anti-cancer treatment 
efficacy than the sole use of Mdm2-inhibitors (Figure 6D).
Our results agree with and expand recent reports on 
the use of the Mdm2 inhibitors RG7388 or Nutlin-3 and 
the Wip1 inhibitor GSK2830371 [29, 30]. In addition to 
their observations, we provide evidence that inhibition of 
both targets prevents the outgrowth of cells for ten days 
(Figure 1), the accumulation of acetylated p53 (Figures 2 
and 3), and the finding that each of the inhibitors induces 
a largely distinct set of genes, whereas the combination 
of both promotes the enhanced expression of a gene 
set highly enriched of p53-induced and physically p53-
associated genes (Figures 4 and 5). 
What makes tumor cells susceptible to the combined 
treatment? Firstly, a wildtype status for p53 is needed 
(Figure 3). Furthermore, hyperactive or amplified Wip1 
might well render cells more responsive towards Wip1 
inhibition. Indeed, MCF-7, U2OS and HCT116 cells all 
either overexpress Wip1 by means of gene amplification, 
or carry an activating truncation that removes a regulatory 
domain from the carboxyterminal portion of the protein 
[20, 29]. 
Of note, p53 activation may not always lead to 
tumor cell killing or permanent cell cycle arrest. On the 
contrary, we and others have previously observed that 
p53 activation by Nutlin can have a protective function 
on cells. Nutlin protects p53-proficient cells against 
nucleoside analogues and other inducers of replicative 
stress [44, 45], by temporarily preventing the entry to S 
phase but perhaps also by regulation of BRCA1 expression 
[46]. This is generally true with regard to p53-inducing 
agents [47-50]. Moreover, we have recently shown that 
Nutlin also provides resistance of cells towards inhibitors 
of Wee1, a kinase that prevents premature mitosis [51]. 
Thus, when taking Nutlin and Wip1i to the clinics, care 
must be taken not to schedule their administration with 
drugs that require cell cycle progression for their efficacy. 
Besides nucleoside analogues, antagonists of the mitotic 
spindle, e. g. taxanes, were shown to be impaired in their 
efficacy by Nutlin [52], and we anticipate that the same 
will happen when trying to combine Wip1i, Nutlin, and 
spindle poisons. 
On the other hand, some treatments might further 
synergize with inhibitors of Wip1 and Mdm2. In 
particular, it is conceivable that the induction of DNA 
damage, e. g. through ionizing irradiation, will trigger an 
ATM-driven response which is no longer counterbalanced 
by Wip1. This might then further augment the activity of 
p53 and other pro-apoptotic factors, thereby inducing cell 
death rather than the mere arrest of cell proliferation. A 
similar cooperative effect might also be achieved using 
BH3 mimetics [53] to increase the pro-apoptotic signal 
at the mitochondria, thereby tipping the balance towards 
apoptotic cell death.
Finally, interfering with the interaction of p53 and 
Mdm2 may not provide a block of all Mdm2-induced 
oncogenic activities. We have recently shown that 
Mdm2 associates with the polycomb repressor complex 
2 (PRC2) and enhances its activities in suppressing gene 
expression, thus enabling a stem cell phenotype [54]. 
This activity of Mdm2 is not conferred by its p53-binding 
region and is thus not detectably affected by Nutlin. To 
achieve a broader inhibition of Mdm2 in most of its 
actions, inhibition of the RING finger domain and its E3 
ubiquitin ligase activity might be more toxic to cancer 
cells. Such RING finger inhibitors were described [55], 
and their combination with Wip1i might yield a more 
thorough response of tumor cells. Finally, inhibitors that 
simultaneously interfere with the action of Mdm2 and its 
heterodimerization partner MdmX/Mdm4 were recently 
published [56], again showing a broader activity against 
tumor cells, and may thus warrant combination strategies 
with Wip1i.
Interfering with Mdm2 to restore the tumor 
suppressive activity of p53 appears like an attractive 
but insufficient strategy in most cases. However, the 
simultaneous interference with additional negative 
regulators and feedback loops raises the perspective of 
further boosting p53 and its ability to accumulate, activate 
transcription, abolish proliferation, and suppress tumor 
progression. 
MATERIALS AND METHODS
Cell culture and treatment
U2OS (Osteosarcoma, p53 wild type) and MCF-
7 (breast carcinoma, p53 wild type) were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM). HCT116 
cells (colon cancer, p53 wild type or with a targeted 
deletion of p53 [32]) were maintained in McCoys 5A 
medium (1x). Cell culture media were supplemented with 
10% fetal bovine serum (FBS) and antibiotics. Cells were 
maintained at 37°C in a humidified atmosphere with 5% 
CO2. For treatment of cells, Nutlin-3a (Sigma N6287), 
GSK2830371 (Active Biochem,CAS#:1404456-53-6) 
stock solutions were prepared in DMSO and then diluted 
in pre-warmed medium and added to the cells for the 
indicated periods of time.
Cell proliferation assay
Cells were seeded in 24-well plates and the 
treatment was carried out as mentioned. The confluency 
of the cells was measured using a Celigo cell cytometer 
(Nexcelom; labeled as Day 0). After 24/48/72 h, the 
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medium was replaced with fresh media; the confluency 
was determined again (Day 1); subsequent measurements 
were made every 24 h and media was changed every 48 h.
Transfection of human cells
Transient transfection of U2OS cells with siRNAs 
to knock down PPM1D (Ambion silencer select s16288 
and s16289, Thermo Fisher), and a corresponding control 
siRNA was carried out using Lipofectamine 2000. 
Lipofectamine and siRNA were dissolved separately in 
DMEM(without FCS, Glutamine, and antibiotics) and 
incubated at room temperature for 5 min. Later, they 
were combined and incubated for another 20 min. In one 
well of a 6-well plate, around 250,000 cells were seeded 
in 1.5 mL DMEM with supplements, and 500 μl of the 
Lipofectamine-siRNA mix were added drop-wise. The 
cells were harvested 48 h after transfection.
Immunoblot analysis
Cells were harvested in protein lysis buffer (20 
mM TRIS-HCl pH 7.5, 150 mM NaCl, 1 mM Na2EDTA, 
1 mM EGTA, 1 mM beta-glycerophosphate, 2 M Urea, 
Protease inhibitor Cocktail, Roche). After 10 min lysis on 
ice, samples were briefly sonicated to disrupt DNA-protein 
complexes. Total protein concentration was measured 
using a Pierce BCA Protein assay kit (Thermo Scientific 
Fisher). After boiling the samples in Laemmli buffer at 
95°C for 5 min, equal amounts of protein samples were 
separated by SDS-PAGE, transferred onto nitrocellulose, 
and visualized with the following antibodies: PARP1 
(9542, Cell Signalling), γH2AX (S139) (9718, Cell 
Signalling), β-Actin (ab8227 abcam), p21 (2947, Cell 
signalling), Mdm2 (OP 46, Calbiochem), p53K382Ac 
(252S, Cell Signalling), p53phosphoS15 (9287S, Cell 
Signalling), p53 (DO-1 sc-126, Santa Cruz), phospho 
Chk2 (C13C1 2197, Cell Signalling).
Determination of drug synergism
Synergism between Nutlin and Wip1i was 
determined in MCF-7 and U2OS cells. 2000 cells of 
MCF-7 and U2OS were seeded on 24-well plates. 
After 24 h, they were treated with the IC 25 and IC 50 
concentrations of the individual drugs, Nutlin-3a (Nutlin) 
and GSK2830371 (Wip1i). For MCF-7 cells, IC 25 and 
IC 50 for Nutlin was found to be 10µM and 20µM, and 
IC 25 and IC 50 for Wip1i was 20µM and 40µM. For 
U2OS cells, IC 25 and IC 50 for Nutlin was found to be 
10µM and 20µM, and for Wip1i, IC 25 and IC 50 was 
30µM and 40µM. The confluency of cells was measured 
using a Celigo cell cytometer (Nexcelom). The cell 
confluency obtained for each drug concentration was 
normalized to treatment with the DMSO solvent alone. 
Using the software CompuSyn (www.combosyn.com), 
the combination index (CI) for the drug combinations was 
calculated (Chou, Talalay 2010). CI values > 1 describe 
antagonistic or non-synergistic effects of two drugs, CI = 
1 indicates additive effects and CI values < 1 correspond 
to synergistic effects of combined drug treatment. 
RNA extraction, reverse transcription, and real 
time quantitative PCR
Total RNA was extracted from cells using TRIzol® 
(Invitrogen). mRNA was reverse-transcribed using oligo-
dT and random hexameric primers, followed by qRT-PCR 
analysis using SYBR Green (Invitrogen). Gene expression 
levels were normalized to the mRNA encoding HPRT1, 
and the analysis was conducted using the ΔΔCt method. 
qRT-PCR primer sets were chosen as follows:
Primer sequences for gene expression studies in human 
cells
Gene name Primer sequence
HPRT1
For- ATG CTG AGG ATT TGG AAA GG
Rev- TCA TCA CAT CTC GAG CAA 
GAC
P21
For- CCT GGC ACC TCA CCT GCT 
CTG CTG
Rev- GCA GAA GAT GTA GAG CGG 
PUMA
For- GCC AGA TTT GTG AGA CAA 
GAG G
Rev- CAG GCA CCT AAT TGG GCT C
GADD45α For- TCA GCG CAC GAT CAC TGT CRev- CCA GCA GGC ACA ACA CCA C
Wip1 For- CTG AAC CTG ACT GAC AGC CCRev- CTT GGC CAT GGA TCC TCC TC
PIG3 For- GCT TCA AAT GGC AGA AAA GCRev- GTT CTT GTT GGC CTC CAT GT
RNA sequencing
For RNA-sequencing, the quality of total RNA was 
determined using the Bioanalyzer 2100 from Agilent. All 
samples analyzed exhibited a RNA Integrity Number > 
8. Library preparation was conducted using the TruSeq 
RNA LT SamplePrep Kit (Illumina), starting from 1000 
ng of total RNA. Barcodes for sample preparation were 
used according to the indications given by the protocol. 
Accurate quantitation of cDNA libraries was performed 
with the QuantiFluor™dsDNA System (Promega). 
The size range of final cDNA libraries was determined 
applying the DNA 1000 chip on the Bioanalyzer 2100, 
(Agilent; 290-310 bp). cDNA libraries were amplified 
and sequenced via cBot and HiSeq 2000 (Illumina; SR, 
1×50 bp, 6 Gb/sample ca. 30 million reads per sample). 
Sequence images were transformed with Illumina software 
BaseCaller to bcl files, which were demultiplexed to 
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fastq files with CASAVA (version 1.8.2). Quality check 
was performed via FastQC (version 0.10.1, Babraham 
Bioinformatics). Fastq files were mapped to the human 
reference transcriptome (UCSC hg19) using Tophat 
(Galaxy Version 0.9) [57] Read counts for each sample 
and each gene were aggregated using a htseq-count 
[58]. DESeq2 (version 1.10.1) was used for measuring 
differential expression[59]. RNA library preparation and 
sequencing was done by the Transcriptome Analysis 
Laboratory (TAL, Göttingen).
Gene set enrichment analysis (GSEA) from C2 
curated gene sets (provided by the Molecular Signatures 
Database (MSigDB) v5.0) was performed using variance 
stabilized normalized read counts. [60, 61]. The threshold 
of significant enrichment (q≤0.25) was implied according 
to the GSEA standards (http://www.broadinstitute.org/
gsea/doc/GSEAUserGuideFrame.html). 
Correlation of RNA-Seq and p53 ChIP-seq data
Raw data for p53 ChIP-Sequencing [40] were 
downloaded from the Gene Omibus database (ID 
GSE47043). The reads were mapped to the human 
reference genome (UCSC hg19) using Bowtie (version 
1.0.0) [62]. Peak calling was done by Model-based 
Analysis of ChIP-Seq (version 1.4.2 [63]. Coverage was 
determined by normalizing the total number of mapped 
reads per hundred million. p53 enrichment was analyzed 
on the transcriptional start sites (TSSs) of genes that 
were upregulated in MCF-7 cells after Nutlin and after 
Nutlin+Wip1i treatment using deeptools functions [64] 
based on the Galaxy framework [65].
Caspase activity assay
Cells were seeded in 6-well plates and treated 
with drugs, At 24h post-treatment, cells were harvested 
(inclusive of medium) and centrifuged at 1500xg for 
5 min at 4oC. The pelleted cells were resuspended in 
250µl caspase lysis buffer (1M Tris-HCl, 2mM MgCl2, 
150mM NaCl, 10mM DTT, protease-inhibitor (Roche 
complete mini)). They were shock-frozen thrice in 
liquid nitrogen and centrifuged at 15,000xg for 15 min 
at 4oC. 40µl of lysate was pipetted per well in a 96-well 
plate in triplicates. 10µl of Ac-DEVD-AMC substrate 
(working concentration 25µM) (ALX-260-031 Enzo) was 
added to each sample. Caspase activity was measured 
using a fluorometer (Synergy MX 267137) at excitation 
wavelength 380nm and emission wavelength 460nm every 
10 min for 4 h at 37oC. 
Cell cycle analysis by flow cytometry
Cells were seeded in 6-well plates and treated with 
DMSO, Nutlin, Wip1i, and Nutlin+Wip1i. After fixation 
in ethanol, the cells were washed with 0.05% Triton-X 
in PBS. Subsequently, the cells were resuspended in 
1 mg/ml RNAse A solution in PBS and incubated for 
30 min at 37°C, and then with propidium iodide (final 
concentration: 30 µg/ml). Flow cytometry was performed 
using the Guava PCA-96 Base System (Millipore), and 
the percentage of cells in each phase of the cell cycle was 
determined using the Guava Express Pro software.
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SUPPLEMENTAL FIGURE 1. Wip1i titration in U2OS cells. Related to Fig. 1 
U2OS cells were treated with varying concentrations of Wip1i GSK 2830371. After 24 h, the 
cells were harvested, followed by immunoblot analysis to detect the DNA damage-induced 
kinase substrates p53, phospho-p53, phospho-H2AX, and phospho-Chk2. PARP staining 
revealed the absence of detectable caspase activity. Actin staining served as the loading 
control. 
 SUPPLEMENTAL FIGURE 2. Lack of caspase activation upon simultaneous inhibition of 
Mdm2 and Wip1. Related to Fig. 2 
U2OS cells were treated as indicated, followed by harvest and lysis to assay for Caspase 3 
activity after 24h. A fluorescent substrate to Caspase 3 was added to the lysates, and cleavage 
was followed over time. Note that Wip1i alone induces a moderate degree of Caspase 
activation, but Nutlin or the combinations do not. This assay could only be carried out in U2OS 
cells but not in MCF-7 cells, since the latter are lacking functional caspase 3 [66]. 
 
 
 
 
 
 
 
  
 
SUPPLEMENTAL FIGURE 3. Wip1 knockdown along with Nutlin treatment leads to the 
activation of p53 target genes and cooperatively reduces cell proliferation. Related to Fig. 
3 
siRNA knockdown of Wip1 was combined with Nutlin treatment in U2OS cells. Two sets of 
siRNA against Wip1 were used.  
A-D Quantitative RT-PCR was carried out to quantify the expression of p53 target genes, 
namely p21, PUMA and PIG3.   
E the proliferation of U2OS cells was monitored after Wip1 knockdown and/or Nutlin treatment 
for 48 h.  
 
 
 
 SUPPLEMENTAL FIGURE 4. Cell cycle analysis upon treatment with Nutlin, Wip1i and 
their combination, at different time points after treatment. Related to Fig. 6 
 
U2OS and HCT116 (p53 proficient or deficient) cells were treated with Nutlin, Wip1i and their 
combination for 24 h. The cells were then harvested for cell cycle analysis immediately (referred 
to as 0h), or incubated with fresh medium and harvested after 48h or 96h. The cell cycle profiles 
were determined by propidium iodide staining and flow cytometry, and are provided along with 
the percentage of cells in each phase. 
 
 
 
 
 Table S1_MCF-7_RNASeq, related to Fig. 4 
MCF-7 cells were treated with 10 µM of Nutlin, 10 µM of GSK 2830371 or a combination of both 
drugs for 16 h. Global gene expression was analyzed via next generation RNA-sequencing (cf. 
Fig. 4A). Normalized RNA-seq reads were analyzed by DESeq2. Base mean values, log2 fold 
change (FC) and adjusted p values are shown for each gene.  
 
Table S2 _MCF-7_C2GSEA, related to Fig. 4 
Gene set enrichment analysis (GSEA) from C2 curated gene sets (provided by the Molecular 
Signatures Database (MSigDB) v5.0) was performed using variance stabilized MCF-7 RNA-Seq 
data from Nutlin and Nutlin+Wip1i treated samples [60, 61]. The threshold of significant 
enrichment (q≤0.25) was implied according to the GSEA standards 
(http://www.broadinstitute.org/gsea/doc/GSEAUserGuideFrame.html). 
 
Table S3 _MCF-7_p53TSS_intensity, related to Fig. 5 
p53 enrichment was analyzed on the transcriptional start sites (TSSs) of genes that were 
regulated in MCF-7 cells after Nutlin and after Nutlin+Wip1i treatment. Tabs 1-4 denote the 
following regulation patterns: 1) genes upregulated after Nutlin and Nutlin+Wip1i treatment; 2) 
genes only upregulated after Nutlin+Wip1i treatment; 3) genes downregulated after Nutlin and 
Nutlin+Wip1i treatment; 4) genes downregulated only upon Nutlin+Wip1i treatment. Raw data 
for p53 ChIP-Sequencing [39] were downloaded from the Gene Omnibus database (ID 
GSE47043).  
 
RESULTS 
  
 
57 
 
3.3 Publication III 
 
CDK4 inhibition diminishes p53 activation by MDM2-antagonists 
Anusha Sriraman 
1
, Antje Dickmanns 
1
, Zeynab Najafova 
2
, Steven A. Johnsen 
2
, and Matthias 
Dobbelstein 
1,3
 
 
 
 
 
This manuscript has been peer-reviewed and is currently under consideration at Cell Death and 
Disease. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Own contribution:  
Experiments and data analyses for all figures except Fig5. Involved in the conception, figure 
arrangement and contributions in writing and revising the manuscript.  
RESULTS 
  
58 
 
 
 
ABSTRACT 
The genes encoding MDM2 and CDK4 are frequently co-amplified in sarcomas, and inhibitors 
to both targets are approved or clinically tested for therapy. However, we show that inhibitors 
of MDM2 and CDK4 antagonize each other in their cytotoxicity towards sarcoma cells. CDK4 
inhibition attenuates the induction of p53-responsive genes upon MDM2 inhibition, and p53 
was also attenuated when co-depleting MDM2 and CDK4 with siRNA, compared to MDM2 
single knockdown. The complexes of p53 and MDM2, as well as CDK4 and Cyclin D1, 
physically associated with each other, suggesting direct regulation of p53 by CDK4. 
Interestingly, CDK4 inhibition did not reduce p53 binding or histone acetylation at promoters, 
but rather attenuated the subsequent recruitment of RNA Polymerase II. Taken together, our 
results suggest that caution must be used when considering combined CDK4 and MDM2 
inhibition for patient treatment. Moreover, we uncover a hitherto unknown role for CDK4 and 
Cyclin D1 in sustaining p53 activity. 
 
HIGHLIGHTS 
 Inhibitors of MDM2 and CDK4 antagonize one another’s cytotoxicity 
 CDK4 inhibition attenuates p53 activity 
 The CDK4/CyclinD1 complex physically associates with p53 
 CDK4 inhibition diminishes RNA Polymerase II recruitment to p53-responsive promoters 
 
 
 
SIGNIFICANCE 
CDK4 and MDM2 are subject to co-amplification in a number of malignancies, supporting the idea of 
combining inhibitors to both for cancer therapy. Indeed, such combinations are currently undergoing 
clinical testing. However, our results raise strong reservations against such an approach, since the 
drugs work in an antagonistic fashion. CDK4 inhibitors interfere with p53 activity and block the 
recruitment of RNA Polymerase II to p53-inducible promoters. Our results establish a previously 
unknown function of CDK4 in supporting the activity of the most frequently mutated tumor suppressor 
p53. 
 
 
.
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INTRODUCTION 
Cyclin-dependent kinase 4 (CDK4) is a key promoter of cell proliferation. It enables the transition through 
the G1 phase of the cell cycle, a prerequisite for subsequent entry to S phase and cell division. Tumor 
cells often activate CDK4 to ensure proliferation, either by silencing genes that encode CDK4 antagonists 
or by enhancing CDK4 expression, e. g. through gene amplification. Pharmacological inhibitors of CDK4 
have proven to be effective in cancer treatment, leading to FDA approval of Palbociclib (PD0332991), 
Ribociclib (LEE011) and Abemaciclib (LY2835319) [181].  
The MDM2 oncoprotein has also been extensively evaluated as a drug target. MDM2 antagonizes the 
tumor suppressor p53 by physical interaction and subsequent ubiquitination of p53. The interaction of 
p53 and MDM2 is amenable to targeting by small compounds, with Nutlin-3a (referred to here as “Nutlin”) 
representing the prototype [166] and many similar and further refined compounds being developed ever 
since [182, 183]. Pre-clinical analysis of MDM2 inhibitors have raised high expectations, especially when 
treating sarcoma [184] or glioblastoma [185] which contain MDM2 gene amplifications. Clinical studies 
using MDM2-targeting drugs [186], however, have currently not met the initial expectations [165], at least 
not when used as single drugs. This has spurred the search for optimized combinations of MDM2 
inhibitors with other cancer drugs. 
Certain sarcomas, specifically liposarcomas, represent particularly promising cancer entities for 
treatment with MDM2 antagonists. These tumors contain amplifications of the MDM2 gene in more than 
90% of all cases [187], and liposarcoma-derived cell lines undergo apoptosis when treated with MDM2-
antagonizing drugs [184, 188]. As expected, the response requires a wild-type p53 status and MDM2 
overexpression [189]. However, attempts to treat liposarcoma patients with MDM2 antagonists have so 
far not yielded the expected clinical success [167, 190].  
The amplification of the MDM2 gene in sarcomas is often associated with CDK4 amplifications [187]. 
Other examples of tumors containing both amplifications include melanomas [191] and periosteal 
osteosarcomas [192]. Both genes are located close to each other on chromosome 12q13-15, but 
nonetheless, the amplifications appear independent in most cases [187, 193]. The co-amplification of 
both genes might constitute tumor cell addiction to the simultaneous activity of both gene products. This 
argued that targeting both MDM2 and CDK4 should yield synergistic tumor cell killing. And indeed, a 
recent report argued that this synergism might be achievable [194]. Moreover, a combination of MDM2 
and CDK4 inhibitors is currently being evaluated in a Phase I clinical study (NCT02343172). However, 
in the previous report [194], the impact of drug combinations on tumor growth was only marginally 
increased when compared to CDK4 inhibitor alone. Thus, potential synergies between CDK4 and MDM2 
inhibitors remain to be investigated. 
Here we show that the inhibition of CDK4 attenuates MDM2 inhibitor-induced activity of p53, leading to 
decreased rather than synergistic cytotoxicity. In parallel, the complexes of MDM2 and p53, as well as 
CDK4 and Cyclin D1, physically associate with each other. CDK4 inhibition still allows efficient binding 
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of p53 to its target genes. In contrast, combined inhibition of CDK4/6 and MDM2 led to diminished RNA 
Polymerase II recruitment and thus decreased transcription of p53 target genes. 
RESULTS 
Inhibitors of CDK4 and MDM2 lack synergistic cytotoxicity towards sarcoma cells  
Given the co-amplification of the MDM2 and CDK4 genes in sarcoma, we sought to test whether the 
combined inhibition of both gene products might synergistically eliminate cancer cells. We treated SJSA 
cells (osteosarcoma cells with amplifications of MDM2 and CKD4, cf. www.cbioportal.org and Figure 
3.3.S1 A) with combinations of the CDK4 inhibitor Palbociclib (PD0332991) and the MDM2 antagonist 
Nutlin. As expected, Nutlin induced p53 accumulation and its target genes p21 and MDM2 (Figure 
3.3.S1B), and PD0332991 abolished the phosphorylation of the CDK4 substrate pRb at Serine 807/811 
[195] (Figure 3.3.S1 C). Nutlin also reduced pRb phosphorylation, likely due to the induction of the CDK4 
inhibitor p21. Importantly, Nutlin profoundly decreased the viability of SJSA cells, as reported previously 
[196], and Palbociclib also reduced their viability (Figure 3.3.1A,B).  
 
 
Figure 3.3 1 CDK4 inhibitors and MDM2 antagonists fail to synergize with regard to cytotoxicity towards 
sarcoma cells 
A.  SJSA cells were treated with DMSO, Nutlin, PD0332991 and its combination at the indicated 
concentrations adhering to the depicted schedule.  
B. Cell viability was measured by quantification of the ATP content. The combination of PD0332991 and Nutlin 
showed a protective effect in comparison to Nutlin alone.  
Strikingly, however, Palbociclib completely failed to enhance the cytotoxic effects elicited by Nutlin. 
Instead, Nutlin-treated cells even survived to a significantly greater extent when co-treated with 
Palbociclib. Similarly, the long-term survival of SJSA cells was strongly decreased by Nutlin alone, but 
was rescued by co-treatment with Palbociclib (Figure 3.3.1C,D).  
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Figure 3.3 1 CDK4 inhibitors and MDM2 antagonists fail to synergize with regard to cytotoxicity towards 
sarcoma cells.  
 
C. Schedule to determine cell proliferation upon drug treatment.  
 
D. Cell proliferation was assessed by daily measuring the confluency of cells using a Celigo cell cytometer. 
The medium was changed every 24 hours. Nutlin treatment reduced cellular proliferation. However, pre-
treatment with PD0332991 in combination with Nutlin led to increased cell numbers, indicating that the two 
drugs do not synergize but rather act in an antagonistic fashion. Mean of three biological replicates.  
 
 
Moreover, SJSA cells treated with Nutlin alone displayed morphology with round and shrunk cells, 
corresponding to apoptosis [197] (Figure 3.3.1E).  
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Figure 3.3 1 CDK4 inhibitors and MDM2 antagonists fail to synergize with regard to cytotoxicity towards 
sarcoma cells.  
E. Morphology of SJSA cells, observed by bright field microscopy. Upon treatment with Nutlin, the cells shrank 
and detached. Pretreatment with PD0332991 protected the cells from this cytotoxic effect of Nutlin. 
However, removal of PD0332991 followed by Nutlin treatment did not result in cell protection. 
Again, this occurred to a lesser extent when the cells had first been treated with Palbociclib. Combination 
of the drugs at different concentrations in various MDM2-amplified sarcoma cell lines also revealed no 
synergism with regard to viability of cells (Figure 3.3.S1 D-G; note that here, viability was assayed 
immediately after a 72 hrs treatment, without allowing the cells to further proliferate). Taken together, 
these results strongly suggest that at least under some circumstances Palbociclib is capable of 
antagonizing the cytotoxic activity of Nutlin. 
CDK4 is required for p53-induced gene expression  
To further investigate why CDK4 inhibition attenuates Nutlin-induced cell death, we asked whether CDK4 
inhibitors might interfere with p53-induced gene expression. A panel of sarcoma cells, including SJSA 
cells, as well as CRL3043 [198], CRL3044 [198] and GOT-3 [199] (the latter three derived from well-
differentiated liposarcoma and with amplifications of CDK4 and MDM2 genes), was treated with 
Palbociclib to inhibit CDK4, as well as Nutlin to block the MDM2-p53-interaction. The levels of p53-
responsive gene products were then assessed by immunoblot analysis. Nutlin alone increased the levels 
of p53 and its target gene products MDM2 and CDKN1A/p21, as expected. In contrast, Palbociclib alone 
had little effect on them, while it did reduce the amount of phosphorylated pRb. Importantly, however, in 
combination with Nutlin, Palbociclib markedly decreased the protein levels of the p53 target gene 
products MDM2 and p21 (Fig. 3.3.2A).  
 
 
Figure 3.3 2 CDK4 is required for p53-induced gene expression.  
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A. SJSA (osteosarcoma), CRL3043, CRL3044 and GOT-3 (all liposarcoma) cells were treated with DMSO, 
Nutlin, PD0332991 or the drug combination for 48 hours. Cells were harvested for immunoblot analysis to 
detect p53 and its target gene products p21 and MDM2. Upon Nutlin treatment, increased levels of MDM2, 
p53 and p21 were observed. However, the combination of Nutlin with PD0332991 decreased p53-induced 
target gene expression. pRb phosphorylated at 807/811 was detected as a positive control for the activities 
of Nutlin and PD0332991. ß-actin served as loading control. 
To determine whether the impairment of p53 target gene expression was specific to Palbociclib or 
whether it was due to inhibition of CDK4/6 kinase activity, in general, we treated SJSA cells with alternate, 
FDA approved CDK4/6 inhibitors, namely LEE011 (Ribociclib) and LY2835219 (Abemaciclib), alone or 
in combination with Nutlin. Again, p53 target gene expression was decreased when Nutlin was combined 
with the CDK4/6 inhibitors, at the protein (Figure 3.3.2B) and mRNA (Figure 3.3.2C) levels. Thus, CDK4 
inhibition generally reduces p53 activity. The failure of Nutlin to fully induce pre-apoptotic genes in the 
presence of CDK4 inhibitor may also explain why CDK4 inhibition attenuates the cytotoxic effects of 
Nutlin (Figure 3.3.1).  
 
Figure 3.3 2 CDK4 is required for p53-induced gene expression.  
 
A. SJSA cells were treated with the alternate CDK4/6 inhibitors Ribociclib (LEE011) and Abemaciclib 
(LY2835219) for 30 hours, alone or in combination with Nutlin at 20µM for 6 hours. Immunoblot analysis 
was performed as in A. Like Palbociclib (PD0332991), the combination of Nutlin with alternate CDK4/6 
inhibitors diminished p53 target gene expression when compared to Nutlin treatment alone.  
 
B. SJSA cells were treated with the alternate CDK4/6 inhibitors Ribociclib (LEE011) and Abemaciclib 
(LY2835219), alone and in combination with Nutlin as in B. mRNA levels corresponding to p53 target gene 
expression were assessed by quantitative Real Time-PCR. RPLP0 was used as a reference gene. Again, 
p53-induced gene expression was found diminished by CDK4/6 inhibitors. Mean of three biological 
replicates. 
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We next increased p53 activity by inducing a DNA damage response, which enhances p53 
phosphorylation through the kinases ATM and Chk2 [200]. To this end we used neocarzinostatin (NCS), 
a radiomimetic compound that induces double strand DNA breaks in a manner similar to ionizing 
radiation [201]. Strikingly, Palbociclib pretreatment strongly decreased the accumulation of p53 and its 
target gene product p21 in response to NCS (Figure 3.3.2D).  
 
 
 
 
 
Figure 3.3 2 CDK4 is required for p53-induced gene expression.  
 
C. SJSA cells were treated with DMSO, Nutlin, Neocarzinostatin (NCS), PD0332991 and their combinations 
at the indicated concentrations for 6 hours. Lysates were subjected to immunoblot analysis. Upon NCS 
treatment, increased levels of p21 and ϒH2AX were found, indicative of a DNA damage response. As in 
the case of Nutlin, NCS-induced p53 activity, revealed by p21 accumulation, was found reduced by the 
CDK4/6 inhibitor.   
 
Hence, CDK4 inhibition can also interfere with the p53-inducing ability of DNA damaging drugs, giving 
rise to caution when combining CDK4 inhibitors with conventional chemotherapy in cancer treatment. 
Furthermore, we performed analogous investigations replacing pharmacological inhibitors with siRNAs 
targeting MDM2 and CDK4. This revealed corresponding changes in p53-induced p21, i.e. induction by 
MDM2 knockdown alone, but far less induction by the simultaneous depletion of MDM2 and CDK4 
(Figure 3.3.2E).  
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Figure 3.3 2 CDK4 is required for p53-induced gene expression.  
 
D. SJSA, CRL3043, CRL3044 and GOT-3 cells were depleted of endogenous MDM2, CDK4 by siRNA 
transfection, in comparison to control (ctrl) siRNA. Cells were harvested for immunoblot after 48 hours to 
detect p53 and its target gene product p21. Upon depletion of MDM2, the expected increase in p21 and 
p53 levels was observed. In contrast, the co-depletion of CDK4 along with MDM2 induced p21 and p53 
levels only to a lesser extent. 
 
Similarly, impaired p53 target gene expression upon CDK4 inhibition was also observed when using 
different time schedules, drug concentrations, or the alternate MDM2 antagonist RG7388 (Figure 3.3.S2, 
A-E). Moreover, to exclude any role of the p53 kinase HIPK2 [100, 101] in this context, we performed a 
parallel experiment replacing CDK4 inhibitors with the HIPK2 inhibitor A64 (PubChem Substance ID 
329826044) but did not observe any detectable change in p53 activity (Figure 3.3.S2F,G). Taken 
together, these results strongly suggest that CDK4 inhibition or depletion severely diminishes the 
transcriptional activity of p53 in response to MDM2 antagonists. This raises an important potential caveat 
regarding the combination of CDK4 inhibitors with p53-activating drugs for cancer therapy.  
Short-term reactivation of CDK4 is sufficient to rescue p53 activity 
To test whether the impact of CDK4 inhibition on p53 activity is mediated by cell cycle arrest, we analyzed 
the timing needed for the two drugs to interact. One possibility for the observed effects is that a cell cycle 
arrest induced by CDK4 inhibition might impair p53 activity. As expected, flow cytometric analysis verified 
that Palbociclib arrested the majority of treated cells in G1 (Figure 3.3.3A,B). 
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Figure 3.3 3 Short-term reactivation of CDK4 is sufficient to rescue p53 activity which is independent of cell 
cycle.  
A. SJSA cells were treated as indicated in the schedule.  
B. Flow cytometry analysis of the DNA content. PD0332991 induced cell cycle arrest in G1, irrespective of the 
(short-term) Nutlin treatment.  
Although cell cycle arrest is not generally considered as a way to inhibit p53 activity, we still investigated 
whether this arrest in G1 represents the reason for the attenuated p53 response. To this end, we 
removed the CDK4/6 inhibitor from the cells for 6 hours (compared to continued CDK4 inhibition) and 
then immediately treated with Nutlin. This brief removal of the CDK4 inhibitor was not enough to resume 
the cell cycle, at least as far as can be judged by propidium iodide staining (Figure 3.3.3B). However, 
p53 activity was still markedly increased upon Palbociclib removal, when compared to cells that were 
treated with Nutlin in the continued presence of Palbociclib, as determined by immunoblot analysis of 
p53 target gene products (Figure 3.3.3C) and also by assessing the mRNA levels corresponding to such 
genes (Figure 3.3.3D). Thus, we conclude that CDK4 activity is required for maximal p53-induced gene 
expression, regardless of cell cycle progression. 
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Figure 3.3 3 Short-term reactivation of CDK4 is sufficient to rescue p53 activity which is independent of cell 
cycle.  
 
C. To investigate the p53 target gene expression, immunoblot analysis was carried out. Nutlin treatment led 
to the accumulation of p53, p21 and MDM2, which was diminished by PD0332991. Upon removal of 
PD0332991 during Nutlin treatment, however, p21 and MDM2 levels were restored.  
 
D. Cells were treated as in A-C, followed by quantitative RT-PCR to quantify the expression of the p53 target 
genes MDM2, p21 and PIG3, in comparison to the reference gene RPLP0. Nutlin induced these genes 
while PD0332991 significantly decreased their expression levels. Removal of PD0332991 during Nutlin 
addition reactivated p53 target gene expression. Mean of three biological replicates. 
 
CDK4 inhibition attenuates the expression of a broad range of p53-induced genes  
Next, we assessed the extent to which the induction of genes by p53 is affected by CDK4 inhibition, and 
whether CDK4 inhibition might display a similarly broad impact on unrelated gene sets. We treated SJSA 
cells with Palbociclib and/or Nutlin (Figure 3.3.4A), followed by next generation RNA sequencing analysis 
(RNA-Seq). This approach revealed that most p53-responsive genes, as identified through their induction 
by Nutlin, were expressed to a lesser degree when cells were pretreated with the CDK4/6 inhibitor (Figure 
3.3.4B).  
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Figure 3.3 4 CDK4 inhibition attenuates the expression of a broad range of p53-responsive genes. 
A. SJSA cells were treated with DMSO, Nutlin, PD0332991 and its combination as indicated in the schedule, 
followed by RNA deep sequencing analysis.  
B. Heatmap depicting differentially regulated genes sorted according to the z-scores of Nutlin vs DMSO. Only 
genes with basemean>20, log2fold>1, log2fold<-1, and adjusted p value <0.05 were taken into 
consideration. 6 samples with biological triplicates are represented. N refers to Nutlin, PD refers to 
PD0332991, and DMSO as control. RNA-Sequencing data of this study were submitted to the GEO, 
GSE113369. 
C. Gene Set Enrichment Analysis (GSEA) from C2 curated gene sets, provided by the Molecular Signatures 
Database (MSigDB) v5.0 [202], was performed using variance stabilized RNA-Seq reads from Nutlin 
(represented as N) and Nutlin+PD0332991 (represented as N+PD30) treated samples. The table was 
generated by selecting False Discovery Rate (FDR) < 25% and Enrichment Score (ES) in the descending 
order.  
Comparing Nutlin-treated cells with or without CDK4 inhibitor, it was still the p53-responsive genes that 
were differentially expressed to the greatest extent after the cell cycle targets, as determined by gene 
set enrichment analysis (GSEA) (Figure 3.3.4C-D).  
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Figure 3.3 4 CDK4 inhibition attenuates the expression of a broad range of p53-responsive genes.  
 
D. Selected enrichment plots from gene sets induced by Nutlin vs Nutlin+PD0332991 are provided as 
examples. 
 
We conclude that, when cells are subjected to MDM2 inhibition, a CDK4/6 inhibitor specifically attenuates 
the expression of p53-responsive genes more than any other distinguishable group of genes except the 
cell cycle regulators. This suggests that CDK4 activity has a direct and specific impact on p53-induced 
transcription.  
p53 physically interacts with CDK4 and Cyclin D1 
To elucidate how CDK4 might affect the activity of p53, we tested whether the two molecules might 
physically associate with each other. We tested this in cell lysates from SJSA cells treated with a 
proteasome inhibitor. Indeed, co-immunoprecipitation analysis revealed the interaction of the MDM2-p53 
and the CDK4-Cyclin D complexes (Figure 3.3.5A).  
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Figure 3.3 5 Association of the CDK4/Cyclin D1 complex and the p53/MDM2 complex.  
A. Co-immunoprecipitation of endogenous proteins was carried out with lysates of SJSA cells treated with the 
proteasome inhibitor 20µM MG132 for 5 hours. Antibodies to precipitate MDM2 or p53 were compared with 
an anti-beta-galactosidase antibody as a control, and antibodies to CDK4 and cyclin D1 were compared to 
pre-immune IgG. Immunoblot analysis of the precipitated material showed association of the CDK4/cyclin 
D1 complex with the MDM2/p53 complex. Representative figure of three biological repeats. * indicates the 
immunoglobulin heavy chain IgL 
 
The interaction of p53 and CDK4 was also found in Nutlin-treated cells (Figure 3.3.5B,C).  
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Figure 3.3 5 Association of the CDK4/Cyclin D1 complex and the p53/MDM2 complex.  
 
B. Scheme used for the treatment of SJSA cells with Nutlin and PD0332991.  
 
C. Co-immunoprecipitation was performed from lysates of SJSA cells as described in B. Upon 
Immunoprecipitation (IP) with antibodies to CDK4, p53 accumulation was observed. When directly 
precipitating CDK4 or cyclin D1 complex formation between the two decreased upon combined treatment, 
in comparison to single treatment with Nutlin alone (quantification of the bands in Fig. S3). * indicates the 
immunoglobulin heavy chain IgH. 
 
Combined inhibition of MDM2 and CDK4 led to decreased association of Cyclin D1 and CDK4 when 
compared to Nutlin alone (Figure 3.3.5C with quantification in Figure 3.3.S3). Possibly, the CDK4 
inhibitor diminishes the proper folding of CDK4 [203] and thus reduces Cyclin D1 binding. The interaction 
of p53 with Cyclin D1 was further confirmed by plasmid-based overexpression of both components 
(Figure 3.3.5D). 
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Figure 3.3 5 Association of the CDK4/Cyclin D1 complex and the p53/MDM2 complex.  
D. Co-immunoprecipitation was carried out from lysates of H1299 cells upon plasmid-based overexpression 
of p53 or cyclinD1, revealing the association of the two, and also the association of MDM2 with p53 in this 
context.  
 In sum, p53 physically associates with CDK4 and CyclinD1, suggesting a mechanism by which CDK4 
might directly regulate the activity of p53 as a transcription factor. 
CDK4 inhibition does not interfere with p53 binding to its cognate promoter elements 
but diminishes the recruitment of RNA Polymerase II 
To mechanistically understand how CDK4/6 inhibition reduces the activity of p53 as a transcription factor, 
we performed immunoblot analysis to detect the acetylation of p53 on Lys 382, an activating modification 
of p53 [204, 205]. Surprisingly, we observed that the acetylation of p53 was even stronger when 
PD0332991 was combined with Nutlin than Nutlin alone (Figure 3.3.6A,B). In contrast, we still observed 
decreased expression of p53 target genes, at the protein (Figure 3.3.6B) and mRNA (Figure 3.3.6C) 
level, when adding the CDK4/6 inhibitor to Nutlin.  
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Figure 3.3 6 CDK4 inhibition does not interfere with p53 binding to its cognate promoter elements.  
A.  Scheme indicating the treatment regimen used for the individual and combinatorial treatment of SJSA cells 
with Nutlin and/or PD0332991.  
B. Immunoblot analysis following treatment as in A. Apart from p53 and its target gene products p21 and 
MDM2, the acetylation of p53 at Lys 382 was detected. This acetylation was increased, rather than 
attenuated, upon the combined treatment of Nutlin with PD0332991 in comparison to Nutlin treatment 
alone.  
C. Quantitative Real-Time PCR was carried out to quantify mRNA expression levels of p53 target genes upon 
treatment as in A, with similar results as in Fig. 2C. Mean of four independent experiments. 
 
To determine differences in nascent pre-mRNA levels, we designed PCR primers spanning exon-intron 
boundaries of p53-responsive transcripts, namely p21 and MDM2. We observed that CDK4/6 inhibition 
mostly reduced pre-mRNA levels proximal to the promoters of p53-responsive genes in response to 
Nutlin (Figure 3.3.6D), arguing that the initiation of transcription depends most strongly on cyclin-
dependent kinases.  
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Figure 3.3 6 CDK4 inhibition does not interfere with p53 binding to its cognate promoter elements. 
D. Primers spanning Intron-exon junctions were used to quantify pre-mRNA for p21 and MDM2. The origin of 
the PCR products, with respect of the gene structures, are indicated in the figure. Upon treatment as in A, 
SJSA cells were subjected to mRNA analysis. It was observed that nascent RNA of p21 and MDM2 was 
increased upon Nutlin treatment. With the combination, the relative gene expression was reduced, in 
particular at sites proximal to the promoter.  
 
Finally, we performed chromatin immunoprecipitation (ChIP) analysis to examine p53 occupancy on 
target gene promoters. Nutlin increased the amount of p53 associated with its cognate promoter 
elements, as expected. Interestingly, however, CDK4/6 inhibition did not decrease, but even further 
increased the extent of p53 occupancy on target gene promoters (Figure 3.3.6E), despite the decreased 
expression of the respective target genes. Similarly, the acetylation of histone H3 at lysine 27 (H3K27ac) 
at p53-responsive promoters was not impaired, but rather increased (Figure 3.3.6F), still in line with the 
notion that p53 binding and the subsequent recruitment of histone acetyltransferases [204] is still intact 
on these promoters. On the other hand, however, the association of RNA Polymerase II with p53-
responsive genes was decreased in response to CDK4/6 inhibition (Figure 3.3.6G), suggesting that 
CDK4/6 activity is required for p53-mediated recruitment of RNA Polymerase II.  
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Figure 3.3 6 CDK4 inhibition does not interfere with p53 binding to its cognate promoter elements.  
E. Chromatin Immunoprecipitation of p53 was carried out upon treatment with Nutlin and PD0332991 as in A. 
The occupancy of promoters by p53 remained similar with Nutlin treatment, compared with the combination 
of Nutlin with PD0332991, at the transcriptional start site (TSS) of p53 target genes p21 and MDM2, and 
at an enhancer site on p21 which contains another p53 responsive element. IgG was used as a negative 
control. Mean of four independent experiments.  
 
F. Upon Chromatin immunoprecipitation of histone H3 with acetylation at K27, followed by quantitative real-
time PCR at the TSSs of p21 and MDM2 as well as the enhancer site of p21, we observed that the 
enrichment of H3K27ac was increased upon the combination of Nutlin and PD0332991 when compared to 
Nutlin treatment alone. IgG is used as a negative control. Mean of three biological replicates.  
 
G. Immunoprecipitation for the enzyme pivotal for transcription, RNA Polymerase II. We observed that at the 
TSSs of the p53 target genes p21, MDM2, PUMA, and PIG3, RNA Polymerase II was enriched with Nutlin 
treatment. Upon combining this with the CDK4/6 inhibitor, we observed decreased occupancy at the p53 
TSS sites. HNRNPK, TFF1_6kb (6kb downstream region of TFF1 gene), and myoD served as negative 
controls, not associating with the RNA Polymerase II. IgG is used as a negative control as well. Mean of 
three biological repeats. 
 
This was confirmed by two different antibodies to RNA Polymerase II (Figure 3.3.S4, A-C). In conclusion, 
CDK4/6 inhibition interferes with the recruitment of RNA Polymerase II by p53, thereby diminishing the 
initiation of transcription at p53 target genes. 
 
DISCUSSION 
Despite the co-amplification of genes encoding CDK4 and MDM2 in human malignancies, our results 
indicate that targeting both simultaneously may be counterproductive for cancer therapy. CDK4 inhibition 
attenuates the p53-response to MDM2-targeted drugs, resulting in decreased cytotoxicity. The CDK4-
Cyclin D1 complex associates with p53, and its activity is required for gene induction and RNA 
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Polymerase II recruitment by p53. Moreover, cell proliferation is diminished in response to Nutlin alone 
but partially re-established by co-treatment with Nutlin and a CDK4 inhibitor. 
We show that the complexes of CDK4 and Cyclin D1 on the one hand, and MDM2 and p53 on the other 
hand, associate with each other. These findings are in line with a previous report that MDMX, another 
close binding partner of MDM2 and p53, is phosphorylated by CDK4 [206]. According to this report, 
CDK4-mediated phosphorylation of MDMX stabilizes its interaction with MDM2 to antagonize p53. This 
type of regulation would be different from the support of p53 activity by CDK4 reported here. However, 
since CDK4 needs to associate with MDMX at least temporarily to phosphorylate it, it is conceivable that 
this interaction further enables the association between the two complexes. This notion is further 
strengthened by a recent report on a physical association between Cyclin D1 and MDM2 [207]. p53 is a 
phosphoprotein that undergoes numerous posttranslational modifications. Given that we observed an 
interaction of CDK4-Cyclin D1 with p53, one might ask whether p53 might be a substrate for the kinase 
CDK4. However, in vitro kinase assays did not reveal any such direct phosphorylation [208].  
How could CDK4 and/or Cyclin D1 assist in the recruitment of RNA Polymerase II to p53-responsive 
promoters? Previous studies revealed that Cyclin D1 [209, 210] as well as the CDK4-related kinase 
CDK6 [211] can associate with target genes and function as transcriptional regulators. Interestingly, one 
of the genome-wide ChIP analysis revealed that Cyclin D1 binds with some preference to sites that also 
associate with p53, among other transcription factors [212]. These observations further support the idea 
that CDK4/CyclinD1 might act as a co-factor for p53 in target gene activation. 
A previous report is in seeming contradiction with our findings, claiming that Palbociclib cooperates with 
the MDM2 antagonist Idasanutlin (RG-7388) in killing liposarcoma cells [194]. Despite testing numerous 
conditions, we were unable to observe a similar synergy. One of the differences might be that in their 
study, the authors mostly used Idasanutlin concentrations that had little effect on tumor cell growth on 
their own, thus precluding any possible antagonism to begin with. While we can never rule out that the 
drugs might cooperate more favorably under clinical conditions, our results do give rise to caution when 
treating patients. We suggest that the combination of inhibitors to CDK4 and MDM2 in the clinic should 
be either avoided entirely or otherwise should be used only after carefully balancing the potential 
benefits with the antagonism reported here. 
Another previous report argued that the cytotoxic effects of Nutlin on p53-proficient cells might depend 
on the ability of MDM2 to degrade the retinoblastoma protein Rb [197]. In cells where accumulated MDM2 
leads to the degradation of hypophosphorylated Rb, apoptosis can be induced, but when Rb remains, 
the cells merely arrest. Such a scenario would argue against the efficacy of combining CDK4 inhibition 
with Nutlin, in line with our observations. CDK4 inhibition can be expected to increase the accumulation 
of hypophosphorylated Rb, since CDK4 is a key driver of Rb phosphorylation [195]. This, perhaps in 
addition to the diminished p53 activity reported here, would then result in decreased apoptosis [197]. 
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Some conventional chemotherapeutic drugs depend on the activation of p53 for their efficacy. Comparing 
p53-proficient and -deficient HCT116 cells, such a dependency was found in particular for 5-fluorouracil 
(5-FU) [213]. On the other hand, the same report showed that p53-deficient cells displayed a higher 
sensitivity towards topoisomerase inhibitors such as Adriamycin. In analogy, the combination of CDK4 
inhibitors and the resulting p53 attenuation would be counterproductive for 5-FU but might be beneficial 
for Adriamycin. However, given the additional cell cycle regulatory functions of CDK4 inhibition, each 
combination remains to be tested individually. 
What combinations could be more promising for cancer treatment? Our previous work suggests that the 
phosphatase PPM1D/Wip1 might represent a suitable target of drugs that synergize with MDM2 
antagonists [177, 214]. Wip1 dephosphorylates p53, thereby compromising its activity as a transcription 
factor. Interfering with this dephosphorylation enhances activating p53 modifications. When this is 
combined with MDM2 inhibitors, both stability and activity of p53 are increased, leading to pronounced 
cell death. The DNA-damaging drug Trabectedin, currently used in second line for treating soft tissue 
sarcoma, was also reported to synergize with the MDM2 inhibitor RG7112 [215], perhaps as a result of 
p53 accumulation (through MDM2 inhibition) and activating p53 modifications (through DNA damage 
response). In pre-clinical investigations and cell culture, MDM2 antagonists also cooperated efficiently 
with MEK or PI3K inhibitors, BH3 mimetics, BCR-ABL antagonists, and HDAC inhibitors [216]. For 
neuroblastoma cells, MDM2 inhibitors cooperate with ALK inhibition [217]. In the case of CDK4 inhibitors, 
combination partners are less obvious. In breast cancer treatment, the CDK4/6 inhibitor Palbociclib is 
often combined with Letrozole, an inhibitor of aromatase in estrogen production, but this only makes 
sense when treating estrogen-dependent tumors [181]. CDK4 inhibition was reported to antagonize 
drugs that require entry into mitosis for their efficacy, such as taxanes [218], probably due to inhibited 
cell cycle progression. On the other hand, CDK4 inhibitors were found to cooperate with inhibitors of 
signaling kinases, such as MEK and PI3K [218, 219]. The underlying mechanisms for this cooperation, 
however, remain to be elucidated. 
On the other hand, the drug antagonism reported here may be used in a beneficial way. In cases where 
p53 is mutated in a tumor, p53-activation by chemotherapeutics can be considered irrelevant. In such a 
scenario, it may be beneficial for normal cells if p53-induced cell death is attenuated. Thus, combining 
CDK4 inhibitors with DNA damaging chemotherapy might turn out to protect non-cancerous tissue in a 
patient, giving rise to a potential strategy for avoiding undesired general toxicities.  
 
Under physiological conditions, the CDK4-Cyclin D1 complex is active in cycling cells and stem cells, 
whereas it is inactive in post-mitotic and terminally differentiated cells [220]. The positive impact of the 
CDK4-Cyclin D1 complex on p53 activity may thus constitute a greater sensitivity of cycling cells towards 
p53 activation, as compared to resting cells. Physiologically, this would make sense, since cycling cells 
are at higher risk for giving rise to cancer, whereas post-mitotic cells are unlikely to resume proliferation 
anyway, and preserving them despite genotoxic stress might help the organism to survive. Thus, the 
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dependence of p53 activity on CDK4 appears as a mechanism to channel tumor suppression on cancer-
prone, proliferating cells, while sparing differentiated cells despite DNA damage.  
MATERIALS AND METHODS 
Cell culture, treatment, siRNA and plasmid transfections 
Human CRL-3043 (93T449) and CRL-3044 (94T778) cell lines were purchased from ATCC. GOT-3 cells 
were a gift from Pierre Åman, University of Gothenburg, Sweden. SJSA and H1299 cells were obtained 
from the German Collection of Cell lines (DSMZ, Braunschweig) and maintained in Dulbecco’s modified 
Eagle’s medium (DMEM). CRL-3043, CRL-3044, GOT-3 cells were maintained in RPMI medium. Cell 
culture media was supplemented with 10% fetal bovine serum (FBS) and antibiotics including 
penicillin/streptomycin and ciprofloxacin. Cells were maintained at 37°C with 5% CO2. For treatment of 
cells, Neocarzinostatin (NCS, 0.5 mg/mL, Sigma-Aldrich), Nutlin-3a (Sigma N6287 and BOC life sciences 
675576-98-4), Palbociclib (PD0332991 isethionate, Sigma PZ0199), Ribociclib (LEE011, Selleckchem 
S7440), Abemaciclib (LY2835219, Selleckchem S7158), MG-132 (Calbiochem 474791) were diluted in 
pre-warmed medium and added to the cells for the indicated periods of time. For siRNA mediated 
transfection using Lipofectamine 2000 (Life Technologies), cells were reverse transfected with 10nM 
siRNA to MDM2 (Ambion; custom made, AAGCCAUUGCUUUUGAAGUUAtt (sense), 
UAACUUCAAAAGCAAUGGCUUtt (antisense)); CDK4 (s2822, Ambion) and a negative control siRNA. 
Medium was changed after 24 hours and cells were harvested 24 hours later. For plasmid 
overexpression, 2µg of plasmid was transfected along with Lipofectamine 2000 by forward transfection. 
Medium was changed after 4 hours and the cells were harvested 24 hours later.  
Plasmid Origin 
pCMV6XL5 Origene 
pCMV-MDM2 B. Vogelstein [221] 
pCMV-cyclinD1 Addgene 19927 
Quantitative mRNA analysis by qRT-PCR. 
Total RNA was isolated using TRIzol (Invitrogen), followed by cDNA synthesis using  Moloney Murine 
Leukemia Virus reverse transcriptase and random hexamer primers (Thermo Scientific). Home-made 
SYBR green master mix was used for quantification using real-time PCR. Gene expression levels were 
normalized to the mRNA from the RPLP0 gene and the analysis was conducted using the ΔΔCt method. 
qRT-PCR primer sets were chosen as follows: 
 
Table 1 List of primers used for gene expression studies  
RPLP0 for GATTGGCTACCCAACTGTTG 
RPLP0 rev CAGGGGCAGCAGCCACAAA 
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p21/CDKN1A for TAGGCGGTTGAATGAGAGG 
p21/CDKN1A rev AAGTGGGGAGGAGGAAGTAG 
MDM2 for TCAGGATTCAGTTTCAGATCAG 
MDM2 rev CATTTCCAATAGTCAGCTAAGG 
PUMA/BBC3 for GCCAGATTTGTGAGACAAGAGG 
PUMA/BBC3 rev CAGGCACCTAATTGGGCTC 
PIG3/TP53I3 for GCTTCAAATGGCAGAAAAGC 
PIG3/TP53I3 rev GTTCTTGTTGGCCTCCATGT 
p21/CDKN1A ie for GTGGCTATTTTGTCCTTGGGC 
p21/CDKN1A ie rev TGGCAGATCACATACCCTGTTC 
MDM2 ie for - a CGGAGAGTGGAATGATCCCC 
MDM2 ie rev - a GCTGGGAACCAGCGATAGAG 
MDM2 ie for - b CCACAGATGTTTCATGATTTCCAG 
MDM2 ie rev - b AGGTGGTTACAGCACCATCAG 
MDM2 ie for - c AGGAGATTTGTTTGGCGTGC 
MDM2 ie rev - c GGTGAACTGAAATGTTAGCCCAG 
 
Immunoblot analysis  
Cells were harvested in protein lysis buffer (1% Triton-X 100, 1% Sodium-deoxycholate, 0.1% SDS, 
150mM NaCl, 10MM EDTA, 20mM Tris-Hcl pH 7.5, 2M Urea). After scraping the cells with the lysis 
buffer, samples were briefly sonicated for 10mins at high speed to disrupt DNA-protein complexes. The 
total amount of protein present in each sample was measured by Pierce BCA Protein assay kit (Thermo 
Scientific Fisher). Prior to loading the samples on the SDS gels, the samples were boiled with 6x-laemmli 
at 95°C for 5 min. Equal amounts of protein samples were separated by SDS-PAGE. This was followed 
by wet-transfer using nitrocellulose membrane and finally visualized with the following antibodies- H2AX 
(S139) (9718, Cell Signalling), -Actin (ab8227, Abcam), p21 (2947, Cell Signalling), pRb (S807/811) 
(9308, Cell Signalling), Rb (9309, Cell Signalling), MDM2 (OP 46, Calbiochem), p53 (DO-1, sc-126, 
Santa Cruz), p53-HRP (DO-1, sc-126, Santa Cruz), CDK4 (ab68266 abcam; DCS-35, sc-23896, Santa 
Cruz), p53 K382ac ( 2525, Cell Signalling), cyclin D1 (ab134175, Abcam). 
Cell proliferation assay (Celigo) 
To determine the proliferation of cells under different treatment conditions, cells were seeded at a density 
6*103 cells/well in 24-well plates. They were treated with Palbociclib and or Nutlin with DMSO as the 
control at the indicated concentrations. Their proliferation capacity was measured using the CeligoTM 
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Cytometer (Nexcelom, software version 2.0). Cell confluence of triplicate samples was measured every 
24 hours for up to 8 days for each time point. 
 
 
Cell viability assay 
In order to measure cell viability after drug treatment, the cells were seeded at a density of 2*104 cells/well 
in 96-well plates having white walls and bottom. These cells were treated with Nutlin and or Palbociclib 
at the indicated concentrations with the highest concentration of DMSO as a control. To the wells without 
any treatment, PBS or empty DMEM was added to account for background luminescence. The drugs 
were incubated for 48 or 72 hours as indicated. Following this, luminescence was measured using the 
CellTiter-Glo® Luminescence Cell Viability Assay (Promega). The CellTiter-Glo® Reagents were mixed 
and added in a 1:1 ratio to each well. The solutions were incubated in an orbital shaker for 10 mins to 
facilitate lysis of the cells. Subsequently, the luciferase signal was measured on a 
LuminometerDLReady™Centro LB 960 reader and the measurements for each condition was 
processed.  
Cell cycle analysis  
To analyse the cell-cycle profile under different treatment conditions, the cells were trypsinized and 
centrifuged to obtain the cell pellets. To each cell pellet, 100% ethanol was used for fixation overnight. 
Following fixation, the cells were washed to allow for rehydration. Finally, for analysing cell cycle analysis, 
propidium iodide was added and the profiles were obtained using Guava system (Millipore). Three 
biological replicates were processed for each condition using the same gate settings. 
Protein co-immunoprecipitation 
To carry out endogenous co-immunoprecipitation in SJSA cells, individual 15cm dishes were used for 
precipitation with one antibody. The cells were harvested in Co-IP buffer 50mM Tris-HCl pH 7.5, 300mM 
NaCl, 1% NP-40 and 0.1% Sodium deoxycholate) along with protease inhibitors (Roche). The 
homogenized cell lysates were pre-cleared with Protein G sepharose beads (GE Healthcare). Equal 
amounts of cell lysates were used for overnight precipitation along with 3 μg of each antibody. The 
following day, the cell lysates were incubated with Protein G sepharose beads for two hours. 
Subsequently, the samples were washed using the Co-IP buffer and the beads were re-suspended in 6x 
Laemmli Buffer. These samples were subjected to SDS-PAGE followed by immunoblot analysis. For 
exogenous Co-IP, cells were transfected in 6 well plates with plasmids 24 hours prior to harvesting. The 
IP procedure was done as described above, using one well per antibody precipitation. 
Chromatin Immunoprecipitation (ChIP) 
Chromatin immunoprecipitation (ChIP) was done according to the protocol published by Denissov and 
colleagues [222]. Briefly, the cells were fixed in 1.1 % formaldehyde (PFA) for 20 min, and quenched 
with 0.125 M glycine and lysed in a lysis buffer containing 0.1 % SDS. Sonication was done using a 
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Bioruptor Pico device (Diagenode) in Pico Microtubes for 15 cycles. The samples were subjected to 
incubation with antibody (2 μg) and Protein A/G PLUS-Agarose (Santa Cruz) beads overnight. Bead 
interaction was released via 20 min rotation incubation in 1% SDS and 0.1 M NaHCO3, and the DNA-
protein crosslink was reversed by addition of 0.2 M NaCl and shaking at 65 °C. DNA was purified by the 
MinElute PCR Purification Kit (Qiagen) and used for targeted PCR. For IP, the following antibodies were 
used: p53 (DO-1, sc-126, Santa Cruz), IgG (ab46540, Abcam), H3K27ac (C15410196, Diagenode), RNA 
Polymerase II (MABI0601, MBL Life Sciences; sc-17798, Santa Cruz; sc-899, Santa Cruz). The following 
primers were used for targeted ChIP: 
Table 2 List of primers used for Chromatin Immunoprecipitation 
For transcription start site amplification  
P21/CDKN1A for CTTTCTGGCCGTCAGGAACA 
P21/CDKN1A rev CTTCTATGCCAGAGCTCAACATGT 
MDM2 for TTCAGTGGGCAGGTTGACTC 
MDM2 rev CCAGCTGGAGACAAGTCAGG 
PUMA/BBC3 for  CCCTGCTCTGGTTTGGTGAG 
PUMA/BBC3 rev AGTCACTCTGGTGAGGCGAT 
PIG3/TP53I3 for CCCTGGGTACCTGCATTAAG 
PIG3/TP53I3 rev TAGCCGTGCACTTTGACAAG 
myo for CTCATGATGCCCCTTCTTCT 
myo rev GAAGGCGTCTGAGGACTTAAA 
p21/CDKN1A TR for CCAGGGCCTTCCTTGTATCTCT 
p21/CDKN1A TR rev ACATCCCCAGCCGGTTCT 
TFF1 6kb for CAGGCTTCTCCCTTGATGAAT 
TFF1 6kb rev ACACCCACCTTCCACAACAC 
HNRNPK for ATCCGCCCCTGAACGCCCAT 
HNRNPK rev ACATACCGCTCGGGGCCACT 
  
For H3K27ac ChIP 
p21 TSS(K27ac) for TCAGGTGAGGAAGGGGATGG 
p21 TSS(K27ac) rev TGTCGCAAGGATCTGCTGG 
MDM2 TSS(K27ac) for AGATGGAGCAAGAAGCCGAG 
MDM2 TSS(K27ac) rev GTACGCACTAATCCGGGGAG 
p21_u2.2kb_for AGCAGGCTGTGGCTCTGATT 
p21_u2.2kb_rev CAAAATAGCCACCAGCCTCTTCT 
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RNA sequencing (same as [177]) 
For RNA-sequencing, the quality of total RNA was determined using the Bioanalyzer 2100 from Agilent 
Genomics. All samples that were analyzed exhibited an RNA Integrity Number > 8. Library preparation 
was carried out using the TruSeq RNA LT SamplePrep Kit (Illumina), starting from 1 µg of total RNA. 
Barcodes for sample preparation were used according to the indications given by the manufacturer. 
Accurate quantitation of cDNA libraries was performed with the QuantiFluor™dsDNA System (Promega). 
The size range of final cDNA libraries was determined applying the DNA 1000 chip on the Bioanalyzer 
2100. cDNA libraries were amplified and sequenced via cBot and HiSeq 4000 (Illumina; SR, 1×50 bp, 6 
Gb/sample ca. 40-50 million reads per sample). Sequence images were transformed using the Illumina 
software from BaseCaller to bcl files. They were demultiplexed to fastq files with CASAVA (version 1.8.2). 
The quality check was performed using FastQC (version 0.10.1 Babraham Bioinformatics). Fastq files 
were mapped to the human reference transcriptome (UCSC hg19) using TopHat gapped-read mapper 
with very sensitive Bowtie2 settings on Galaxy Platform (Version 0.9). Bowtie 2 (version 2.1.0) 
(Langmead and Salzberg, 2012). The read counting was performed via HTSeq (38) (version 0.6.0) with 
the following parameters: -f bam -r pos -s reverse -a 10 -t exon -m union. The count files were 
subsequently subjected for differential analysis using the DESeq2 Package (39) on R (Bioconductor 
version 3.2.2). Heatmap was generated using z-score analysis. RNA library preparation and sequencing 
was done by the Transcriptome Analysis Laboratory (TAL, Göttingen). 
Statistical testing (same as [177]) 
The statistical testing was performed using Graph Pad Prism 6 software. An unpaired t-test with 95% 
confidence was performed with an assumed significance for p-values ≤ 5%. Asterisks represent 
significance. ***, p ≤ 0.001; **, p ≤ 0.01; *, p ≤ 0.05.  
CONFLICT OF INTEREST 
The authors declare no conflict of interest. 
ACKNOWLEDGEMENTS 
RNA-Sequencing data of this study were submitted to the GEO, GSE113369. We thank Pierre Åman, 
University of Gothenburg, Sweden, for GOT3 cells and the Transcriptome Analysis Laboratory (TAL) of 
the University Medical Center Göttingen for performing RNA sequencing. Our work was supported by 
the Else Kröner-Fresenius-Stiftung, the Deutsche Krebshilfe, the Wilhelm Sander-Stiftung, the Deutsche 
José Carreras Stiftung, and the Deutsche Forschungsgemeinschaft. 
AUTHOR CONTRIBUTIONS 
AS and MD conceived the project and designed experiments. ZN and AS carried out the analysis of 
RNA-sequencing data with supervision by SAJ. AD did the co-immunoprecipitations. AS conducted all 
other experiments. MD drafted the manuscript. AS and SAJ revised the manuscript. All authors read and 
approved the manuscript 
RESULTS 
  
83 
 
3.3.1 Supplemental figures  
 
Figure 3.3 S 1 Combined treatment of Nutlin with PD0332991 revealed antagonistic effects with regard to 
cell viability. 
A. Snapshot of the cBioportal dataset from the cancer cell line collections CCLE and NCI-60, with the cell line 
SJSA containing amplifications of CDK4 and MDM2, according to www.cbioportal.org. 
 
 
.  
 
 
Figure 3.3.S 1 Combined treatment of Nutlin with PD0332991 revealed antagonistic effects with regard to 
cell viability.  
 
B. SJSA, CRL3043, CRL3044 and GOT-3 cells treated with Nutlin at the indicated concentrations for 24 hours. 
Lysates were harvested for immunoblot analysis to check for specificity of inhibitor towards its target. Nutlin 
induced p53 and its target genes – p21 and MDM2.  
 
C. To check for specificity of PD0332991 towards its target – pRb (807/811), SJSA, CRL3043, CRL3044 and 
GOT-3 cells were treated with PD0332991 at the indicated concentrations for 24 hours. Lysates were 
harvested and it was noted that PD0332991 reduced phosphorylation on Rb at S807/811. 
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Figure 3.3.S 1 Combined treatment of Nutlin with PD0332991 revealed antagonistic effects with regard to 
cell viability. 
 
D. Combinatorial treatment with Nutlin and PD0332991 in SJSA cells with increasing concentrations of the 
two drugs revealed antagonism with respect to cell viability, by luciferase assay to determine ATP levels 
72 hours post-treatment.  
 
E. Varying drug concentrations were used to treat CRL3043 cells. Cell viability assays (ATP-luciferase) were 
performed after 72 hours to reveal antagonistic cytotoxicity of inhibitors to Mdm2 and CDK4/6.  
 
F. CRL3044 cells were treated with increasing concentrations of Nutlin and PD0332991, alone or in 
combination, followed by viability assays as in E. 
 
G. Viability analysis as in E and F, using another liposarcoma cell line, GOT-3, with similar results.  
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Figure 3.3 S 2. Alternate CDK4/6 inhibitors and MDM2 antagonists decrease p53 target gene expression in 
various sarcoma cell lines. 
A. Treatment scheme is indicated with timings and concentrations of the drugs used.  
B. CRL3043 cells (93 T449) were treated with the different drugs and harvested for immunoblot analysis. 
Upon Nutlin treatment, there was an induction of p53 target genes – p21 and MDM2. This was reduced 
upon co-treatment with PD0332991. ß-actin serves as loading control.  
C. CRL3044 cells (94 T778) were treated with Nutlin and PD0332991 at the indicated concentrations and time 
points. Nutlin indices p53 and its target gene expression namely p21 and MDM2. However, the combination 
of Nutlin with PD0332991 decreased the expression of its targets.  
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Figure 3.3 S 2 Alternate CDK4/6 inhibitors and MDM2 antagonists decrease p53 target gene expression in 
various sarcoma cell lines. 
 
D. SJSA cells were treated with RG7388; another MDM2 antagonist alone and in combination with various 
CDK4/6 inhibitors that are currently FDA approved – LEE011 (Ribociclib) and LY2835219 (Abemaciclib) 
and PD0332991 (Palbociclib). We again observed that RG7388 treatment accumulates p53 and its target 
genes while treatment with CDK4/6 inhibitors decreases the activation.  
 
 
 
E. SJSA cells treated with various CDK4/6 inhibitors for 24 hours to show that they reduce pRb (807/811), its 
primary target. 
 
Figure 3.3 S 2 Alternate CDK4/6 inhibitors and MDM2 antagonists decrease p53 target gene expression in 
various sarcoma cell lines. 
 
F. SJSA cells were treated with Nutlin and the HIPK2 inhibitor A-64 as indicated.  
 
G. SJSA cells were harvested for immunoblot analysis after treatment as in F. Upon Nutlin treatment, p53 as 
well as MDM2 and p21 proteins accumulated. Their levels remained similar upon co-treatment with the 
HIPK2 inhibitor A-64. 
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Figure 3.3 S 3. Impaired complex formation of CDK4 with cyclin D1 upon combined inhibition of MDM2 and 
CDK4/6.  
A. Normalized band intensities from Fig. 3.3.5C, corresponding to CDK4 and cyclin D1, upon treatment with 
Nutlin alone or Nutlin with the CDK4 inhibitor and precipitation with antibodies to Cyclin D1 and CDK4, 
respectively. The reduction shows diminished interaction upon CDK4 treatment. Mean of three biological 
experiments. 
 
 
 
Figure 3.3 S 4. Alternate RNA polymerase II antibodies indicate decreased occupancy upon combined 
treatment. 
A.  SJSA cells were treated with Nutlin and PD0332991 as indicated in the scheme.  
B. RNA polymerase enzyme from MBL life sciences was used for the chromatin immunoprecipitation (ChIP). 
We observed that with Nutlin treatment, there is an enhanced occupancy of RNA polymerase II at the TSS 
of p53 target genes which is decreased when the cells are co-treated with PD0332991. MyoD serves as a 
negative site. IgG is a negative control. Mean of two independent experiments.  
C. RNA polymerase enzyme from Santa Cruz A-10 was utilized for checking the occupancy with Nutlin and 
Nutlin and PD0332991 treatments. As observed previously, there was decreased occupancy of RNA pol II 
with  combined treatment suggesting that the decreased p53 target gene expression is due to defect in 
recruitment of RNA polymerase II enzyme.  
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Supplemental tables and RNA-sequencing data have been deposited to the GEO database. The 
accession number is GSE113369. 
 
References for this section is included along with the introduction and discussion at the end of the thesis. 
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4. DISCUSSION 
In this thesis, we analyzed different strategies for therapeutically targeting p53, a widely studied tumor 
suppressor, referred to as the ‘cellular gatekeeper of growth and division’ [223] or ‘guardian angel of our 
genome’ [224]. Here, we demonstrate the various outcomes of p53 activation upon combining MDM2 
inhibitors with other drugs (Figure 4 1) 
1) Notably, prior activation of p53 led to the protection of p53-proficient cells against the cytotoxic 
effects of WEE1 inhibition and gemcitabine. This protective effect was achieved by p53-mediated 
cell-cycle arrest carried out by p21.  
2) Moreover, pharmacological inhibition of two negative regulators of p53, WIP1 and MDM2 led to 
increased stability and transactivation of p53 target genes. This enabled the cells to attain a state 
of pronounced cell-cycle arrest with mild senescent phenotype.   
3) Finally, we observed an antagonistic effect on cellular cytotoxicity and p53 activity upon targeting 
CDK4 and MDM2 in sarcoma cell lines harboring amplifications of the two genes. This study led 
to the identification of a novel interaction partner of p53, namely the CDK4-cyclin D1 complex. 
Additionally, the combined inhibition led to the decreased recruitment of RNA polymerase II to 
the promoters of p53 target genes, thereby elucidating a supportive role of CDK4 in regulating 
p53 activity.  
 
Figure 4 1 Scheme employed for fortifying p53 activity and the resulting outcomes generated in our study. 
Upon combined inhibition of MDM2 and WIP1, we observed a synergistic decrease in cell viability with increased 
activation of p53 which led to cell-cycle arrest with a mild senescent phenotype. Chemoprotection with MDM2 
antagonist, Nutlin was achieved in p53-proficient cells against cytotoxic compounds such as WEE1 inhibition and 
gemcitabine. Moreover, combined inhibition of MDM2 and CDK4 displayed antagonism with regard to cell viability 
and p53 transcriptional response. Finally, we also demonstrate a novel interaction partner for the p53-MDM2 
complex, namely the CDK4-cyclin D1. Red dotted lines indicate the results generated in our study.  
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4.1 Targeting the tumor suppressor p53  
TP53 gene is inactivated in 50% of human cancers usually by mutations in its DNA binding domain, or 
abrogation of its signaling response either by overexpression of its negative regulators – MDM2 and 
WIP1, downregulation of p14ARF by methylation of the CDKN2A locus, or by degradation of p53 via 
Human Papillomavirus E6 (HPV-E6) [4, 5, 46, 47, 119, 120, 225, 226]. As mentioned in the introduction, 
targeting the interaction between p53 and its negative regulator MDM2 using derivatives that bind to 
MDM2, mimicking three key residues of p53 i.e. Phe19, Trp23 and Leu26 have been studied extensively 
[166]. A few MDM2 inhibitors were tested in clinics but their efficacies were limited. Moreover, these 
attempts have not been very successful so far [167, 168]. Hence, identifying ways to manipulate p53 in 
a targeted manner for improving its therapeutic potential and efficacy in patients is still of great 
importance. In this thesis, we suggest three different strategies of using MDM2 inhibitors. 
4.2 Strategies of MDM2 inhibition  
4.2.1  p53 accumulation protects cells against toxic effects of WEE1 inhibition 
In this study, we demonstrate that pre-accumulated p53 safeguarded p53-proficient cells from the toxic 
effects that are generally observed upon combined WEE1 inhibition and gemcitabine treatment 
(Publication 3.1 Figure 2A-D). WEE1 is a Ser/Thr kinase that phosphorylates its substrate CDK1 at Thr14 
and Tyr15. The phosphorylated CDK1 prevents the entry of cells into M phase [227]. Exposure to WEE1 
inhibitors results in pre-mature mitosis due to lack of phosphorylated CDK1 (active), which allows cells 
to bypass the G2-M checkpoint of the cell-cycle even with unreplicated DNA, ultimately leading to 
apoptosis [228]. Due to its cytotoxic effects that lead to myelosuppression, WEE1 inhibitors have not 
achieved clinical approval so far [229]. On the other hand, gemcitabine is a nucleoside analog that 
causes replicative stress in cells during S-phase [230]. Here, we demonstrate that by pre-treating cells 
with MDM2 antagonists, the toxicity of WEE1 inhibitors and gemcitabine can be reduced due to cell-
cycle arrest caused by p21 via p53 accumulation. This approach of chemoprotection selectively arrests 
p53-proficient cells at G1-S and G2-M phases of the cell-cycle and reduces the toxicity of these inhibitors.  
In agreement with our work, the protective effect of MDM2 inhibition was demonstrated when p53-
proficient cells were exposed to nucleoside analogues such as gemcitabine and Ara-C but not 
chemotherapeutic agents like doxorubicin and cisplatin [231]. In this study, accumulation of p53 
preserved the cells from replicative stress in S-phase by arresting them at G1 and G2 phases of the cell-
cycle. This was determined using clonogenic colony formation assays and flow cytometry analysis. 
Analogous studies using drugs affecting the mitotic spindle, for instance paclitaxel, epothilones A and B, 
and vincristine achieved protection upon doxorubicin pre-treatment. This was possible by induction of 
G2- arrest that was dependent on p53 and p21 levels [232]. Moreover, normal cells could be protected 
from the toxic effects of mitotic inhibitors such as paclitaxel by prior treatment with Nutlin [233, 234]. Pre-
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treatment with Nutlin helped the p53-proficient cells to achieve cell-cycle arrest while the p53-deficient 
cells underwent apoptosis. All these studies indicate a strong dependency on wild-type functional p53 to 
confer protective effects.  
Our study raises concern regarding the schedule for administration of Nutlin, WEE1 inhibitor and 
gemcitabine. Addition of WEE1 inhibitor and gemcitabine must precede p53 activation to achieve 
cytotoxicity in tumor cells. The toxic effects of WEE1 inhibition and gemcitabine might be compromised 
if p53 is already activated. Therefore, this strategy can only be exploited in the case of tumors devoid of 
normal p53; where MDM2 inhibition would not be able to confer protective effects due to lack of cell-
cycle arrest mediated by p21 (Publication 3.1 Figure 3A-C). Meanwhile, chemoprotection would be 
accomplished in normal p53-wild-type cells by using low, non-genotoxic doses of p53 activators (such 
as MDM2 antagonists). This ensures p53-dependent cell-cycle arrest that protects the normal cells from 
the toxic effects of chemotherapeutic drugs. This treatment protocol, referred to as cyclotherapy, allows 
p53-deficient tumors to remain susceptible towards chemotherapy [235]. 
An important caveat of MDM2 antagonists is adverse side-effects including neutropenia and 
thrombocytopenia [165]. These side-effects were observed in liposarcoma patients treated with RG7388, 
an MDM2 antagonist [167]. In vivo studies using xenografts of HCT116 cells indicated that pre-treatment 
with Nutlin reduced neutropenia when combined with BI-2536, a PLK inhibitor [236]. This justifies great 
optimism for such studies that utilize chemoprotection to enter clinical trials. Nevertheless, using 
concentrations of MDM2 antagonists that cause cytostatic rather than cytotoxic effects would be pivotal 
to eliminate adverse side-effects. 
4.2.2 MDM2 and WIP1 inhibitors in combination are synergistic in activating p53  
Apart from MDM2, WIP1 is another negative regulator of p53. Induced by p53 upon its activation, WIP1 
dephosphorylates p53 primarily at Ser15, rendering it less active. Interfering with MDM2 and WIP1 in a 
panel of cell lines harboring amplified or truncated WIP1 led to a synergistic decrease in cellular 
proliferation with increased accumulation of phosphorylated (p53PS15) and acetylated p53 
(p53K382ac). Both drugs synergistically increased the expression of p53 target genes leading to cell-
cycle arrest at the G2 phase of the cell-cycle with mild senescence in cells (Publication 3.2 Figure 6). 
Two other groups also indicated similar results upon combining MDM2 and WIP1 inhibitors [237, 238]. 
Our results agree with their reports, including a genome-wide mRNA sequencing indicating augmented 
expression of p53 target genes (Publication 3.2 Figure 4) upon combined inhibition. We also 
demonstrated enhanced promoter occupancy of p53 (Publication 3.2 Figure 5) that in part, might be 
contributed by increased acetylation of p53 at Lys382 (Publication 3.2 Figure 2). Although Pechackova 
et al observed increased caspase activity indicative of apoptosis which we did not, this could be attributed 
to differences in the duration and concentration of the drug treatments. In our cell system, we did not 
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observe morphological differences in cells that would indicate apoptosis or cleavage of PARP upon 
immunoblot analysis when treated with WIP1 and MDM2 inhibitors. 
Therapeutic benefits of WIP1 inhibition can be maximized by choosing p53-proficient tumors having 
WIP1 hyper-activation via amplification or truncation of the gene. This would render the combination of 
the two drugs most sensitive. Although we only observed a mild senescent phenotype with a strong cell-
cycle arrest, elimination of these tumor cells could be fortified by additional inhibitors which accentuate 
apoptosis including BH3-mimetics, PI3K and AKT inhibitors. Apart from MDM2 and WIP1 inhibition, 
treatment with ionizing radiation would enhance ATM-mediated p53 activation at Ser15 which would no 
longer be counterbalanced by the phosphatase activity of WIP1. This might be a combination that could 
enhance apoptosis in tumor cells. 
4.2.3 Antagonism of MDM2 and CDK4/6 inhibitors in sarcoma cells 
Clinical trials on liposarcoma patients with MDM2 inhibitors indicated insufficient therapeutic efficiency. 
The genetic landscape of well-differentiated and de-differentiated liposarcomas is characterized by an 
amplification of chromosome 12q13-15 region within which resides the gene encoding MDM2, and also 
CDK4 [239]. An ongoing clinical trial on well-differentiated and de-differentiated liposarcoma patients 
(NCT02343172) using the MDM2 antagonist HDM-201 and the CDK4/6 inhibitor Ribociclib prompted us 
to test this combination in a panel of sarcoma cell lines. We noted that the combined inhibition of MDM2 
and CDK4/6 led to antagonistic effects on cellular cytotoxicity and p53 transcriptional activity. 
Interestingly, we were able to demonstrate the interaction of p53-MDM2 and CDK4-cyclin D1 complexes. 
Furthermore, the combination treatment diminished the interaction of CDK4-cyclin D1 and p53 
complexes with decreased recruitment of RNA polymerase II to the target genes of p53. Our study 
uncovers a novel role of the CDK4-cyclin D1 complex in maintaining p53 activity. This, in turn, provides 
evidence that the combination of MDM2 and CDK4/6 inhibition is unwarranted in liposarcoma patients 
due to the lack of synergism with viability and p53 transcriptional activity.  
A recent report published by Laroche-Clary and co-workers is contradictory to the effects we have 
demonstrated [194]. They detect synergism in cell viability and p53 activity upon combining Idasanutlin, 
an MDM2 antagonist and PD0332991 in one cell line - IB115 derived from a patient sample. Xenograft 
tumors generated from this cell line indicated reduced tumor burden with increased survival rates upon 
MDM2 and CDK4/6 inhibition. However, the concentration of MDM2 antagonists used in this study is 
low, which suggests that their results are mostly due to CDK4/6 inhibition. We tested this combination in 
not just liposarcoma cell lines, but also in an osteosarcoma cell line (U-2 OS) and non-transformed breast 
epithelial cells (MCF10A) that indicated antagonism in the p53 transcriptional activity (Figure 5.A1.A-C). 
This is also suggestive that the attenuated p53 activity is not completely dependent on the amplified 
MDM2 and CDK4 genes upon their inhibition. Moreover, varying time points and concentrations of 
CDK4/6 inhibitors in combination with MDM2 inhibitors were tested (Figure 5.A1.D-E). This resulted in 
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decreased expression of p53 target genes; even upon combined inhibition for 6 hours. Furthermore, we 
consistently observed the reduced transcriptional activity of p53 with different MDM2 and CDK4/6 
inhibitors (Figure 3.3 2B-C).  
In our study, we show that CDK4, a kinase and p53, a protein that undergoes extensive phosphorylations 
interact with each other (Figure 3.3 5). The immediate question that arises is whether p53 is 
phosphorylated by CDK4. Our experiments revealed no differences in the phosphorylation of p53 at 
Ser20 and Ser46 residues upon single treatment with drugs accumulating p53 and in combination with 
CDK4/6 inhibitor (Figure 5.A2.A-D). This agrees with a study carried out in the lab of Carol Prives using 
in vitro kinase assays which revealed that the phosphorylation of p53 is mediated by S and G2/M CDKs 
but not CDK4 or CDK6 [208]. Since CDK2 has been implicated in phosphorylating p53 [240], we depleted 
the cells of CDK2 (Figure 5.A3.F-G). This did not rescue the downregulated transcriptional response of 
p53 target genes upon MDM2 and CDK4/6 inhibition. Besides, arresting the cells at the G1 phase of the 
cell-cycle by CDK4/6 inhibitors excludes the G2/M CDKs. However, we cannot eliminate the off-target 
effects contributed by CDK4/6 kinase inhibitors utilized in our experiments as they inhibit the ATP-kinase 
domain [241-243]. Is it possible that CDK4/6 inhibitors are indirectly affecting other kinases that 
phosphorylate p53? Performing a phosphoproteomic screen of cells treated with MDM2 inhibition alone 
and in combination with CDK4/6 inhibitors might suggest differences in post-translational modification 
(PTM) of proteins, in particular of p53 that might explain the transcriptional attenuation. 
We observe consistently that the protein levels of MDM2 are more diminished upon combined inhibition 
of CDK4/6 and MDM2 in various cell lines as compared to the mRNA expression of MDM2. This 
difference in MDM2 protein and mRNA stability has also been previously described [244]. They suggest 
that the decreased MDM2 protein levels are post-translationally regulated in part by HAUSP, a 
deubiquitinating enzyme. In our studies, we observed that upon inhibiting the proteasome using MG132, 
the MDM2 protein levels were not completely rescued (Figure 5.A3 A-B). Therefore, we hypothesized 
that another factor regulating the stability of MDM2 is affected upon combined inhibition of MDM2 and 
CDK4/6. In order to address this, several candidates such as HIPK2, EZH2, p73, and MDMX were tested 
(Figure 5.A3.C-E; H-I). These proteins were chosen as candidates since they have been described to 
interact with and regulate the stability of MDM2 [164, 245-247]. However, none of these proteins were 
found to affect the stability of MDM2 upon their depletion or inhibition.  
Contrary to our observations, two groups demonstrated synergistic activation of p53 target genes using 
pan-CDK inhibitor like roscovitine and a CDK9 inhibitor known as DRB (5,6-dichloro-1-β-D-
ribofuranosylbenzimidazole) that can inhibit other kinases including casein kinase II [248, 249]. These 
drugs were found to synergize with DNA damaging agents like camptothecin and MDM2 antagonists in 
the induction of p53 activity and stability. This also led to the abrogation of MDM2 levels which they 
propose could be a result of CDK9 and CDK7 inhibition that in turn affects RNA polymerase II activity. 
The similarities between these studies and ours are the downregulation of MDM2 protein levels. A follow-
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up experiment that could provide more useful information would be to use a more specific CDK9 inhibitor 
such as NVP-2 [250] in combination with Nutlin. This would provide further insight into MDM2 stability 
and p53 activity with CDK9 inhibition in our settings.  
Decreased recruitment of RNA polymerase II to p53 target genes upon combined inhibition could suggest 
a role for CDK4/6 to phosphorylate this enzyme or other key transcriptional regulators. RNA polymerase 
II seemed to be a good candidate since it undergoes extensive phosphorylations at its C-terminal domain 
(CTD) (reviewed in [251]). Moreover, since CDK9, CDK12, and CDK7 are known kinases that 
phosphorylate RNA polymerase II [252], it seemed plausible that CDK4/6 kinase might be implicated as 
well. To test this hypothesis, we looked at total Ser2 and Ser5 phosphorylation sites of RNA polymerase 
II at specific p53 target gene promoters via chromatin immunoprecipitation (Figure 5.A4 A-C). Although 
the signals from these experiments upon treatment were not very high, our data does not indicate a role 
of the kinase activity of CDK4/6 in phosphorylating the CTD of RNA polymerase II at p53 target genes. 
Are there any other candidates involved in the transcriptional regulation? Transcription factor IIA (TFIIA), 
a member of the general transcriptional factors (GTF) has been described to be phosphorylated by TBP-
associated factor 250 (TAF250) [253]. It will be interesting to check for the occupancy of TFIIA, TAFII250 
and Tata-box binding protein (TBP) of the TFIID complex using chromatin immunoprecipitation with the 
single and double treatments of MDM2 and CDK4/6 inhibitors. This will enable us to have a better 
understanding of the transcriptional machinery and determine if these general transcription factors are 
sufficiently recruited to the promoters of p53 target genes.  
We displayed the interaction of CDK4-cyclin D complex with p53-MDM2 (Figure 3.3.5A). A study by Yang 
and colleagues exhibited an interaction between MDM2 and cyclin D1 proteins, and also suggest that 
the increased cyclin D1 expression following Nutlin treatment is due to increased MDM2 expression 
[207]. This further supports our data regarding the interaction between these complexes. Furthermore, 
a recent investigation proposed a novel phosphorylation site at Ser314 on MDMX by CDK4 [206]. They 
demonstrated that RTK Human Epidermal Receptor growth factor 4 (Her4) inhibits the transcriptional 
activity of p53 by phosphorylation of MDMX by CDK4 which stabilizes the MDM2/MDMX complex. 
Although we did not observe increased accumulation of MDM2 in our studies with the combination of 
MDM2 and CDK4/6 inhibitors, it is conceivable that MDMX and CDK4 probably interact with each other 
and subsequently phosphorylate MDMX. This agrees with our observation that MDM2 and CDK4 
complexes interact with one another. The decreased interaction of CDK4 and cyclin D1 proteins upon 
addition of CDK4/6 inhibitors could be attributed to differences in protein stability by its displacement 
from the Cdc37-Hsp90 chaperone complex [203]. 
As most transcription factors would require co-factor binding, the question arises concerning the 
possibility of CDK4 or cyclin D1 as a co-factor essential for efficient transcription of p53 target genes. 
There is currently no literature supporting the role of CDK4 as a transcription factor, although CDK6 has 
been characterized [254, 255]. Conversely, cyclin D1 is shown to act as a transcriptional regulator [256, 
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257], which is suggestive of a putative transcriptional regulatory role in accentuating p53 activity in our 
study. However, endogenous Chromatin-immunoprecipitation (ChIP) of CDK4 and cyclin D1 did not 
reveal efficient binding to target genes of p53 which could be due to non-availability of ChIP-grade 
antibodies, weak binding to the chromatin or less efficiency of ChIP (Figure 5.A5 A-D). Tagged cyclin D1 
or CDK4 might help dissect the role of these proteins, if any, in the transcriptional activation of p53 target 
genes. Interestingly, ChIP sequencing of cyclin D1 in mice showed significant enrichment towards p53 
binding sites [257]. Thus, it is possible that cyclin D1 might be an essential regulator of p53 target gene 
expression. Disrupting the CDK4-cyclin D1 complex with CDK4/6 inhibitors might impair the regulation 
of these genes. Thus, investigating the possibility of cyclin D1 on the chromatin would provide us with a 
mechanistic insight in elucidating the antagonistic effects of MDM2 and CDK4/6 inhibition in the p53 
transcriptional response. In this regard, using tagged cyclin D1 for pull-down in chromatin 
immunoprecipitation experiments would provide useful information. 
4.3 Concerns regarding therapeutic inhibition of the MDM2-p53 interaction  
In addition to using MDM2 inhibitors as standalone drugs for the treatment of tumor cells, or xenograft 
models and patients, identifying potent drug(s) for combination studies is pivotal. Along the same lines, 
identifying the characteristics of tumors that respond to the combination is principal. In this thesis, we 
combined MDM2 and WIP1 inhibitors in cells to combat two negative regulators of p53. Two important 
factors taken into consideration were p53 and WIP1 status of the tumor cells. We used cell lines having 
wild-type p53 and truncated/amplified WIP1 to maximize the effects of the inhibitors. This led to a strong 
p53 activation followed by senescence in cells treated with the combination of MDM2 and WIP1 inhibitors 
[177]. On the other hand, combining MDM2 and CDK4/6 inhibitors in liposarcoma cells that have an 
amplification of both these genes resulted in drug antagonism with respect to cell viability and p53 
transcriptional activity. Consequently, having a clear understanding of the tumor type and drug 
combination is essential. 
Chemotherapy is a commonly used treatment procedure where agents causing DNA damage and 
impairment of mitosis such as alkylating agents, microtubule and topoisomerase inhibitors, 
antimetabolites, antifolates and cytotoxic antibiotics [258] are administered to cancer patients. A 
fascinating study by Bunz and colleagues studied the response of p53 towards different 
chemotherapeutics namely adriamycin, radiation and 5-fluorouracil (5-FU) using an isogenic pair of 
colorectal cell lines – HCT116 p53 +/+ and HCT116 p53-/- [213]. While DNA damaging agents such as 
adriamycin and ionizing radiation induced cell death in p53 null cells, these cells were resistant to 
apoptosis upon 5-FU treatment. Moreover, the tumor responses observed using xenograft models upon 
treatment with these agents were diminished in comparison to the cellular responses in vitro. Thus, 
having a clear understanding of the tumor status (p53 wild-type, p53 mutant or p53-null) and type of the 
treatment is very critical.    
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Comprehending the circumstances by which p53 mediates cell death and cell survival in p53-proficient 
tumors is vital. In cases where p53 remains in its normal state, apart from MDM2 inhibition, induction of 
apoptosis can be fortified using BH3-mimetics, as reviewed in [214], and death ligands such as tumor 
necrosis factor-related apoptosis-inducing ligand (TRAIL) [259]. In cases where p53 is non-functional, 
which occurs in nearly 50% of human cancers, taking advantage of the situation is paramount. Exploiting 
the pro-survival functions of p53 in normal cells can be performed by MDM2 inhibition in combination 
with chemotherapeutics such as gemcitabine, WEE1 inhibitors, cisplatin, actinomycin-D and etoposide 
[176, 260, 261]. This concept known as ‘cyclotherapy’ [235] is based on the induction of cell-cycle arrest 
by CDKN1A expression in normal cells by MDM2 inhibition which helps to repair the damaged DNA that 
is induced by cytotoxic compounds. In the tumor, however, due to the absence of p53, cells remain 
cycling. Further addition of chemotherapeutics and genotoxic compounds cause replicative stress that 
leads to mitotic arrest and accumulation of damage that ultimately results in apoptosis. Applicability of 
cyclotherapy in clinics still requires further studies. Moreover, the impact of pre-activated p53 in 
combination with chemotherapeutics on non-proliferating cells such as cardiomyocytes or neurons needs 
additional testing.  
Clinical trials and in vivo studies using MDM2 inhibitors indicated the emergence of p53 mutations in 
patients [165, 262]. There is a significant tendency of mutual exclusivity in overexpression of 
MDM2/MDMX and mutations in p53. Cancers where these mutual exclusivities are often observed 
include liposarcoma, glioblastoma multiforme, melanoma, prostate, Estrogen Receptor –positive (ER) 
breast cancer and bladder cancer. Therefore, treating such patients with MDM2 antagonists might be a 
good starting point as a precaution for the emergence of p53 mutations.  
Of prime concern were hematological and gastrointestinal toxicities that patients administered with 
MDM2 antagonists faced which were dose- limiting [167, 263]. The major question that needs to be 
addressed is how p53 can be targeted in a focused fashion to avoid these adverse effects. Remarkably, 
in xenograft models upon pre-treatment with Nutlin followed by BI-2536, an inhibitor of PLK1, reduced 
neutropenia was observed [236]. Currently, different MDM2 inhibitors are in clinical trials. Few of them 
include, AMG-232 [264] for patients diagnosed with glioblastoma and soft tissue sarcoma, DS-3032b for 
hematological malignancies [265], and HDM201 in the case of solid tumors [266]. Some others include 
RO6839921; a pegylated form of Idasanutlin which is a prodrug formulated for intravenous administration 
for treating Acute Myeloid Leukemia (AML) patients (NCT02098967), and APG-115; an analogue of 
SAR405838 that is used in patients diagnosed with advanced solid tumors and lymphomas. The outcome 
of these studies might unravel drugs having lower toxicity and reduced adverse effects with increased 
efficacy for treatment of patients.  
4.4 Alternatives to the classical MDM2-p53 inhibitors  
Having mentioned the concerns regarding the usage of MDM2 inhibitors to activate p53, the question 
emerges relating to alternatives. Similar to MDM2 inhibition leading to cell-cycle arrest via p21 due to 
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p53 activation, CDK4/6 inhibitors such as Palbociclib, Ribociclib and Abemaciclib also cause cell-cycle 
arrest. This is carried out by inhibiting the phosphorylation of Rb by CDK4/6 which prevents E2F1 to 
transcribe its target genes that allows cells to progress into the S-phase of the cell-cycle. Therefore, the 
addition of these drugs would arrest both, the normal cells and tumor cells. Furthermore, combining them 
with cytotoxic compounds would not be targeted towards a selected population of cells. Hence, it might 
not represent a viable strategy for treating p53-proficient cancers.  
Nonetheless, CDK4/6 inhibitors might be beneficial for the treatment of Rb negative or Human 
Papillomavirus E7 (HPV-E7) positive tumors in combination with S or M-phase poisons. Since Rb-
mediated cell-cycle arrest would be circumvented in the tumor cells upon addition of CDK4/6 inhibitors, 
they would be most sensitive towards the toxic effects of DNA damaging agents and chemotherapeutics. 
On the other hand, normal cells that retain functional RB gene will undergo cell-cycle arrest, thus 
protecting them from the cytotoxic impact of these poisons.   
Apart from the plethora of drugs that inhibit the binding of p53 and MDM2 like Nutlins, few compounds 
are available in the market which are directed towards the C-terminus RING domain of MDM2. These 
drugs JNJ-26854165 [267], HLI98 [170], MPD [268], MEL 22/23 [169] and others inhibit the ubiquitin 
ligase activity of MDM2. Treatment of p53-proficient cells with these inhibitors resulted in decreased 
degradation of p53 by MDM2, along with cell-cycle arrest or apoptosis-related gene expression. Our 
group showed that the interaction of MDM2 with Polycomb group (PcG) member PRC2 complex leads 
to the enhancement of repressive marks via H3K27me3 and H2AK119ub on Hox genes that are involved 
in maintaining stemness [164]. The resulting fate of cells upon targeting both, the N-terminal p53-binding 
domain and C-terminal RING-finger domain of MDM2 using these drugs might be of interest. 
Combination of these drugs with WIP1 inhibitors, ionizing radiation, DNA damaging agents, and 
chemotherapeutic drugs causing replicative stress would be extremely interesting to study.  
Thus, simultaneously targeting the ubiquitin ligase function of MDM2 along with activation of p53 will be 
of utmost interest to clinics. It would also be appealing to study the differentially regulated genes when 
MDM2 is inhibited at both N and C-terminal domains in a p53 proficient background. This might provide 
further insight into the role of MDM2 – is its purpose primarily p53-dependent?, is there a balance 
between its chromatin-bound RING-finger domain effects and p53-dependent functions? or would the 
scale shift towards its E3 ubiquitin ligase functions? 
4.5 Harnessing mutant p53 
50% of tumors have a mutated p53 protein [4, 5]. An appealing approach enabling p53 to carry out its 
tumor suppressive functions is to identify therapeutic agents that allow mutant p53 to regain its wild-type 
p53 functions. PRIMA-1 (p53-reactivation and induction of massive apoptosis) was recently 
demonstrated to re-activate p53-dependent apoptosis via NOXA in esophageal squamous cell 
carcinoma cells having missense mutations in TP53 [269]. It acts upon conversion to methylene 
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quinuclidinone which binds covalently to cysteine residues in p53 that is sufficient to re-activate the 
protein [270]. In-silico predictions have suggested multiple peptides that enable reactivation of mutant 
p53, including proof-of-principle strategies [271-273]. APR-246, a p53-mutant-reactivator and methylated 
form of PRIMA-1 [173] showed a moderate response in p53-mutated patients diagnosed with Acute 
Myeloid Leukemia (AML) and Chronic Lymphoid Leukemia (CLL) [274] that is under clinical trials. A 
fraction of mutant p53 has been described to form aggregates [275] which when targeted restores wild-
type p53 functions in a xenograft model using small peptide inhibitor ReACp53 [276]. The therapeutic 
effects of these inhibitors need to be studied in the clinics.  
Apart from reactivating mutant p53, inhibiting it seems to depict an alternative route since tumors often 
get addicted to mutant p53 [277]. Destabilizing mutant p53 has been extensively exhibited using indirect 
inhibitors of HSP90, HDAC and SIRT1 [278]. Thus, targeting mutant p53 is a strategy that needs to be 
extensively examined. This might enable us to treat a wider set of patients that could translate to a better 
prognosis. 
4.6 Concluding remarks and future perspectives  
In this thesis, we describe strategies of targeting the MDM2-p53 interaction using small-molecule 
inhibitors that antagonize MDM2, an E3 ubiquitin ligase which causes proteasomal degradation of p53.  
Using precise combinations of drugs for the treatment of individual tumors is crucial. Understanding the 
cancer cell-type, its genetic landscape, and sensitivity of the tumors to each drug is indicative of the 
response and efficacy of treatment. We observed that MDM2 inhibition alone was not sufficient to 
increase p53 activation to eliminate tumors. Thus, we performed combination studies by choosing cell 
lines that would be most sensitive towards these drugs.  
Interestingly, we found that inhibiting the function of proteins that are oncogenic in tumor cell lines by its 
amplification using drugs is not a determinant of its sensitivity. On the one hand, we observed synergistic 
effects of decreased cell survival and increased p53 activation upon combined MDM2 and WIP1 
inhibition in WIP1 amplified/truncated tumors. On the other hand, we observed antagonistic effects on 
cell viability and p53 response in tumors with amplified MDM2 and CDK4 in response to inhibitors of both 
these genes. Thus, the combination of inhibitors needs prior testing in cell lines to ensure that drugs 
which indicate synergism proceed to clinical trials. 
Although we observed an unexpected effect upon combining MDM2 and CDK4/6 inhibitors, this led us 
to uncover a novel role of CDK4 in regulating p53 transcriptional activity. Despite almost four decades of 
work on the tumor suppressor TP53, we are still deciphering its numerous functions. We could 
demonstrate a new interacting partner for the MDM2-p53 complex, namely CDK4-cyclin D1. The 
interaction between CDK4 and cyclin D1 was weakened upon CDK4/6 and MDM2 inhibition; which might 
indicate a necessity of the complex for proper p53 activation.  
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Consequently, having a clear understanding of the pathways regulating p53 transcription is critical for 
therapeutic benefits. To put this study in perspective, actively dividing cells require CDK4-cyclin D1. In 
such cases, p53 is required to mediate repair or arrest of the cells in case of damage. However, in post-
mitotic, senescent or differentiated cells, activation of p53 is not critical since these cells would not 
accumulate mutations. Therefore, this might be a strategy that cells exploit to keep p53 active in 
proliferating cells.   
p53 plays a key role in myocardial infarction (MI) by inducing apoptosis at the infarcted myocardial tissue 
[279]. Targeted deletion of p53 in mice with ligated coronary artery to mimic MI was found to improve 
their survival rates. Since we observe decreased transcriptional activation of p53 upon CDK4/6 inhibition, 
it is possible that upon treatment of mice with these inhibitors, apoptosis at the site of the infarcted tissue 
could be reduced. This would also be helpful in the case of reducing hypoxia-induced endothelial cell 
death during stroke since it is a p53-dependent process [280]. Moreover, cells lacking p53 have longer 
survival rates during hypoxia indicating that targeting p53 under such conditions would be beneficial 
[281]. Thus, it makes it conceivable that CDK4/6 inhibitors can be utilized as p53 inhibitors, which would 
help to extend the survival rates of patients diagnosed with such conditions. 
Finally, we demonstrate a scenario where p53-deficient tumors can be eliminated by cytotoxic drugs 
such as WEE1 inhibitors and nucleoside analogs like gemcitabine while conferring a protective effect on 
the p53-proficient cells by prior activation of p53 using MDM2 antagonists. Exploiting cyclotherapy might 
be beneficial for the treatment of tumor patients having p53-null or mutant tumors. Moreover, CDK4/6 
inhibitors might be better drugs for achieving chemoprotection in normal cells due to the reduced adverse 
effects of myelosuppression observed in patients [282]. This is due to reversible cell-cycle arrest but not 
apoptosis of the bone marrow cells. Protecting these cells from chemotherapeutics and damaging agents 
is also possible if the tumors are deficient for RB. Thus, exploring this avenue further would be interesting. 
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5. APPENDIX 
 
 
Figure 5 A 1 Alternate cell lines also show diminished activation of p53 when combined with 
CDK4/6 inhibitor.  
A. Scheme denoting the treatment scheme.  
B. U-2 OS (osteosarcoma) cells were exposed to DMSO, Nutlin, PD0332991 and the combination 
treatment. Cells were harvested for immunoblot analysis to check for the expression levels of 
MDM2, p53 and p21. In both cell lines, treatment of Nutlin with PD0332991 reduced the protein 
levels of p53 and its target genes p21 and MDM2 in comparison to Nutlin treatment alone. β-
actin serves as loading control. 
C. MCF10A (non-tumorigenic breast epithelial) cells were treated with DMSO, Nutlin and 
PD0332991 at different concentrations. The cells were harvested for immunoblot analysis to 
check for the expression of p53 target genes such as p21 and MDM2. β-actin serves as loading 
control. 
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Figure 5 A 1 Various concentrations and time points of cells treated with PD0332991. 
D. SJSA cells were treated with PD0332991 at varying time points as mentioned. Immunoblot 
analysis revealed diminished MDM2 expression even upon 6h combined treatment with Nutlin.  
 
E. SJSA cells were treated with different concentrations of CDK4/6 inhibitor and the cell lysates 
were assessed for p53 target genes- MDM2 and p21 using immunoblot analysis. We noted 
decreased MDM2 levels even with 1µM PD0332991 in combination with Nutlin. β-actin serves 
as loading control. 
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Figure 5 A 2 Phosphorylation of p53 at S20 and S46 upon p53 accumulation and CDK4/6 
inhibition.  
A. CRL3044 cells were treated with DMSO, Nutlin, NCS alone and in combination with PD0332991 
for 6 hours. Immunoblots depicting p53 and its target gene expression shows attenuated 
response upon combined Nutlin/NCS treatment with PD0332991. pS20 p53, a site 
phosphorylated upon p53 activation remained unchanged upon Nutlin treatment alone or in the 
combination.  
B. SJSA cells were treated with DMSO, NCS, Nutlin, PD0332991 with the combinations for 6 hours 
and the cell lysates were harvested for immunoblot analysis to check for p53 activation and 
stabilization. Again, there were no differences observed in the phosphorylation of p53 at S20 
with Nutlin treatment alone or in combination with PD0332991 treatment. 
C. Treatment scheme for MCF10A cells.  
D. To investigate changes, if any in the pS46 p53 upon Nutlin/NCS treatment alone or in 
combination with PD0332991, cells were harvested for immunoblot analysis. Probing for pS46 
p53 did not indicate strong differences, although we still noted the decreased activation of p53 
response. β-actin serves as loading control. 
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Figure 5 A 3 Treatment with proteasome inhibitor partly rescued MDM2 protein expression.  
A.  Scheme used for treatment protocol.  
B. SJSA cells were probed for p53 and its target genes upon addition of MG132, an inhibitor of the 
proteasome to check whether the stability of the protein is affected. Immunoblot analysis 
revealed only partial rescue of MDM2 protein levels upon combined addition of Nutlin and 
PD0332991 with MG132 in comparison to Nutlin and PD0332991 treatment alone. β-actin serves 
as loading control. 
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Figure 5 A 3 MDM2 stability and expression remains largely unaffected upon depletion of EZH2 
or p73. 
C. Treatment protocol.  
 
D. SJSA cells were depleted of EZH2 using two different siRNAs. We observe very slight decrease 
in protein stability of MDM2 with siEZH2-2 but not siEZH2-1 upon Nutlin treatment.  
 
E. SJSA cells were transfected with three siRNAs towards p73. Two siRNAs – sip73-2 and sip73-
3 decreased the expression of MDM2 in combination with Nutlin treatment. However, the p53 
and p21 levels rather increased with sip73-3. β-actin serves as loading control.  
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Figure 5 A 3 MDM2 stability and expression remains largely unaffected upon depletion of CDK2. 
F. Scheme exhibiting the treatment protocol.  
 
G. Exhausting the cells of CDK2 utilizing two siRNAs in combination with Nutlin and PD0332991 
treatment did not rescue MDM2 levels. β-actin serves as loading control. 
 
Figure 5 A 3 MDM2 stability and expression remains largely unaffected upon depletion of MDMX, 
its dimerization partner.  
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H. Removal of MDMX from SJSA cells with Nutlin and PD0332991 treatment did not rescue the 
MDM2 protein levels as observed with control knockdown and the combination treatment. β-
actin serves as loading control.  
 
I. Three different siRNAs to MDMX showed decreased expression upon its depletion using 
quantitative RT-PCRs. The siRNA to MDMX used in H was a pool of the three siRNAs shown in 
I. RPLP0 is used as housekeeping gene. 
 
 
 
 
Figure 5 A 4 Combination of MDM2 antagonist with CDK4/6 inhibitor does not largely affect pS2 
and pS5 RNA polymerase II at p53 target genes.  
A. Protocol for treatment of SJSA cells with MDM2 antagonist and CDK4/6 inhibitor.  
B. Chromatin immunoprecipitation carried out for pS2 RNA polymerase II with IgG as negative 
control. Targeted qPCRs were performed at the promoters of p53 target genes. The enrichment 
of pS2 RNA polymerase II (an indicator of transcriptional elongation) upon combined treatment 
of MDM2 and CDK4/6 inhibition in comparison to Nutlin alone was similar. 
C. Chromatin immunoprecipitation conducted for pS5 RNA polymerase II with IgG as negative 
control. Targeted ChIP-qPCRs were performed at the promoters of p53 target genes. The 
enrichment of pS5 RNA polymerase II (represents initiation of transcription) upon combined 
inhibition of MDM2 and CDK4/6 in comparison to MDM2 inhibition alone was similar. 
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Figure 5 A 5. CDK4 and MDM2 inhibition leads to slightly elevated enrichment of cyclin D1 at the 
promoters of p53 target genes.  
A-D. Upon performing chromatin immunoprecipitation in SJSA cells after 6 hours treatment with MDM2 
and CDK4/6 inhibitors, we observed increased occupancy of p53 at its target genes upon combined 
MDM2 and CDK4/6 inhibition in comparison to single treatment alone. Moreover, the combined MDM2 
and CDK4/6 inhibition resulted in reduced MDM2 enrichment and RNA polymerase II occupancy at these 
sites. Precipitation with cyclin D1 led to signals with enrichment just above the negative control IgG. In 
case of MDM2 and PIG3 promoters, the enrichment was increased in comparison to Nutlin treatment 
alone. Cyclin D1 has been suggested to act as a transcriptional regulator. In this case, it is tempting to 
suggest the role of cyclin D1 as a transcriptional repressor of p53 target genes.
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8. ABBREVIATIONS 
 
% percentage 
µg microgram 
µl microliter 
µM micromolar 
5-FU 5-fluorouracil 
ACC Adrenocortical carcinoma 
AML Acute Myeloid Leukemia 
APAF-1 Apoptosis-peptidase activating factor-1 
ARF Alternate reading frame 
ATM Ataxia Telangiectasia Mutated 
ATR Ataxia Telangiectasia and Rad-3 related 
bam Binary version of SAM files 
BAX Bcl-2-Associated X protein 
BCA Bicinchoninic acid 
Bcl-2 B-cell lymphoma 2 
BTG2 BTG anti-proliferation factor 2 
Caspases Cysteine aspartic proteases 
CBP cAMP-response element -binding protein 
CCND1 Cyclin D1 
CDK Cell-cycle dependent kinase 
ChIP Chromatin Immunoprecipitation 
CI combination index 
CK2 Casein Kinase 2 
CLL Chronic Lymphoid Leukemia 
CO2 Carbon dioxide 
Co-IP Co-immunoprecipitation 
COP1 COnstitutively Photomorphogenic 1 
CTD C-terminal domain 
DBD DNA binding domain 
DDB2 DNA damage binding protein 2 
DDR DNA damage response 
DMEM Dulbecco’s modified Eagle’s medium 
DMSO Dimethyl sulfoxide 
DNA-PK DNA-dependent protein kinase 
DRB 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole 
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DREAM MuvB-p107/p130-DP-E2F4 
DSB DNA-Double-Strand Breaks 
DUBs Deubiquitinating enzymes 
EdU 5-ethynyl-2'-deoxyuridine 
ER Estrogen Receptor 
ES Enrichment score 
Fas ligand Fas-L 
Fbx11 F-box protein 11 
FDA Food and Drug Administration 
FDR False discovery rate 
GADD45α Growth- arrest and DNA-damage-inducible 45 α 
Gemcitabine 2’, 2’-difluorodeoxycytidine 
GRO-Seq Global-Run on sequencing 
GSEA Gene set enrichment analysis 
H3 Histone3 
H3K27ac Acetylation of histone H3 at lysine 27 
HATs Histone acetyltransferases 
HAUSP Herpes-Specific Ubiquitin Specific Protease 
HDACs Histone deacetylases 
HER Human Epidermal receptor 
hg19 Human Genome project version 19 
HIPK2 Homeodomain interacting protein kinase 2 
HPV-E6 Human Papillomavirus E6 
IC Inhibitory concentration 
ICAD Inhibitor of the caspase-activated DNAse 
IgG Immunoglobulin G 
JNK Jun NH2-terminal kinase 
kb Kilo base pairs 
kg Kilo gram 
M Molar 
M/R/N Mre11/Rad50/Nbs1 
MDM2 Murine double-minute 2 
mg Milli gram 
MI Myocardial infarction 
MK-1775 Wee1 inhibitor 
ml Milli liter 
mM Milli molar 
ABBREVIATIONS 
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MSigDB Molecular Signatures Database 
mTOR Mammalian target of rapamycin 
nM Nano molar 
n.s. not significant 
NCS Neocarzinostatin 
NER Nucleotide excision repair 
NES Nuclear export signal 
NF-κB Nuclear factor ‘kappa-light-chain-enhancer’ of activated B-cells 
Nutlin Nutlin-3a 
p-value Probability value of rejectign a null hypothesis 
PACT p53-associated cellular protein-testes derived 
PAI 1 Plasminogen Activator Inhibitor-1 
PARP Poly- ADP ribose polymerase 
PcG Polycomb group 
PCNA Proliferating cell nuclear antigen 
PI Propidium iodide 
PML Promyelocytic Leukemia protein 
POLH Pol eta 
PP Proline rich domain 
PRC Polycomb repressive complex 
PRIMA 1 p53-reactivation and induction of massive apoptosis 1 
PTM Post-translational modifications 
PUMA p53 Upregulated Modulator of Apoptosis 
qPCR Quantitative real-time PCR 
RAD21 Double-strand break repair protein 
Rb Retinoblastoma 
RECQL4 ATP-dependent DNA helicase Q4 
RG-7388 Idasanutlin 
RING Really Interesting New Gene 
RNA pol II RNA polymerase II 
RNA-Seq RNA sequencing analysis 
RT Room temperature 
SAB Senescence-associated beta-galactosidase 
siRNA Small interfering RNA 
SIRT1 Sirtuin1 
TAD Transactivation domains 
TAFII250 TATA-box binding protein associated factor 250kDa 
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TBP TATA-box binding protein 
TFIIH Transcription factor II H 
TLR Toll-like receptor 
TLS Translesion synthesis 
TNFS6 Tumor necrosis factor S6 
TNF-α Tumor-necrosis factor-α 
TRAIL Tumor necrosis factor-related apoptosis-inducing ligand 
TRRAP Transformation/transcription domain-associated protein 
TSS Transcription start site 
UTR Untranslated region 
UV Ultraviolet 
WIP1 Wild-type p53 induced phosphatase 
WT Wildtype 
XPC2 Xeroderma pigmentosum complementation group C 
γH2AX Phosphorylation of Histone2AX 
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